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A B S T R A C T
Background
There has been renewal of interest in the use of prophylactic antibiotics to reduce the frequency of exacerbations and improve quality
of life in chronic obstructive pulmonary disease (COPD).
Objectives
To determine whether or not regular (continuous, intermittent or pulsed) treatment of COPD patients with prophylactic antibiotics
reduces exacerbations or affects quality of life.
Search methods
We searched the Cochrane Airways Group Trials Register and bibliographies of relevant studies. The latest literature search was
performed on 27 July 2018.
Selection criteria
Randomised controlled trials (RCTs) that compared prophylactic antibiotics with placebo in patients with COPD.
Data collection and analysis
We used the standard Cochrane methods. Two independent review authors selected studies for inclusion, extracted data, and assessed
risk of bias. We resolved discrepancies by involving a third review author.
Main results
We included 14 studies involving 3932 participants in this review. We identified two further studies meeting inclusion criteria but both
were terminated early without providing results. All studies were published between 2001 and 2015. Nine studies were of continuous
macrolide antibiotics, two studies were of intermittent antibiotic prophylaxis (three times per week) and two were of pulsed antibiotic
regimens (e.g. five days every eight weeks). The final study included one continuous, one intermittent and one pulsed arm. The
antibiotics investigated were azithromycin, erythromycin, clarithromycin, doxycyline, roxithromycin and moxifloxacin. The study
duration varied from three months to 36 months and all used intention-to-treat analysis. Most of the pooled results were of moderate
quality. The risk of bias of the included studies was generally low.
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The studies recruited participants with a mean age between 65 and 72 years and mostly at least moderate-severity COPD. Five studies
only included participants with frequent exacerbations and two studies recruited participants requiring systemic steroids or antibiotics or
both, or who were at the end stage of their disease and required oxygen. One study recruited participants with pulmonary hypertension
secondary to COPD and a further study was specifically designed to asses whether eradication of Chlamydia pneumoniae reduced
exacerbation rates.
The co-primary outcomes for this review were the number of exacerbations and quality of life.
With use of prophylactic antibiotics, the number of participants experiencing one or more exacerbations was reduced (odds ratio (OR)
0.57, 95% CI 0.42 to 0.78; participants = 2716; studies = 8; moderate-quality evidence). This represented a reduction from 61% of
participants in the control group compared to 47% in the treatment group (95% CI 39% to 55%). The number needed to treat for an
additional beneficial outcome with prophylactic antibiotics given for three to 12 months to prevent one person from experiencing an
exacerbation (NNTB) was 8 (95% CI 5 to 17). The test for subgroup difference suggested that continuous and intermittent antibiotics
may be more effective than pulsed antibiotics (P = 0.02, I² = 73.3%).
The frequency of exacerbations per patient per year was also reduced with prophylactic antibiotic treatment (rate ratio 0.67; 95% CI
0.54 to 0.83; participants = 1384; studies = 5; moderate-quality evidence). Although we were unable to pool the result, six of the
seven studies reporting time to first exacerbation identified an increase (i.e. benefit) with antibiotics, which was reported as statistically
significant in four studies.
There was a statistically significant improvement in quality of life as measured by the St George’s Respiratory Questionnaire (SGRQ)
with prophylactic antibiotic treatment, but this was smaller than the four unit improvement that is regarded as being clinically significant
(mean difference (MD) -1.94, 95% CI -3.13 to -0.75; participants = 2237; studies = 7, high-quality evidence).
Prophylactic antibiotics showed no significant effect on the secondary outcomes of frequency of hospital admissions, change in forced
expiratory volume in one second (FEV1), serious adverse events or all-cause mortality (moderate-quality evidence). There was some
evidence of benefit in exercise tolerance, but this was driven by a single study of lower methodological quality.
The adverse events that were recorded varied among the studies depending on the antibiotics used. Azithromycin was associated with
significant hearing loss in the treatment group, which was in many cases reversible or partially reversible. The moxifloxacin pulsed
study reported a significantly higher number of adverse events in the treatment arm due to the marked increase in gastrointestinal
adverse events (P < 0.001). Some adverse events that led to drug discontinuation, such as development of long QTc or tinnitus, were
not significantly more frequent in the treatment group than the placebo group but pose important considerations in clinical practice.
The development of antibiotic resistance in the community is of major concern. Six studies reported on this, but we were unable to
combine results. One study found newly colonised participants to have higher rates of antibiotic resistance. Participants colonised with
moxifloxacin-sensitive pseudomonas at initiation of therapy rapidly became resistant with the quinolone treatment. A further study
with three active treatment arms found an increase in the degree of antibiotic resistance of isolates in all three arms after 13 weeks
treatment.
Authors’ conclusions
Use of continuous and intermittent prophylactic antibiotics results in a clinically significant benefit in reducing exacerbations in COPD
patients. All studies of continuous and intermittent antibiotics used macrolides, hence the noted benefit applies only to the use of
macrolide antibiotics prescribed at least three times per week. The impact of pulsed antibiotics remains uncertain and requires further
research.
The studies in this review included mostly participants who were frequent exacerbators with at least moderate-severity COPD. There
were also older individuals with a mean age over 65 years. The results of these studies apply only to the group of participants who were
studied in these studies and may not be generalisable to other groups.
Because of concerns about antibiotic resistance and specific adverse effects, consideration of prophylactic antibiotic use should bemindful
of the balance between benefits to individual patients and the potential harms to society created by antibiotic overuse. Monitoring of
significant side effects including hearing loss, tinnitus, and long QTc in the community in this elderly patient group may require extra
health resources.
P L A I N L A N G U A G E S U M M A R Y
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Preventative antibiotic therapy for people with COPD
What is COPD?
COPD is a common chronic respiratory disease mainly affecting people who smoke now or have done so previously. It could become
the third leading cause of death worldwide by 2020. People with COPD experience gradually worsening shortness of breath and
cough with sputum (phlegm) because of permanent damage to their airways and lungs. Those with COPD may have flare-ups (or
exacerbations) most commonly with respiratory infections. Exacerbations may lead to further irreversible loss of lung function, as well
as days off work, hospital admission, reduction in quality of life, or even death.
Why did we do this review?
We wanted to find out if giving antibiotics to prevent a flare-up (’prophylactic’ antibiotics) would reduce the frequency of flare-ups
and improve quality of life. Studies that were taken into consideration used either continuous prophylactic antibiotics (every day), or
antibiotics that were used intermittently (three times per week) or pulsed (e.g. for five days every eight weeks)
What evidence did we find?
We carried out the latest search for studies in July 2018. We found 14 randomised controlled trials (RCTs) involving 3932 participants.
All studies were published between 2001 and 2015. Nine studies were of continuous antibiotics, two studies were of intermittent
antibiotic prophylaxis and two were of pulsed antibiotics. The final study included one continuous, one intermittent, one pulsed
and one placebo arm. The antibiotics investigated were azithromycin, erythromycin, clarithromycin, roxithromycin, doxycycline and
moxifloxacin. On average, the people involved in the studies were 65 to 72 years old and had moderate or severe COPD. Three studies
included participants with frequent exacerbations and two of the studies recruited participants requiring steroid tablets or antibiotics or
both, or who were at the end stage of their disease and required oxygen. One study only included people with a particular complication
of COPD, involving the heart and blood vessels in the lungs (known as pulmonary hypertension).
Results and conclusions
We found that, with the use of antibiotics, the number of participants who developed an exacerbation reduced markedly. For every
eight participants treated, one person would be prevented from suffering an exacerbation. However, not all the antibiotic regimens had
the same impact on exacerbations. The results suggested that antibiotics given at least three times per week may be more effective than
antibiotics given daily for a few days followed by a break of several weeks. We also found there may have been a benefit on patient-
reported quality of life with the antibiotics. On the other hand, use of antibiotics did not significantly affect the number of deaths due
to any cause, the frequency of hospitalisation, or the loss of lung function during the study period.
Even though there may be fewer exacerbations with antibiotics, there are considerable drawbacks of taking antibiotics. First, there were
specific adverse events associated with the antibiotics, which differed according to the antibiotic used; second, patients have to take
antibiotics regularly for months or years; finally, the resulting increase in antibiotic resistance will have implications for both individual
patients and the wider community through reducing the effectiveness of currently available antibiotics.
Because of concerns about antibiotic resistance and specific adverse effects, consideration of prophylactic antibiotic use should be
mindful of the balance between benefits to individual patients and the potential harms to society created by antibiotic overuse.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Antibiotics versus placebo for COPD (data from pulsed and continuous courses of antibiotics presented in the same table)
Patient or population: Adults (aged 40 or over) with COPD present ing with 1 or more exacerbat ions in the previous year. The two larger studies (Albert 2011; Sethi 2010)
recruited part icipants who required systemic steroids or ant ibiot ics for exacerbat ions or part icipants on supplemental oxygen
Settings: Outpat ients present ing to hospital clinics
Intervention: Administrat ion of an oral prophylact ic ant ibiot ic cont inuously or interm it tent ly
Comparison: Administrat ion of a placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Antibiotics versus
placebo
Number of people with
one or more exacerba-
tions
WMD of follow-up of 49
weeks
606 per 1,000 468 per 1,000
(393 to 546)
OR 0.57
(0.42 to 0.78)
2716
(8 RCTs)
⊕⊕⊕©
Moderate1
Sub-
group analysis of con-
t inuous versus interm it-
tent versus pulsed an-
t ibiot ics suggested that
pulsed ant ibiot ics were
less ef fect ive at reduc-
ing exacerbat ions (P =
0.01 for subgroup dif -
ference; I2 = 77.3%)
Rate of exacerbation
per patient/ year
WMD of follow-up 54
weeks
Rate ratio 0.67
(0.54 to 0.83)
1384
(5 RCTs)
⊕⊕⊕©
Moderate2
Test for subgroup dif -
ference between con-
t inuous and interm it-
tent ant ibiot ics not sig-
nif icant (P = 0.38; I2 =
0%)
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HRQoL, SGRQ (total
score)
Scale f rom: 0 to 100.
SGRQ comprises re-
sponses to 50 items, 0
being the best possi-
ble score and 100 the
worst.
WMD of follow-up 48
weeks
The mean change in
SGRQ ranged across
control groups f rom a
0.9 unit increase to a
5.7 unit decrease
The mean HRQoL
(SGRQ total score) in
the intervent ion group
was 1.94 lower (3.13
lower to 0.75 lower)
2237
(7 RCTs)
⊕⊕⊕⊕
High
The minimally clinically
important response to
treatment is described
as 4 points
Test for subgroup dif -
ferences between con-
t inuous, interm it tent
and pulsed ant ibiot ics
not signif icant (P = 0.
35; I² = 5.2%)
All- cause mortality
WMD of follow-up 70
weeks
78 per 1000 68 per 1,000
(53 to 88)
OR 0.87
(0.66 to 1.15)
3309
(6 RCTs)
⊕⊕⊕©
Moderate3
Test for subgroup dif -
ferences between con-
t inuous, interm it tent
and pulsed ant ibiot ics
not signif icant (P = 0.
60; I² = 0%)
Serious adverse events
WMD of follow-up 51
weeks
253 per 1000 229 per 1,000
(200 to 262)
OR 0.88
(0.74 to 1.05)
2978
(9 RCTs)
⊕⊕⊕©
Moderate3
See Ef fects of
intervent ions for spe-
cif ic adverse events re-
lated to the individual
ant ibiot ics
Test for subgroup dif -
ferences between con-
t inuous, interm it tent
and pulsed ant ibiot ics
not signif icant (P = 0.
60; I² = 0%)
Any adverse event
WMD of follow-up 47
weeks
640 per 1,000 655 per 1,000
(551 to 748)
OR 1.07
(0.69 to 1.67)
512
(4 RCTs)
⊕⊕⊕©
Moderate3
Test for subgroup dif -
ferences between con-
t inuous, interm it tent
and pulsed ant ibiot ics
not signif icant (P = 0.
28), I² = 21.9%)
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FEV1 (mL)
WMD of follow-up 26
weeks
The mean FEV1 in the
control group ranged
f rom 1,000 to 2,320 mL
The mean FEV1 in the
intervent ion group was
20.21 mL higher (26.19
lower to 66.61 higher)
- 658
(6 RCTs)
⊕⊕⊕©
Moderate4
MCID for this outcomes
was approximately 100
mLs. Mean dif ference
and conf idence interval
lied within this MCID
Test for subgroup dif -
ferences between con-
t inuous, interm it tent
and pulsed ant ibiot ics
not signif icant (P = 0.
37; I² = 0.6%)
* The basis for the assumed risk was the mean control group risk across studies. The corresponding risk (and its 95% conf idence interval) is based on the assumed risk in the
comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: Conf idence interval; FEV 1:f orcedexpiratoryvolumein1second;HRQoL:health−relatedqualityof lif e;MCID:minimumclinicallyimportantdiff erence; OR: Odds rat io;
SGRQ:StGeorge′srespiratoryquestionnaire WMD: weight mean durat ion
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1 Clinical and stat ist ical heterogeneity between studies (I2 = 58%), part ly explained by ant ibiot ic regimen. Downgraded once
for inconsistency
2 Clinical and stat ist ical heterogeneity between trials (I2 = 52%). Downgraded once for inconsistency
3 Conf idence intervals included the possibility that prophylact ic ant ibiot ics may increase or decrease mortality or adverse
events. Downgraded once for imprecision
4Conf idence interval included both a decrease or increase in FEV1 associated with the intervent ion. However, the mean
dif ference and conf idence interval lay within the MCID. No downgrade
5Studies contribut ing majority of weight in analysis reported outcome at approximately 3 months. Durat ion may be too short
to detect a dif ference in lung funct ion between groups. Downgraded once for indirectness
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B A C K G R O U N D
Description of the condition
The Global Initiative for Chronic Obstructive Lung Diseases
(GOLD) defines chronic obstructive pulmonary disease (COPD)
as “a common, preventable and treatable disease, that is charac-
terised by persistent respiratory symptoms and airflow limitation
that is due to airway and/or alveolar (small air sacs within the lungs
where gas exchange takes place) abnormalities usually caused by sig-
nificant exposure to noxious particles or gases” (GOLD 2018). It
has become a leading cause of morbidity and mortality worldwide,
with latest figures suggesting it was responsible for approximately
3.2 million deaths globally in 2015, making it the fourth leading
cause of death that year (WHO). Projections estimate it will be-
come the third leading cause of death worldwide by 2020, due to
an aging global populationwith prolonged exposure toCOPDrisk
factors (GOLD 2018). COPD in high-income countries is almost
exclusively a disease of tobacco smoking, although a small pro-
portion of nonsmokers have COPD secondary to passive smoking
or genetic diseases, including alpha1 antitrypsin deficiency (non-
smokers with COPD are usually excluded from clinical trials). In
lower-income countries the major risk factor is indoor pollution
(burning wood for heating or biomass fuels for cooking) which
contributes more than smoking to the disease burden (WHO).
Most reported deaths due to COPD are from high- and middle-
income countries; however, it is estimated that 90% of COPD-
related deaths occur in low-middle-income countries, where pop-
ulation-based prevention strategies are either inaccessible or not
implemented (WHO).
COPD is diagnosed by spirometry (a type of breathing assessment)
and clinical symptoms of dyspnoea (difficulty breathing), chronic
cough, or sputum production and a history of exposure to known
risk factors, e.g. smoking. To make the diagnosis, a post-bron-
chodilator cut-off of a ratio of forced expiratory volume in one
second to forced vital capacity (FEV1/FVC) less than 0.7 is used
as an objective measure of airflow limitation. To individualise the
management of COPD for each patient, GOLD has developed
staging systems to classify severity. Patients are graded from stage
one to stage four according to spirometric criteria, with stage one
representing mild airflow obstruction (FEV1 ≥ 80% predicted),
stage two moderate (FEV1 < 80% but ≥ 50% predicted), stage
three severe (FEV1 < 50% but ≥ 30% predicted) and stage four
very severe (FEV1 < 30%) (GOLD 2018). However, the most
recent report de-emphasises FEV1 as a useful prognostic tool at
an individual level and instead focuses on functional limitation
and symptoms to guide therapy for stable COPD (Group A: 0
to 1 exacerbations not leading to hospital admission and COPD
assessment test (CAT) score < 10 or Modified Medical Research
Council Dyspnea Scale (MMRC) 0 to 1; group B: 0 to 1 exacerba-
tions not leading to hospital admission and CAT≥ 10 or MMRC
≥ 2; group C: ≥ 2 exacerbations or ≥ 1 exacerbation leading to
hospital admission and CAT < 10 or MMRC 0 to 1; group D: ≥
2 exacerbations or≥ 1 exacerbation leading to hospital admission
and CAT ≥ 10 or MMRC ≥ 2)).
Many people with COPD experience acute exacerbations, which
are defined as “an acute worsening of respiratory symptoms that
result in additional therapy” (GOLD 2018). Exacerbations of
COPD range in severity between individuals, have a substantial
impact on quality of life and contribute to overall disease progres-
sion (GOLD 2018). Therefore, preventing and treating exacer-
bations is an important part of COPD management in order to
improve quality of life and prognostic outcomes. Exacerbations
of COPD are a common cause of days off work and hospital ad-
missions (TSANZ 2004), and so have a significant socioeconomic
impact globally. Furthermore the long-term prognosis following
hospitalisation for an exacerbation of COPD is poor, with a five-
year mortality rate of approximately 50% (GOLD 2018).
Respiratory infections are known triggers for COPD exacerba-
tions, with current evidence suggesting that viral infections ac-
count for the majority of exacerbations (GOLD 2018; Woodhead
2011). However, bacterial respiratory infections and changes in
the local environment, such as an increase in air pollution, are
also recognised as exacerbation triggers (Papi 2006). The role of
bacteria in exacerbations is an area that has been greatly studied,
yet remains controversial. It has been demonstrated that respira-
tory bacterial loads are greater in patients with stable COPD com-
pared to healthy individuals, and that the bacterial loads increase
with disease severity (Beasley 2012). However, the high bacterial
isolation rates in stable COPD makes it difficult to identify a
causative role of bacteria in exacerbations. Despite this, studies do
suggest an increase in bacterial infection rates amongst participants
with acute COPD exacerbations (Beasley 2012). Wilkinson 2006
found that the prevalence of potentially pathogenic microorgan-
isms rose from 48.2% at baseline in stable COPD participants to
69.6% in the same group of participants at the time of an exacerba-
tion. The most commonly isolated bacterial organisms in COPD
exacerbations include “Haemophilus influenzae (11% of all exac-
erbating participants), Streptococcus pneumoniae (10%),Moraxella
catarrhalis (10%) and Pseudomonas aeruginosa (4%), with Gram-
negative bacteria occurring more rarely” (Sapey 2006).
There are numerous evidence-based approaches that aim to re-
duce the number of COPD exacerbations. An essential first step
is the avoidance of cigarette smoke and air pollution, wherever
possible. Furthermore, vaccination against influenza is a univer-
sally accepted measure to prevent COPD exacerbations. Vaccina-
tion for pneumococcal disease may also reduce pneumonia and
COPD exacerbations (Lee 2007). Inhaled medications shown to
reduce exacerbation frequency include tiotropium, a long-acting
muscarinic antagonist (LAMA, UPLIFT 2008), long-acting beta
agonists (LABA, Wang 2012) and corticosteroids (ICS, TORCH
2007). Oral medications shown to reduce exacerbations include
phosphodiesterase 4 (PDE4) inhibitors (Chong 2017) and mu-
colytic agents (drugs that help break down sputum making it eas-
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ier to cough up) (Poole 2012).
Description of the intervention
One approach to reduce exacerbation frequency has been to use
prophylactic antibiotics. The word prophylactic comes from the
Greek for ’an advance guard’, an apt term for a measure taken
to fend off a disease or another unwanted consequence. A pro-
phylactic intervention is a medication or treatment designed and
used to prevent a disease from occurring. Thirty years ago, the use
of prophylactic antibiotics was common for chronic bronchitis in
both the United Kingdom and elsewhere, but concerns over effec-
tiveness and antibiotic resistance led to a decline in this approach.
How the intervention might work
COPD is characterised by persistent airways inflammation due to
chronic bacterial colonisation of the damaged respiratory epithe-
lium (the layer of cells lining the airways) leading to the continuing
release of bacterial and host-mediated pro-inflammatory factors
and additional epithelial damage (Matkovic 2013; Sethi 2008). In
an exacerbation, there is superimposed acute inflammation (Hurst
2006). By reducing bacterial colonisation, chronic antibiotic ther-
apy could help in reducing progression of the disease by breaking
the above vicious cycle. In addition, some antibiotics have intrin-
sic anti-inflammatory properties (Martinez 2008).
Why it is important to do this review
This review incorporates and builds upon earlier Cochrane re-
views.The most recent review concluded that the “use of contin-
uous prophylactic macrolide antibiotics for a period of up to 12
months is likely to reduce the number of patients with exacerba-
tions and exacerbation frequency, increase the median time to first
exacerbation and possibly health-related quality of life” (Herath
2013). However, adverse effects and the potential for the devel-
opment of antibiotic resistance remain a concern. Since the 2013
review, a number of new studies into prophylactic antibiotic use
in COPD have been published. Given the fine balance between
the need to reduce exacerbation frequency in COPD, with the
threat of widespread antibiotic resistance, it is important that the
most up-to-date research is incorporated into this review, so that
physicians and patients can make well informed decisions before
embarking on long-term treatment. This updated review also ex-
pands on the analysis of specific prophylactic antibiotic regimens
including continuous, intermittent, and pulsed regimens to de-
termine their relative efficacy and safety. Furthermore, many of
the new studies have included more comprehensive assessments
of quality of life indicators, which were not previously explored in
great detail.
O B J E C T I V E S
To determine whether or not regular (continuous, intermittent or
pulsed) treatment of COPDpatients with prophylactic antibiotics
reduces exacerbations or affects quality of life.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials of antibiotic versus placebo. Trials
comparing different antibiotics head-to-head will form the basis
of another review.We planned to include cluster-randomised trials
and crossover trials, if found.
Types of participants
We included studies of adults (older than 18 years of age) with a
diagnosis of COPD, as defined by the American Thoracic Society,
European Respiratory Society or GOLD, with airflow obstruc-
tion evident by spirometry (post-bronchodilator FEV1 of less than
80% of the predicted value and an FEV1/FVC of 0.7 or less). The
review included studies only if they confirmed diagnosis with lung
function testing (spirometry).
We excluded studies of participantswith bronchiectasis, asthma, or
genetic diseases, such as cystic fibrosis or primary ciliary dyskinesia
(which may also lead to chronic airflow limitation as part of a sec-
ondary process).Where we encountered trials that included partic-
ipants with these diseases in addition to participants with COPD,
we only extracted the data for the participants with COPD, where
the data were presented separately. However, although the studies
excluded participants with clinical presentation of bronchiectasis,
computed tomography (CT) screening to confirm radiological ev-
idence of bronchiectasis was performed only in two studies (Albert
2011 and Uzun 2014) prior to study entry.
Types of interventions
We included studies of oral antibiotics, including peni-
cillin (amoxycillin, amoxicillin, clavulanic acid), tetracy-
cline (doxycycline, tetracycline), quinolones (ciprofloxacin,
moxifloxacin), macrolides (clarithromycin, erythromycin, rox-
ithromycin, azithromycin) and sulphonamides (co-trimoxazole),
administered in appropriate doses for a period of at least three
months.
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Types of outcome measures
Primary outcomes
1. Number of exacerbations, using an accepted definition.
This included total numbers of participants with one or more
exacerbation as well as the frequency of exacerbations in the
study period and time to first exacerbation.
2. Health-related quality of life, using an accepted measure
such as the St George’s Respiratory Questionnaire (SGRQ)
(Jones 2009) or Chronic Respiratory Diseases Questionnaire
(CRQ) (Guyatt 1987).
Secondary outcomes
1. Duration and severity (using an accepted definition) of
exacerbations;
2. Days of disability (defined as days where the participant was
unable to undertake normal activities);
3. Frequency and duration of hospital admissions;
4. Reduction in lung function from baseline, as measured by
FEV1 and FVC;
5. Drug resistance as measured by microbial sensitivity;
6. Death due to all-cause mortality, as well as due to
respiratory causes;
7. Adverse effects.
Search methods for identification of studies
Electronic searches
We searched the Cochrane Airways Trials Register up to 27 July
2018 with no restrictions on language or type of publication. The
Cochrane Airways Trials Register ismaintained by the information
specialist for Cochrane Airways and contains studies identified
from the following sources:
1. Monthly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL), through the Cochrane Register
of Studies (CRS);
2. Weekly searches of MEDLINE Ovid SP;
3. Weekly searches of Embase Ovid SP;
4. Monthly searches of PsycINFO Ovid SP;
5. Monthly searches of CINAHL EBSCO (Cumulative Index
to Nursing and Allied Health Literature);
6. Monthly searches of AMED EBSCO (Allied and
Complementary Medicine);
7. Handsearches of the proceedings of major respiratory
conferences.
Studies contained in the Trials Register are identified through
search strategies based on the scope of Cochrane Airways. Details
of these strategies, as well as a list of handsearched conference pro-
ceedings, are in Appendix 1. See Appendix 2 for search terms used
to identify studies for this review.
We conducted a search of ClinicalTrials.gov with the search strat-
egy in Appendix 3 up to 27 July 2018. For the 2018 update, we
managed references using Rayyan (Ouzzani 2016).
Searching other resources
We checked the reference lists of all eligible primary studies and
review articles for additional references. For the original review,
we contacted authors of Mygind 2010 and asked them to supply
the data from their unpublished study. For the 2018 update, we
contacted the authors of all newly included studies and we are
grateful for the responses received from the authors of Berkhof
2013; Shafuddin 2015; Simpson 2014 and Uzun 2014. We have
checked the references of the included and excluded studies from
the previous review on chronic bronchitis for possible studies (
Staykova 2003).
Data collection and analysis
Selection of studies
For this update, two review authors (SH and RN) independently
screened the abstracts of studies identified by the search as to
whether or not they met our inclusion criteria. We obtained the
full texts of publications for those that were considered definite or
possible for inclusion. These were then reviewed independently
by two review authors (SH and RN) to assess eligibility. We re-
solved any disagreement by discussion and consensus followed by
an independent opinion from the third investigator (PP).
Data extraction and management
Both review authors independently extracted the data from the
eligible studies.
We extracted the following data.
• Methods: study design, duration of follow-up.
• Participants: age, gender, smoking status, study setting,
inclusion and exclusion criteria.
• Intervention: drug name, dose, duration of treatment,
control or standard therapy.
• Information on outcome measures.
Where appropriate, we have combined the data from studies using
RevMan 5 2008.
Assessment of risk of bias in included studies
Two investigators independently assessed risk of bias for each study
using the criteria outlined in theCochraneHandbook for Systematic
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Reviews of Interventions (Higgins 2011). Any disagreement was
resolved by discussion. We assessed the risk of bias according to
the following domains.
1. Random sequence generation.
2. Allocation concealment.
3. Blinding of participants and personnel.
4. Blinding of outcome assessment.
5. Incomplete outcome data.
6. Selective outcome reporting.
7. Other bias.
We graded each potential source of bias as high, low, or unclear
risk.
Measures of treatment effect
Results for continuous variables were expressed using a random-
effectsmodelmean difference (MD)with 95%confidence interval
(CI). Results for pooled outcomes with dichotomous variables
were expressed using a random-effects model odds ratio (OR) with
95% CI. We regarded a P value of less than 0.05 as statistically
significant. We combined rate data (e.g. number of exacerbations
per participant per year) using generic inverse variance (GIV) and
expressed the outcome as a rate ratio.
For ease of communication and clarity, the number needed to treat
for an additional beneficial outcome (NNTB) was derived from
the OR and mean control group event rate using Visual Rx.
Unit of analysis issues
We did not find any crossover trials or cluster-randomised trials
that met our inclusion criteria. However, if we had encountered
them, we planned to evaluate the cluster-randomised trials for trial
quality and, if the design and analysis were of poor quality, exclude
them.We planned to analyse any eligible cluster-randomised trials
with the help of a statistician.
Dealing with missing data
We contacted the investigators from Mygind 2010 in writing in
order to verify key study characteristics and to obtain missing
numerical outcome data. We were unable to get more details.
Assessment of heterogeneity
From the forest plot, we tested for heterogeneity where the CIs did
not overlap with each other. We used the I2 statistic to measure
heterogeneity among the studies in each analysis. Where we iden-
tified heterogeneity (I2 ≥ 40%), we explored this using a prespec-
ified subgroup analysis. We used the following overlapping cut-
off to define heterogeneity (Higgins 2011).
• 0% to 40%: might not be important;
• 30% to 60%: may represent moderate heterogeneity;
• 50% to 90%: may represent substantial heterogeneity;
• 75% to 100%: considerable heterogeneity
Assessment of reporting biases
Where we suspected reporting bias, we attempted to contact the
study authors to ask them to provide the missing outcome data.
Where this was not possible, and the missing data were thought to
introduce serious bias, the impact of including such studies in the
overall assessment of results was explored by a sensitivity analysis.
Data synthesis
For the 2018 update, we subgrouped all meta-analyses by regimen,
grouping interventions into continuous (i.e. daily) antibiotic use,
intermittent (e.g. two or three times per week) antibiotic use and
pulsed (e.g. daily for five days every four weeks) antibiotic use. We
performed meta-analysis only where the study populations were
sufficiently similar for pooling to make sense.
We created a ’Summary of findings’ table using the methods and
recommendations described in Section 8.5 and Chapter 12 of the
CochraneHandbook for Systematic Reviews of Interventions (Higgins
2011) and GRADEpro software for the following outcomes.
1. Number of exacerbations, using an accepted definition.
2. Days of disability (defined as days where the participant was
unable to undertake normal activities).
3. Frequency and duration of hospital admissions.
4. Health-related quality of life, using an accepted measure
such as SGRQ or CRQ.
5. Death.
6. Drug resistance.
7. Other adverse effects of treatment.
Subgroup analysis and investigation of heterogeneity
We planned to carry out the following subgroup analyses for the
primary outcome (number of exacerbations).
1. Severity of COPD according to FEV1 and the GOLD
criteria.
2. Type of antibiotic.
3. Duration of antibiotic use ( ≥ 3 months to < 6 months, ≥
6 months to < 12 months and ≥ 12 months).
4. Year of conduct of study (2005 to 2009, 2010 to 2014 and
2014 to 2019)
5. Whether the antibiotic was used primarily as an
antimicrobial or as an anti-inflammatory agent.
6. Treatment regimen including dose, frequency, route of
administration.
7. History of exacerbations (studies in which participants were
only included in they had experienced at least one exacerbation
in the preceding year versus those in which exacerbation history
was not an inclusion criteria).
Sensitivity analysis
We conducted a sensitivity analysis on our primary outcome (peo-
ple with one or more exacerbations) by removing studies judged
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to be at high or unclear risk of bias for the domains of sequence
generation, allocation concealment, or blinding.
R E S U L T S
Description of studies
Results of the search
We included seven studies in the 2013 version of this review.
For the 2018 update, we identified 202 records through database
searching and a further 76 additional records through other
sources.We screened265 records after removingduplicates.We ex-
cluded 226 records on the basis of the title and abstracts, leaving 39
full-text articles which we assessed for eligibility. Of these, we ex-
cluded 10 studies (12 full-text articles) and identified one as await-
ing classification (Characteristics of studies awaiting classification).
We identified four new ongoing studies, four new references to an
included study (Albert 2011) and one ongoing study was moved
to the included studies section (Uzun 2014). Wemoved one study
from the excluded studies section to be a subreference of an in-
cluded study (Banerjee 2005).
We identified nine new studies that were eligible for inclusion in
this systematic review, taking the total number of eligible studies
to 16 (Figure 1).
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Figure 1. Study flow diagram: review update
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Included studies
We identified 16 studies as eligible for the systematic review (Albert
2011; Banerjee 2005; Berkhof 2013; Brill 2015;He 2010;Mygind
2010; NCT00524095; NCT02628769; Seemungal 2008; Sethi
2010; Shafuddin 2015; Simpson 2014; Suzuki 2001; Tan 2016;
Uzun 2014;Wang 2017). The study durations varied from three to
36months. For reasons not given, one studywas terminated before
the treatment phase (NCT00524095) and another was terminated
after enrolment of five participants due to hepatotoxicity of the
study drug, solithromycin (NCT02628769). See Characteristics
of included studies and Table 1 for further details.
From this point forward, we will describe only the 14 completed
studies, involving 3932 participants.
Nine studies involving 1925 participants investigated continu-
ous macrolide antibiotics administered on at least a daily basis.
These included azithromycin (Albert 2011; Simpson 2014; Wang
2017), erythromycin (He 2010; Seemungal 2008; Suzuki 2001;
Tan 2016), roxithromycin (Shafuddin 2015), and clarithromycin
(Banerjee 2005). Shafuddin 2015 compared the combination of a
macrolide and tetracycline (roxithromycin and doxycycline) with
roxithromycin alone, and included a placebo arm.
Two studies involving 176 participants investigated intermittent
antibiotics which were administered three times a week for 12
weeks and 12 months respectively (Berkhof 2013; Uzun 2014).
Two studies involving 1732 participants investigated pulsed an-
tibiotic prophylaxis (Mygind 2010; Sethi 2010). InMygind 2010,
azithromycin was given for three days every month for 36 months
and in Sethi 2010, moxifloxacin was given for five days every eight
weeks for a total of six antibiotic courses.
One study that involved 99 participants compared three treatment
arms with placebo for a duration of 13 weeks. One arm involved a
continuous regimen (doxycycline 100mg daily), one arm involved
an intermittent regimen (azithromycin 250 mg for 3 times a week)
and one arm involved a pulsed regimen (moxifloxacin daily for
five days every four weeks) (Brill 2015). As such, Brill 2015 was
included in the subgroup analyses for all three regimen groups,
with the control group split three ways.
All except one study (Wang 2017) were randomised, placebo-
controlled, parallel group trials. Ten studies were double-blinded.
One was single-blinded (Brill 2015), one was not blinded (Suzuki
2001), and there were no comments regarding blinding methods
in two of the studies (Tan 2016; Wang 2017). All studies were
published in journals except Mygind 2010, which was an oral
presentation at the European Respiratory Society Conference in
2010. The studies were published or presented between 2001 and
2017.
All studies, except Tan 2016 and Wang 2017, listed exacerbation
frequency and/or health-related quality of life as primary, co-pri-
mary or secondary outcomes. Twelve studies were analysed using
intention-to-treat analysis. For two studies, it was unclear if in-
tention-to-treat analysis was used (Tan 2016; Wang 2017). Sethi
2010 reported both a per protocol analysis as well as an intention-
to-treat analysis, but, for the review, we have included only the
intention-to-treat analysis results.
Of note, the Shafuddin 2015 study was originally designed “to test
the hypothesis that Chlamydia pneumoniae (now Chlamydophilia
pneumoniae) was a pathogenic factor in the aetiology of COPD
and that eradication of C. pneumoniae infections could reduce ex-
acerbation rates”. In view of this original hypothesis, the study
design was such that all included participants tested positive for
C. pneumoniae, and the antibiotic regimens were chosen with the
aim of eradicating C. pneumoniae infection specifically. This in-
cluded a combined treatment arm of roxithromycin and doxy-
cycline, which was thought to be more successful at eradicating
C. pneumoniae compared to roxithromycin alone. In their back-
ground text, the authors explained that “this hypothesis is now
considered unsubstantiated and is no longer believed to be clin-
ically relevant”. However, they have used their collected data to
examine the effect of prophylactic antibiotic therapy on COPD
exacerbations, reporting that their data may reasonably be applied
to the general COPD population with frequent exacerbations, as
differences between their included participants with C. pneumo-
niae are unlikely to have an effect on efficacy endpoints or the
interpretation of results (Shafuddin 2015).
Study funding
Albert 2011 was supported by grants from the National Institutes
of Health, Banerjee 2005 received a grant from Abbott, Berkhof
2013 received financial support from Stichting Astma Bestrijd-
ing, Brill 2015 was funded by the National Institute for Health
Research, He 2010 was supported by grants from the National
Nature Science Foundation of China, Seemungal 2008 was sup-
ported by the British Lung foundation, Sethi 2010 was supported
by a research grant from Bayer HealthCare AB, Shafuddin 2015
was supported by Sanofi-Aventis Australia Pty Ltd, Simpson 2014
was funded by theNational Health andMedical Research Council
of Australia, Tan 2016 was funded by theNational Nature Science
Foundation of China and the Guangxi Natural Science Founda-
tion, and Uzun 2014 was funded by a trust called SoLong, which
is associated with the department of Respiratory Medicine of the
Amphia Hospital in the Netherlands. From the material available
to us, the funding for Mygind 2010 and Suzuki 2001 was unclear.
Wang 2017 reported that they had no grant support or financial
disclosures.
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Excluded studies
Excluded studies are listed in the Characteristics of excluded
studies table, along with the reasons for exclusion.
Risk of bias in included studies
Judgements and reasons for the judgements can be found in
Characteristics of included studies and an overview of our judge-
ments can be found in Figure 2.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Random sequence generationwaswell described in ten of the stud-
ies, which we judged to be at low risk of bias in this domain (Albert
2011; Banerjee 2005; Berkhof 2013; Brill 2015; Seemungal 2008;
Shafuddin 2015; Simpson 2014; Suzuki 2001; Uzun 2014; Wang
2017). Four studies did not describe random sequence generation
clearly andwe judged them to be at unclear risk (He 2010;Mygind
2010; Sethi 2010; Tan 2016).
Allocation concealment was well described in eight studies, which
we judged to be at low risk of bias in this domain (Albert 2011;
Banerjee 2005; Brill 2015; Seemungal 2008; Shafuddin 2015;
Simpson 2014; Suzuki 2001; Uzun 2014). Six studies did not
describe allocation concealment clearly and we judged them to be
at unclear risk in this domain (Berkhof 2013; He 2010; Mygind
2010; Sethi 2010; Tan 2016; Wang 2017).
Mygind 2010 is a conference presentation, and, as such, we had
access to limited data. We were not successful in obtaining further
information from authors despite multiple attempts by email and
post.
Blinding
Blinding of the participants and personnel (performance bias) was
described in ten of the included studies (Albert 2011; Banerjee
2005; Berkhof 2013; He 2010; Mygind 2010; Seemungal 2008;
Sethi 2010; Shafuddin 2015; Simpson 2014; Uzun 2014), which
we rated as low risk. Suzuki 2001 was not blinded and therefore
judged to be at high risk of bias. Brill 2015 was a single-blinded
study with only the participants being blinded to treatment allo-
cation, so we judged this to be at unclear risk of bias. Blinding
of participants and personnel was not described in Tan 2016 or
Wang 2017 and despite multiple attempts by email to obtain fur-
ther information from the corresponding authors, no responses
have been received.We therefore judged these studies to be at high
risk of bias.
Blinding of the outcome assessment (detection bias) was well de-
scribed in six of the included studies (Albert 2011; Berkhof 2013;
Seemungal 2008; Shafuddin 2015; Simpson 2014; Uzun 2014),
while four were judged to be at a high risk of bias (Brill 2015;
Suzuki 2001; Tan 2016;Wang 2017), and the remaining four were
unclear.
Incomplete outcome data
Outcomes of the study participants were well described using ei-
ther a CONSORT diagram (Albert 2011; Berkhof 2013; Brill
2015; He 2010; Seemungal 2008; Sethi 2010; Shafuddin 2015;
Simpson 2014; Uzun 2014) or by a dedicated paragraph or ta-
ble (Banerjee 2005; Suzuki 2001; Tan 2016). Overall, withdrawal
rates were similar between both studies and treatments and we
judged these studies to be at low risk of attrition bias, with the ex-
ception of four studies (Albert 2011; Sethi 2010; Shafuddin 2015;
Tan 2016).
In both Albert 2011 and Sethi 2010, we noted the reason for
missing health-related quality of life (HRQoL) data was not given,
and we therefore rated the studies at unclear risk. We also judged
Shafuddin 2015 to be at unclear risk because more participants
dropped out of the combined antibiotic treatment arm compared
to the single antibiotic and placebo arms (21 versus 13 versus
10), although all randomised participants were included in the
intention-to-treat analysis. We judged Tan 2016 to be at unclear
risk because the authors did not describe how many participants
were analysed at each time point.
Mygind 2010 was a conference presentation of unpublished data
and thus we had limited information on which to judge the at-
trition bias and we therefore rated the study to be at unclear risk.
Wang 2017 also did not include any information on the outcomes
of study participants and we judged it to be at unclear risk.
Selective reporting
Twelve of the included studies reported all prespecified primary
and secondary outcomes and these were judged to be at low risk
of bias. For Tan 2016, we were unable to identify a prospective
trial registration or protocol so it was not clear if outcomes of
interest for this review may have been collected but not reported
(e.g. serious adverse events, exacerbations, and quality of life). We
identified one study as being at high risk for selective reporting
bias (Wang 2017). See Characteristics of included studies to view
bias tables for more details.
Other potential sources of bias
No other potential sources of bias were identified.
Effects of interventions
See: Summary of findings for the main comparison Antibiotics
versus placebo for COPD
An overview of the results together with a summary of the our
confidence in the evidence per outcome is presented in Summary
of findings for the main comparison.
Primary outcome: number of participants with one
or more exacerbations
We included eight studies in the meta-analysis of the number of
participants experiencing one or more exacerbations of COPD
(Albert 2011; Berkhof 2013; Brill 2015; He 2010; Seemungal
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2008; Sethi 2010; Simpson 2014; Uzun 2014). Suzuki 2001 was
not included in the meta-analysis as this study was not blinded.
We found that prophylactic antibiotics reduce the overall odds
of having one or more exacerbations over the treatment period
compared to placebo (OR 0.57, 95%CI 0.42 to 0.78; participants
= 2716; studies = 8; I2 = 42%; moderate-quality evidence, Analysis
1.1; Figure 3). This equates to a 13.9 percentage-point reduction
in absolute risk. In the control group, 61 people out of 100 had
one or more exacerbations compared to 47 (95% CI 39 to 55) out
of 100 in the antibiotic group (Figure 4). The number needed to
treat for an additional beneficial outcome (NNTB) was 8 (95%
CI 5 to 17).
Figure 3. Forest plot of comparison: 1 Antibiotics versus placebo, outcome: 1.1 Number of people with one
or more exacerbations.
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Figure 4. In the control group, 61 people out of 100 had one or more exacerbations over 12 weeks to 12
months, compared to 47 (95% CI 39 to 55) out of 100 for the antibiotic treatment group (Analysis 1.1)
The heterogeneity of the eight studies analysed for this outcome
was moderate (I2 = 42%), which has been explored using pre-
planned subgroup analyses.
Of these studies, five (including one arm of Brill 2015), were of
continuous antibiotic prophylaxis. Compared to placebo, contin-
uous antibiotics reduced the number of participants experiencing
one ormore exacerbations (OR 0.53, 95%CI 0.36 to 0.79; partic-
ipants = 1325; studies = 5; I2 = 19%; Analysis 1.1). This equated
to a number needed to treat for an additional beneficial outcome
of 7 (95% CI 5 to 19).
Similarly, the analysis of three studies investigating intermittent
antibiotic regimens (including one arm of Brill 2015) suggested a
benefit in favour of antibiotics compared to placebo in reducing
the number of participants experiencing one ormore exacerbations
(OR 0.39, 95% CI 0.19 to 0.77; participants = 209; studies =
3; I2 = 0%; Analysis 1.1).The number needed to treat to for an
additional beneficial outcome was 5 (95% CI 3 to 17).
Pulsed antibiotic regimens did not significantly reduce the number
of people with at least one exacerbation (OR 0.85, 95% CI 0.68
to 1.07; participants = 1182; studies = 2; I2 = 0% Analysis 1.1).
The test for subgroup differences between continuous, intermit-
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tent, and pulsed regimens suggested a statistically significant dif-
ference between the groups (Chi² = 7.49, df = 2 (P = 0.02), I² =
73.3%). However, this was largely driven by the pulsed antibiotic
subgroup, as when this subgroup was removed, the test for sub-
group differences between the continuous and intermittent an-
tibiotic groups was not significant (Chi² = 0.62, df = 1 (P = 0.43),
I² = 0%).
One study of 84participants, that investigated continuous azithro-
mycin versus placebo, reported the number of exacerbations of
COPD that required hospitalisation (Berkhof 2013). The num-
ber of events were too infrequent to draw any conclusion on the
impact of prophylactic antibiotics in this situation.
Primary outcome: rate of exacerbations per patient
per year
The exacerbation rate was expressed as a rate ratio, which was
calculated using the generic inverse variance (GIV) method in
RevMan software.
Five studies contributed data to this analysis, four investigating
continuous regimens (Albert 2011; He 2010; Seemungal 2008;
Simpson 2014) and one investigating an intermittent regimen
(Uzun 2014). Compared to placebo, prophylactic antibiotics re-
duced the rate of exacerbations per patient per year (rate ratio 0.67,
95% CI 0.54 to 0.83; participants = 1384; studies = 5; moderate-
quality evidence; Analysis 1.4; Figure 5). Considering the differ-
ent regimens separately, use of continuous prophylactic antibiotics
was also associated with a reduction (rate ratio 0.69, 95% CI 0.54
to 0.89; participants = 1292; studies = 4) as was use of intermit-
tent antibiotics (rate ratio 0.58, 95% CI 0.42 to 0.80; participants
= 92; studies = 1). There was a moderate level of heterogeneity
among the included studies (I2 = 52%).
Figure 5. Forest plot of comparison: 1 Antibiotics versus placebo, outcome: 1.4 Rate of exacerbation per
patient per year.
A subgroup analysis performed in two studies (Albert 2011; Sethi
2010), according to the severity ofCOPDas definedby theGOLD
criteria which were current at that time (2011), did not show a
difference between the subgroups in the effect of antibiotics on
exacerbation frequency (Analysis 1.8).
Time to first exacerbation
The median time to first exacerbation was analysed using a Ka-
plan-Meier survival curve and log-rank test. We did not perform a
meta-analysis for this outcome and findings from individual stud-
ies are tabulated in Analysis 1.5. Data were available for six stud-
ies involving 2620 participants (Albert 2011; Berkhof 2013; He
2010; Seemungal 2008; Sethi 2010; Uzun 2014).
Three studies used continuous prophylactic antibiotics, involv-
ing 1287 participants. Use of a continuous prophylactic antibi-
otic lengthened the time to first exacerbation in all three studies
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compared with placebo, and this was a statistically significant dif-
ference in all three. In Albert 2011, this was 266 days (antibiotic)
versus 174 days (placebo) (P < 0.001); inHe 2010,155 days versus
86 days (P = 0.032) and in Seemungal 2008, 271 days versus 89
days (P = 0.02).
Two studies, involving a total of 176 participants, investigated in-
termittent antibiotics and similarly found the time to first exac-
erbation was lengthened in both studies. In Uzun 2014, this was
130 days versus 59 days (P = 0.001). In Berkhof 2013, the 20th
percentile time to first exacerbation was 105 days (antibiotic) ver-
sus 66 days (placebo), but this was not statistically significantly
different (P = 0.13).
The median time to the first exacerbation in Sethi 2010 was in-
creased by the use of pulsed antibiotics, but the difference was not
statistically significant: 364 days versus 336 days (P = 0.062).
One study, Shafuddin 2015, that involved 292 participants allo-
cated to receive either continuous roxithromycin and doxycyline,
continuous roxithromycin alone or placebo, reported the mean
time (in days) to first exacerbation of COPD. Their results were
inconclusive for this outcome and there was no significant differ-
ence between the treatment arms (MD -17 days, 95% CI -46 to
13; participants = 266; I2 = 0%)
In Albert 2011, which used continuous azithromycin, a prede-
fined subgroup analysis in 22 subgroups found that prophylactic
antibiotics were associated with greater treatment effects in terms
of lengthening time to first exacerbation in participants who had
given up smoking (test for interaction P = 0.012), were not on
steroid inhaler treatment at enrolment (P = 0.032), or older than
65 years (P = 0.012).
Primary outcome: health-related quality of life
Health-related quality of life was explored in nine studies (Albert
2011; Banerjee 2005; Berkhof 2013; Brill 2015;He 2010;Mygind
2010; Sethi 2010; Simpson 2014; Uzun 2014). The quality of
life assessment tools used in these studies included the St George’s
Respiratory Questionnaire (SGRQ) (Jones 2009), the Leicester
Cough Questionnaire (LCQ) (Birring 2003), the Short Form
Health Survey-36 (SF-36), the Short FormHealth Survey-12 (SF-
12), the Chronic Respiratory Disease Questionnaire (CRQ) and
the Clinical COPD Questionnaire (CCQ). We were not able to
include data from Banerjee 2005 and Mygind 2010 in the meta-
analyses.
Seven studies assessed quality of life using the SGRQ. The meta-
analysis demonstrated a benefit of prophylactic antibiotics com-
pared to placebo (MD -1.94, 95% CI -3.13 to -0.75; participants
= 2237; studies = 7; high-quality evidence; Analysis 1.9; Figure 6).
However, the mean difference did not reach the level of clinical
significance according to the conventional cut-off of at least a four-
unit reduction (Jones 2009).
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Figure 6. Forest plot of comparison: 1 Antibiotics versus placebo, outcome: 1.9 HRQoL, SGRQ (total score).
When we grouped the studies by antibiotic regimen, we noted a
similar improvement with continuous prophylactic antibiotic use
(MD -1.96, 95% CI -3.45 to -0.47; participants = 991; studies =
4). While the pooled mean difference did not exceed the MCID
of four units, it should be noted that Albert 2011 (1142 partic-
ipants) reported a responder analysis, which demonstrated that
more participants in the continuous azithromycin group (43%)
than the placebo group (36%) had at least a four-unit reduction in
the SGRQ (P = 0.03). We found a larger benefit with intermittent
antibiotic use (MD -4.59, 95% CI -8.83 to -0.36; participants =
184; studies = 3). There was no statistically or clinically significant
improvement in SGRQ total scores with pulsed antibiotics (MD
-1.22, 95% CI -3.00 to 0.55; participants = 1062; studies = 2;
Analysis 1.9). However, the formal test for subgroup difference
did not identify a significant difference between continuous, in-
termittent, and pulsed antibiotics.
The SGRQ comprises three subcomponents; symptom score, im-
pact score, and activity score. Four studies presented data for these
subcomponents which were analysed separately (Albert 2011;
Berkhof 2013: Sethi 2010; Uzun 2014). All three domains im-
proved with antibiotics compared to placebo, although the im-
provement in the activity score was more uncertain (symptom
score:MD -4.07, 95%CI -5.72 to -2.41; impact score:MD -2.56,
95% CI -5.02 to -0.10; activity score: MD -0.99, 95% CI -2.62
to 0.65; Analysis 1.10). In terms of clinically significant improve-
ments with antibiotic use versus placebo in the subgroup analy-
sis, the symptom score showed the greatest difference, with three
studies having greater than a four-unit mean difference (Berkhof
2013 9.3 units, Uzun 2014 5.7 units and Sethi 2010 4.4 units).
The authors of Banerjee 2005, Mygind 2010 and Simpson 2014
reported no statistically significant difference in the total SGRQ
scores. However, Banerjee 2005 did report a significant improve-
ment only in the symptomdomain score in the participants treated
with continuous prophylactic clarithromycin over a three-month
period (MD -10.2; 95% CI -18.7 to -1.6).
In addition to the SGRQ, Berkhof 2013 used the LCQ and SF-
36 as quality of life assessment tools. The LCQ is a 19-point
questionnaire designed to assess cough-related quality of life that
is divided into three domains (physical, psychological, and social).
The domain scores range from one to seven and therefore the
total score range is three to 21; higher scores are indicative of a
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better quality of life. The authors of Berkhof 2013 reported an
improvement in total LCQ score with intermittent azithromycin
use (MD 1.30, 95% CI 0.32 to 2.28; Analysis 1.11). The only
domain that did not show a clear improvementwith the antibiotics
was the social domain (MD 0.40, 95% CI -0.15 to 0.95; Analysis
1.14).
Four studies used the SF-36 (Albert 2011; Banerjee 2005; Berkhof
2013; He 2010). The SF-36 is a 36-item nonspecific health-re-
lated quality of life questionnaire. It is divided into eight domains
that are each scored on a 100-point scale where 100 is equiva-
lent to no disability. The domains include general health, physical
functioning, bodily pain, vitality, role emotional, social function-
ing, mental health, and role physical. Three of the four studies
(Albert 2011; Berkhof 2013; He 2010) that used SF-36 to assess
quality of life, involving 1262 participants, presented data that we
were able to extract for meta-analysis. Albert 2011 used continu-
ous azithromycin for 12 months, Berkhof 2013 used intermittent
azithromycin for three months and He 2010 used continuous ery-
thromycin for six months. Given the spread of treatment duration
and the different time points of data available for us to extract,
we chose to extract data as close to six months as possible, which
involved outcomes at six months for Albert 2011 and He 2010,
and three months for Berkhof 2013. Only the general health do-
main showed a clear benefit of antibiotics over placebo (MD 4.06,
95% CI 0.70 to 7.42; participants = 1071; studies = 3; I2 = 18%;
Analysis 1.13) but the confidence intervals for each domain effect
estimate were highly overlapping. Banerjee 2005 also used the SF-
36 but the raw data were not available for extraction for inclusion
in the meta-analysis; however, in their text; they reported a signif-
icant improvement in the physical functioning score in the group
that used prophylactic clarithromycin for threemonths (MD12.9;
95% CI 3.1 to 22.6).
One study used SF-12 in addition to the SGRQ, and found no
difference in the mental (MD 0.90, 95% CI -4.68 to 6.48) nor
the physical (MD -0.40, 95% CI -5.10 to 4.30) health domains
after 12 months of treatment with prophylactic antibiotics (inter-
mittent azithromycin) (overall; MD 0.14, 95% CI -3.45 to 3.73;
Analysis 1.12) (Uzun 2014) . They did, however, report “a signifi-
cant difference in mean change in the mental component score at
three months in favour of azithromycin (MD 6.6; CI 1.4 to 11.8;
P = 0.013)” (Uzun 2014).
Simpson 2014 similarly found no significant improvement in
quality of life as assessed by the CCQ with continuous antibiotic
(azithromycin) use at the end of their treatment period (MD 1.80,
95% CI -5.11 to 8.71; Analysis 1.15). Finally, Shafuddin 2015
used the CRQ (which assesses four domains: dyspnoea, fatigue,
emotional function, and mastery) and found no significant im-
provement in any of these domains with continuous antibiotic use
(roxithromycin/doxycycline or doxycycline alone) (Analysis 1.16).
Secondary outcome: frequency of hospitalisation
The frequency of hospitalisation was assessed using data from four
studies involving 2958 participants (Albert 2011; Mygind 2010;
Sethi 2010; Suzuki 2001). In this update, none of the new studies
presented data on the frequency of hospitalisation and as such,
our data remained unchanged from the previous update (Herath
2013).
The study by Sethi 2010, involving pulsed moxifloxacin in 1157
participants, did not show any improvement in the hospitalisation
frequency (131/569 treatment arm versus 136/580 placebo arm;
P = 0.46; Analysis 1.18).
The study by Albert 2011, involving continuous azithromycin in
1142 participants, calculated the rate of exacerbations requiring
hospitalisation per patient per year according to the severity of
COPD by the GOLD criteria (Analysis 1.18). The rate ratio was
0.77 (GOLD stage 2), 0.89 (GOLD stage 3) and 0.72 (GOLD
stage 4). There were not adequate data to calculate the statistical
significance of this outcome but there did not appear to be a trend.
The other two studies had inadequate data to calculate the mean
event rate per year. Of these, one study involving 109 participants
found a statistically significant reduction (P < 0.001) in hospital-
isation while using erythromycin 200 to 400 mg daily for a 12-
month period (Suzuki 2001). The other study (Mygind 2010) did
not show a statistically significant difference in the frequency of
hospitalisations.
Secondary outcome: duration of exacerbations
The duration of exacerbations was addressed by only two stud-
ies involving 684 participants (Mygind 2010; Seemungal 2008),
again already included in the previous version of this review
(Herath 2013). None of the new studies in this update presented
data on the impact of prophylactic antibiotics on the duration
of exacerbations. Seemungal 2008 showed that antibiotic use was
associated with a lower median number of exacerbation days: 9
days (interquartile range (IQR) 6 to 13 days) compared to 13 days
on placebo (IQR 6 to 24 days) (P = 0.036). Similar findings were
reported by Mygind 2010. This study had 575 participants and
used pulsed azithromycin over a 36-month period. The median
number of exacerbation days (at home or in hospital) was 93 in the
azithromycin group compared to 111 in the placebo group (P =
0.04). Prophylactic pulsed antibiotic use (Mygind 2010) reduced
the number of days with severe exacerbations managed at home:
a median of 31 days versus 42.5 days for the placebo group (P
= 0.01). A meta-analysis was not carried out for this comparison
due to paucity of data.
Furthermore, Mygind 2010 reported data on hospitalisation due
to COPD exacerbations. The study showed no difference in the
number of hospitalisations between the treatment and placebo
arms; however, there was a median reduction in hospital stay from
18 days in the placebo group to 15.5 days in the treatment group.
No P value was stated for this comparison.
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Secondary outcome: days of disability
Only one study reported on the number of days the participant was
unable to undertake normal activity (Mygind 2010). The median
number of days spent at home due to a mild exacerbation was no
different between the treatment and placebo arms (42 days in each
arm). However, there was a reduction in the median number of
days spent at home due to a moderate to severe exacerbation from
42.5 days in the placebo group to 31 days in the azithromycin
group (P = 0.01).
Secondary outcome: change in lung function
Change in lung function was addressed in nine studies (Berkhof
2013; Brill 2015; Mygind 2010; Seemungal 2008; Sethi 2010;
Shafuddin 2015; Simpson 2014; Tan 2016; Uzun 2014). Six anal-
ysed changes in FEV1 in a total of 658 participants. The meta-
analysis showed no significant difference in FEV1 (MD 20 mL,
95% CI -26 to 67; participants = 658; studies = 9; moderate-qual-
ity evidence; Analysis 1.20) with prophylactic antibiotics (con-
tinuous, intermittent, or pulsed) compared to placebo. Similarly,
there was no significant difference in FEV1 % predicted values
(MD0.33, 95%CI -1.56 to 2.22; participants = 1737; studies = 6;
Analysis 1.22). However, there appeared to be an improvement in
FVC with antibiotic use (combining available data for continuous
and intermittent regimens) (MD 0.12 L, 95% CI 0.01 to 0.23;
participants = 514; studies = 4; Analysis 1.21). We did not detect
any statistically significant differences between the antibiotic reg-
imen subgroups.
Secondary outcome: functional capacity
Two studies (Tan 2016 and Uzun 2014) assessed functional ex-
ercise capacity. Both studies measured the six-minute walk test
(6MWT) at baseline, three, six, nine, and 12 months. The meta-
analysis demonstrated a significant difference in favour of antibi-
otics in improving performance at 12 months, but with a high
level of heterogeneity (MD 68 m, 95% CI 16 to 119; participants
= 126; studies = 2; I2 = 64%; Analysis 1.23). Tan 2016, an un-
blinded study considered to be at high risk of bias, investigated
continuous antibiotics and had two treatment arms (group A: ery-
thromycin 125 mg three times a day for 12 months and group
B: erythromycin 125 mg three times a day for six months) and a
placebo arm. Their data suggested an improvement in exercise ca-
pacity at six months with erythromycin use compared to placebo,
with similar results seen for both treatment groups, as would be
expected (group A: mean distance 388 m ± 62 , n = 17; group B:
mean distance 389 m ± 61, n = 17; placebo mean distance 326
m ± 79, n = 15). Uzun 2014 investigated the use of intermittent
azithromycin and, when isolated from Tan 2016, this study did
not show an improvement in 6MWT results with antibiotic use
(MD 36, 95% CI -16 to 88; participants = 77).
Secondary outcome: death (all-cause and respiratory
aetiology)
Mortality data were reported in six studies involving 3309 partici-
pants andwere combined in ameta-analysis (Albert 2011; Berkhof
2013; Mygind 2010; Sethi 2010; Shafuddin 2015; Uzun 2014).
There was no significant difference between the treatment and
placebo arms in all-cause mortality (OR 0.87, 95% CI 0.66 to
1.15; participants = 3309; studies = 6; I2 = 0%; moderate-quality
evidence; Analysis 1.24), but confidence intervals were not suffi-
ciently narrow to exclude a clinically important difference. Data
on mortality secondary to a respiratory cause were available in the
two larger studies (Albert 2011; Sethi 2010), which again showed
no significant difference between groups (OR 1.17, 95% CI 0.63
to 2.19; Analysis 1.25), but the estimate was imprecise.
Secondary outcome: serious adverse events
Adverse events were well explained in ten studies (Albert 2011;
Berkhof 2013; Brill 2015; He 2010; Seemungal 2008; Sethi 2010;
Simpson 2014; Shafuddin 2015; Tan 2016;Uzun 2014), but there
was no uniform system for reporting them.
There was a reduction in serious adverse events as defined by the
trialists, with prophylactic antibiotics, but the confidence interval
included no difference (OR 0.88, 95% CI 0.74 to 1.05; partic-
ipants = 2978; studies = 9; I2 = 0%; moderate-quality evidence;
Analysis 1.26). Similarly, there was no significant difference in the
total number of any adverse event, as defined by the trialists, be-
tween antibiotic prophylaxis and placebo arms (OR 1.07, 95%CI
0.69 to 1.67; participants = 512; studies = 4; I2 = 0%; moderate-
quality evidence; Analysis 1.27), but the confidence interval was
wide.
Looking at specific adverse events, there were no significant differ-
ences in the number of adverse events between the treatment and
placebo arms related to the respiratory system (Analysis 1.28.1),
gastrointestinal system (Analysis 1.28.2), QTc prolongation (
Analysis 1.28.3), musculoskeletal system (Analysis 1.28.5), hy-
persensitivity (Analysis 1.28.6), nervous system (Analysis 1.28.7)
or the cardiovascular system (Analysis 1.28.8), but all estimates
lacked precision.
The adverse event most frequently recorded across the studies (
Albert 2011; Berkhof 2013; He 2010; Seemungal 2008; Sethi
2010; Simpson 2014) was gastrointestinal in origin (OR 1.16,
95% CI 0.43 to 3.11; participants = 2522; studies = 6; I2 = 72%,
Analysis 1.28). There was significant heterogeneity among these
studieswhich suggested differences among the antibiotics and their
adverse events for each study.
Individual studies did show some differences which may have clin-
ical relevance.
Sethi 2010 reported significantly higher numbers of adverse events
in the treatment arm with moxifloxacin (P < 0.001) secondary
to increased gastrointestinal adverse events including diarrhoea,
nausea, and vomiting (OR 7.17; 95% CI 2.49 to 20.63; Analysis
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1.28), representing a number needed to treat for an additional
harmful outcome (NNTH) of 25 (95%CI 98 to 9). The interven-
tion group in this study received moxifloxacin 400 mg daily for 5
days, every 8 weeks for 48 weeks. A single case of diarrhoea was
reported secondary to Clostridium difficile in the placebo group.
Sethi 2010 stated that the adverse events were drug-related.
Albert 2011 reported that azithromycin 250 mg daily for a 12-
month period was associated with a significant increase in hear-
ing impairment (OR 1.39; 95% CI 1.05 to 1.85) representing a
NNTH of 18 (95% CI 128 to 9). The authors reported that the
majority of the drug discontinuations due to a drug-related adverse
events were due to hearing impairment (treatment group, N = 142
(25%) versus placebo group, N = 110 (20%) by three months).
It should be noted that all participants in this study had baseline
audiometry, with participants with hearing impairment below the
95% percentile excluded from the study. Since there were a large
number of participants in both the treatment and placebo arms
that had drug discontinuation secondary to hearing loss, the au-
thors commented that this could be due to a measurement error.
In Albert 2011, while there were no statistically significant differ-
ences observed in cardiovascular disease or QTc prolongation, six
participants in the treatment group had to discontinue the med-
ication due to development of prolonged QTc compared to four
participants in the placebo group (P = 0.55). This study excluded
participants with tachycardia, long QTc, and participants taking
medications that could prolong the QTc.
In the non-blinded study of Suzuki 2001, it was reported that
participants in the treatment group did not have any apparent
adverse effects fromerythromycin therapy during the study period.
Shafuddin 2015 reported one case of an abnormal electrocardio-
gram (ECG)deemed tobe related to the combined roxithromycin/
doxycyline medication.
Brill 2015 found that 40% of adverse events, although reported
as minor, were in the moxifloxacin group, with half of those be-
ing gastrointestinal. In four cases, therapy was withdrawn in this
group.
Secondary outcome: antibiotic resistance
The development of antibiotic resistance was assessed in six studies
involving 2610 participants (Albert 2011; Banerjee 2005; Brill
2015; He 2010; Seemungal 2008; Sethi 2010). Because of the
variety of ways in which resistance was evaluated and reported, it
has proved impossible to combine these results in a meta-analysis.
In Brill 2015, both sputum bacterial load and antibiotic resistance
was assessed pre- and post- 13weeks antibiotic treatment. Bacterial
load was reduced by all three antibiotic treatments, and most sub-
stantially (by 62%) in the pulsed moxifloxacin arm, but there was
not a statistically significant difference when compared to placebo
in any of the three treatment arms. Themost common isolate both
pre and post-treatment was non-Pneumoniae streptococcus species.
Therewere increases in the degree of antibiotic resistance of isolates
in all three antibiotic arms after 13 weeks treatment. Compared
to placebo, moxifloxacin was associated with a factor increase in
mean inhibitory concentration (MIC) of 4.82 (95% CI 1.44 to
16.19, P = 0.01), doxycycline 3.74 (95% CI 1.46 to 9.58, P =
0.01) and azithromycin 6.23 (95% CI 1.66 to 23.35, P = 0.01).
Furthermore, isolates from participants in the doxycycline group
were more likely to be resistant to doxycycline than in the placebo
group (OR 5.77, 95% CI 1.40 to 23.74, P = 0.02). ORs for the
moxifloxacin and azithromycin were also greater than 2, but not
statistically significant.
Albert 2011 used sputum fromparticipants who could expectorate
as well as nasopharyngeal swabs. They found only 15% of partici-
pants were able to expectorate at the end of the three-month treat-
ment period. The commonest organisms identified in the treat-
ment versus placebo groups were: Staphylococcus aureus (N = 60
(10.7%) versus N = 71 (12.7%)); Moraxella spp (N=13 (2.3%)
versus N = 6 (1%)); and S. pneumoniae (N = 6 (1.1%) versus N = 6
(1.1%)). The predominance of S. aureus in this COPDpopulation
was out of keeping with the usual pathogens anticipated and was
thought to be due to the nasopharyngeal sampling. During the
study period, the participants in the placebo group without bac-
terial colonisation (N = 172) became colonised at a significantly
higher rate than those treated with 250 mg of daily azithromycin
(N = 66) (P < 0.001). However, in the group that became newly
colonised throughout the study period, the resistance tomacrolide
was higher in the treatment group: 81% compared to 41% in the
placebo group (P < 0.001).
In Sethi 2010, which used pulsed moxifloxacin over a 48-week
period, the sampling for organisms was carried out using spu-
tum sampling and rectal sampling. Only 24% of all participants
could produce sputum. The commonest organisms isolated were:
H. influenzae (8.3%), Haemophilus parainfluenzae (6.6%) and S.
pneumoniae (4.3%); S. aureus was isolated in 2.6%. The MIC
for moxifloxacin for H. influenzae, H. parainfluenzae, S. pneumo-
niae,M. catarrhalis and S. aureus did not change during the study
period. A single moxifloxacin-resistant S. pneumoniae isolate was
identified at the end of the study period (MIC 4 mg/L). There
were one to three moxifloxacin-resistant isolates at different points
of the study that were not persistent. Participants who had pro-
duced cultures of moxifloxacin-resistant pseudomonas were ex-
cluded from the study. However, participants with moxifloxacin-
sensitive pseudomonas were included. During the 24th week of
the study, themedianMIC ofmoxifloxacin had increased to 4mg/
L, which returned to baseline at the end of the treatment period.
The median MIC of the placebo group with pseudomonas-sensi-
tive moxifloxacin increased from 0.5 mg/L to 2 mg/L at the end of
the treatment period. The study authors recommended not using
moxifloxacin in patients with known pseudomonas colonisation
owing to the possibility of developing rapid resistance.
Seemungal 2008 investigated 109 participants with twice daily
erythromycin 250 mg over a 12-month period. They encountered
only one participant who developed resistance to S. pneumoniae at
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the end of the treatment period. AllH. influenzae isolated (22/109)
were found to be resistant to erythromycin. The microorganism
milieu was as expected for the COPD population: H. influenzae
(N = 22/36), S. pneumoniae (N = 6/36) and M. catarrhalis (N =
3/36).
The other two studies, (Banerjee 2005 using long-acting clar-
ithromycin 500 mg daily (Klaricid XL 500 mg) and He 2010
using erythromycin 125 mg every eight hours), found a similar
milieu of respiratory pathogens. They did not observe significant
differences in the colonisation rate of the organisms or emergence
of resistance. However, these two studies were of a shorter dura-
tion than those mentioned above, six months and three months,
respectively.
Subgroup and sensitivity analyses
Subgroup analyses
We performed subgroup analysis on our primary outcome only:
number of people with one ormore exacerbations.We subgrouped
studies according tomeanbaseline FEV1%predicted but only one
study was included in the > 50% predicted subgroup and thus we
cannot draw any conclusions from this analysis (Analysis 2.1). We
did not find any statistically significant impact of study duration
(three to six months, six to 12 months and over 12 months) on
this outcome (Analysis 2.2). We subgrouped studies according to
their date of publication in five-year groups from 2005 to 2009,
2010 to 2014 and 2015 onwards (Analysis 2.3). Six out of the
eight studies appearing in this analysis were published between
2010 and 2014, so again, this analysis was inconclusive. When
subgrouped according to frequency of antibiotic administration
(once daily, 2 to 3 times daily, 2 to 3 times per week and pulsed),
there was some evidence that pulsed antibiotics were less effective
than regimens that require more frequent dosing, in keeping with
our other findings (Analysis 2.4; test for subgroup differences:
Chi² = 9.51, df = 3 (P = 0.02), I² = 68.4%). Finally, we did
not find a statistically significant subgroup difference when we
grouped studies according to exacerbation history as an inclusion
criterion (studies inwhich participantswere required tohave had at
least one exacerbation in the preceding year versus those in which
exacerbation history was not an inclusion criterion) (Analysis 2.5).
However, it should be noted that many of the studies included
in the second subgroup recruited participants who had a positive
exacerbation history, despite it not being a requirement for study
entry.
Sensitivity analyses
We applied our sensitivity analysis to our primary outcome only:
number of people with one ormore exacerbations. This resulted in
the removal of all three arms of the single-blind study Brill 2015.
This had a minimal impact on the effect estimate (0.54, 95% CI
0.38 to 0.77 versus OR 0.57, 95% CI 0.42 to 0.78).
D I S C U S S I O N
Summary of main results
In this review, we analysed a total of 14 completed studies, in-
volving 3932 participants, that investigated the use of prophy-
lactic antibiotics for the prevention of COPD exacerbations. All
participants were adult (over the age of 40 years), with the mean
age between 65 and 72 years. Most participants had at least
moderate-severity COPD and we only included studies if they
confirmed this diagnosis with spirometry. The antibiotics inves-
tigated were azithromycin, erythromycin, clarithromycin, doxy-
cyline, roxithromycin, and moxifloxacin. Nine studies involving
1925 participants investigated continuous macrolide antibiotic
regimens, two studies involving 176 participants investigated in-
termittent azithromycin antibiotic regimens (administered three
times a week), two studies involving 1732 participants investi-
gated different pulsed antibiotic regimens (one macrolide and
one quinolone) and one study involving 99 participants com-
pared three treatment arms with placebo; one continuous doxy-
cycline regimen, one intermittent azithromycin regimen and one
pulsed moxifloxacin regimen. The study duration varied from
three months to 36 months and all used intention-to-treat analy-
sis. Most of the pooled results were of moderate quality. The risk
of bias of the included studies was generally low, and we did not
downgrade the quality of evidence for risk of bias.
Primary outcomes
Eight studies including 2716 participants were included in the
meta-analysis of the number of people with one or more exacer-
bations (Figure 3). The results of this analysis indicated that the
number of participants experiencing one or more exacerbations
was significantly reduced with the use of prophylactic antibiotics
(OR 0.57, 95% CI 0.42 to 0.78; participants = 2716; studies =
10; I2 = 42%) .The subgroup analysis for this outcome suggested
that there was a statistically significant difference between con-
tinuous and intermittent regimens and pulsed regimens for the
number of people with one or more exacerbations, with pulsed an-
tibiotic regimens having a smaller treatment effect. Similarly, the
rate of exacerbations per patient per year with continuous and in-
termittent antibiotic use were significantly reduced (Analysis 1.4;
moderate-quality evidence). Themedian time to first exacerbation
was lengthened with continuous and intermittent antibiotic pro-
phylaxis (Analysis 1.5), however, only the continuous antibiotic
regimens and one intermittent antibiotic regimen were associated
with statistically significant delays. Pulsed antibiotic prophylaxis
did not appear to be associated with the same benefits.
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Health-related quality of life was explored in nine studies using
different assessment tools, as detailed in the above results. The
results were mixed, with some studies finding no or uncertain im-
provement in quality of life indicators with antibiotic prophylaxis
whilst others found improvement in some quality of life domains.
The most commonly used quality of life scale was the SGRQ.
It was used in seven studies involving 2237 participants and our
meta-analysis suggested a statistically significant benefit in quality
of life total score with antibiotic prophylaxis compared to placebo
(MD -1.94, 95% CI -3.13 to -0.75; participants = 2237; high-
quality evidence) (Analysis 1.9). While this mean difference did
not reach the accepted level of clinical significance (Jones 2009),
a responder analysis carried out in Albert 2011 demonstrated that
more participants in the continuous azithromycin group (43%)
than the placebo group (36%) had at least a four-unit reduction
in the SGRQ (P = 0.03). Again, with subgroup analysis, where
an improvement in quality of life was identified, it appeared to be
with continuous and intermittent antibiotic prophylaxis. No clear
improvement was found with pulsed antibiotic regimens.
Secondary outcomes
One study, Suzuki 2001, found a statistically significant reduction
in hospital admissions with prophylactic erythromycin use, whilst
three other studies found no significant reduction in hospital ad-
missions (Albert 2011; Mygind 2010; Sethi 2010). There was no
statistically significant difference between antibiotic prophylaxis
and placebo in FEV1, all-cause mortality, or adverse events (mod-
erate-quality evidence) but, for both mortality and adverse events,
confidence intervals were too wide to rule out an effect. However,
specific adverse events reported in some of the studies may have
clinical relevance, given their severity.
The 6MWT was used to measure the functional capacity in two
studies in the meta-analysis involving 126 participants (Analysis
1.23). One study, considered to be at high risk of bias (Tan 2016)
investigated continuous antibiotics and demonstrated a statisti-
cally significant benefit in the 6MWT (MD 84.5 m (45.7 to
123.29) with use of antibiotics whilst the result was uncertain in
a study using intermittent antibiotics (Uzun 2014).
The development of antibiotic resistance was addressed in six stud-
ies involving 2486 participants. Due to the multitude of method-
ologies used to detect and report resistance, the data were not
able to be pooled in a meta-analysis. Of concern, four of these
six studies identified evidence of antibiotic resistance. However,
there was not sufficient evidence for us to predict how the use of
prophylactic antibiotics would affect the resistance patterns in the
community and studies with a longer duration of follow-up will
be required to assess this further.
Overall completeness and applicability of
evidence
The participants in the studies in this review were aged 40 years
or over (mean age, 67 years) and had at least moderate-severity
COPD (mean FEV1 1.2 L). Three studies (Albert 2011; Mygind
2010; Sethi 2010) included participants who experienced one to
two exacerbations during the previous year. Uzun 2014 included
participants who had experienced three exacerbations within the
last year. Albert 2011 and Sethi 2010 included participants who
were on long-term supplemental oxygen or systemic steroids, or
both (see Characteristics of included studies, Summary of findings
for the main comparison). Hence, the results can be generalised
only to this group of participants who are at the more severe end
of the COPD spectrum. Such participants may also be more likely
to be receiving high-dose ICS, which have been associated with
an increased risk of pneumonia (Kew 2014). This may further
decrease generalisability to broader COPD populations.
Data fromAlbert 2011 suggested that prophylactic antibioticsmay
bemost useful in patients who have given up smoking, who are not
on any inhaler treatment (long-acting beta agonist (LABA), long-
acting muscarinic antagonist (LAMA), or inhaled corticosteroid
(ICS) in any combination), on oxygen therapy, or older than 65
years.
Although these results were obtained from prespecified subgroup
analyses, the sample sizes were much smaller than the randomised
sample size. There were 22 analyses carried out giving a 62%
chance of one analysis yielding a statistically significant result. For
this reason, the authors are aware that theremay be false positives in
these results and recommend additional studies that are adequately
powered to explore these subgroups.
It is also important to note that the study participants had un-
dergone strict exclusion criteria. Participants with tachycardia, ar-
rhythmia, longQTc, as well as being onmedication that could po-
tentially increase the QTc (a long list), or baseline hearing deficit
based on audiometry were excluded. Participants will likely have
been excluded from the trial if they were currently prescribed an
interacting medication that could not be stopped or substituted
and this may have further limited the applicability of the evidence
to the wider COPD population. There was regular monitoring
throughout the study period and drugs were discontinued in the
event of a significant adverse event. Furthermore, only two studies
(Albert 2011 and Uzun 2014) performed CT chest to screen for
participants with underlying bronchiectasis. This is a drawback
as, although this review had a strict criteria for COPD diagnosis,
many people with COPD (estimates range from 4% to 72%), es-
pecially those with recurrent infections, have a degree of under-
lying bronchiectasis (Martinez-Garcia 2017). Therefore, identify-
ing the group with bronchiectasis and analysing this group as a
subgroup would have given us valuable information on whether
the group would benefit more from prophylactic antibiotics. Fur-
thermore, it is not clear from the studies the extent to which par-
ticipants had other treatments for their COPD optimised (for ex-
ample, smoking cessation programmes, pulmonary rehabilitation,
vaccination).
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In current clinical practice, prophylactic antibiotics tend to be used
as a last resort because of concerns about antibiotic resistance in
the community. If an informed decision is made to start prophy-
lactic antibiotics in a particular patient, there needs to be baseline
checks to confirm the identity of the infection (for example, spu-
tum cultures), ECG, and consideration of audiometry, depending
on the planned antibiotic, as well as ongoing monitoring of the
same.
Although all the included studies were conducted in the last 20
years, even over this time period, the care of people with COPD
has changed markedly, as evidenced by regular guideline updates
(GOLD 2018). The threshold for both admission and duration of
hospital stay once admitted has changed and more care is carried
out at home inmany settings. For example, a retrospective analysis
of data in theUK suggested that themean duration of hospital stay
for an emergency admission with COPD fell by approximately
one day between 2006 and 2010, in keeping with international
trends (Harries 2015).
A further limitation of the evidence presented is that most of the
included studies measured outcomes at or soon after discontinu-
ation of antibiotics. We therefore cannot comment on any possi-
ble prolonged benefits or harms which might extend beyond the
treatment period. Furthermore, drug interactions may also require
consideration, particularly as macrolide antibiotics may interact
with other commonly prescribed drugs in the COPD population,
such as statins and theophylline (BNF 2018).
Finally, the analyses of continuous and intermittent antibiotics
were dominated by macrolide antibiotics (e.g. azithromycin and
erythromycin). The majority of the evidence for pulsed antibiotics
was contributed by studies of moxifloxacin, a quinolone. There-
fore, care should be taken when drawing conclusions about the
relative efficacy of continuous, intermittent and pulsed regimens
as this comparison is confounded by the different classes of an-
tibiotic used in the studies.
Quality of the evidence
Overall, we graded the quality of the evidence to be moderate,
meaning “further research is likely to have an important impact
on our confidence in the estimate of effect and may change the
estimate”. We presented our grade ratings in Summary of findings
for the main comparison.
We downgraded three outcomes (mortality, serious adverse events,
and all adverse events) for imprecision; the confidence intervals
were not sufficiently narrow enough to rule out a potentially im-
portant effect. We downgraded two outcomes (number of partic-
ipants with one or more exacerbations and exacerbation rate) for
inconsistency; the I2 was greater than 50% in both analyses. We
downgraded FEV1 (mL) for indirectness as the studies contribut-
ing the majority of the weight in this analysis were of short dura-
tion. We were not able to create a funnel plot as no analyses con-
tained 10 unique studies, so publication bias could not be formally
assessed. Finally, while we rated four studies to be at high risk of
bias in at least one domain, the overall methodological quality of
the studies contributing data to the meta-analyses was good, and
therefore we did not downgrade any outcome for risk of bias.
Potential biases in the review process
We attempted to minimise bias during the review process by com-
pleting a comprehensive electronic search of all published and un-
published data, as well as handsearching the bibliographies from
selected studies. The data were extracted and full-text articles re-
viewed by three authors with disagreement being resolved by dis-
cussion.
However, not all included studies clearly described the criteria used
to diagnose an acute exacerbation of COPD. This may have led
to us combining results from studies in which different criteria
were used, whichmay impact the interpretability of these analyses.
Furthermore, exacerbation rates in COPD vary markedly between
seasons; shorter studies may therefore fail to accurately reflect the
true year-round exacerbation burden. In addition, our categorisa-
tion of continuous, intermittent, and pulsed regimens was a post
hoc decision for the 2018 update, although taken before data anal-
ysis. We recognise that, due to sustained tissue concentrations of
azithromycin, a three times a week regimen could be considered
essentially continuous (Matzneller 2013). Despite this, we suggest
that intermittent regimens have different implications for patient
adherence and costs and therefore maintained these subgroups for
analysis.
Agreements and disagreements with other
studies or reviews
Our findings are consistent with an earlier Cochrane review of pro-
phylactic antibiotics in chronic bronchitis (Staykova 2003), even
though the definitions of cases are tighter in the present review.
The study findings further strengthen and are in line with the find-
ings of the previous version of this Cochrane review, published in
2013 (Herath 2013).
A case-based review article in the New England Journal of
Medicine (NEJM) on antibiotic prevention of acute exacerbations
ofCOPDrecommends the use of azithromycin 250mg three times
a week to reduce exacerbation frequency in patients on maximal
COPD treatment who were still having two or more exacerbations
per year (Wenzel 2012). Careful selection, prior investigations,
and proper follow-up were emphasised, which is concordant with
our findings and recommendations.
A U T H O R S ’ C O N C L U S I O N S
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Implications for practice
Use of prophylactic macrolide antibiotics for a period of up to 12
months is likely to reduce the number of patients with one or more
exacerbations, exacerbation frequency, increase themedian time to
first exacerbation and improve health-related quality of life. Bene-
fits appear to be driven by continuous and intermittent macrolide
regimens, with pulsed regimens being less effective. However, the
benefits need to be balanced against the risk of harm, notably an-
tibiotic resistance, and the cost and adherence implications for the
patient and the health care system, as well as potential costs of
monitoring for adverse effects.
Reducing the frequency of exacerbations would reduce healthcare
costs and might be expected to preserve lung function and quality
of life, as well as lower the risk of mortality, although we did not
find evidence of any of the latter in this review. In part, this is
due to the dearth of studies that have addressed the frequency and
duration of hospital admissions and the relatively small numbers
of participants in most of the studies; that is, the studies were
underpowered tomeasure these outcomes.Themore recent studies
did not address the days of disability or hospital admissions and
therefore there was no additional contribution in this area since
the 2013 review.
The benefit in prevention of exacerbations was seen in the type of
participants that were included in the studies. These participants
had at least moderately severe COPD and were mostly frequent
exacerbators. Evidence available from a single study suggests that
individuals over 65 years benefitedmore than younger individuals.
Hence, carefully identifying the patient group that would benefit
most from the use of prophylactic antibiotics is of paramount
importance.
Although the selection of patients for prophylactic antibiotics is
critical, the evidence base for making statements about patient se-
lection is poor since not all studies have used the same selection
criteria, only three studies used frequent exacerbations as an in-
clusion criterion, and only two studies screened for bronchiectasis
with CT imaging.
There are some potentially serious adverse effects with prophylac-
tic antibiotics. Furthermore, development of antibiotic resistance
remains of major concern. This is particularly so for those pa-
tients colonised with pseudomonas. More broadly, there are calls
worldwide to reduce the total amount of antibiotics prescribed.
Hence, even though the NNTs to prevent one person having an
exacerbation were relatively small, this has to be balanced with the
risks of harm either to that individual or indirectly to others via
antibiotic resistance. So far, the evidence suggests that, with the
use of prophylactic antibiotics, the sputum bacterial load reduces.
However, included studies reported that, in participants with on-
going bacterial isolation, the isolates had increased resistance to
the given antibiotic, sometimes demonstrating aMIC with a four-
fold rise at the end of the study period. One study that had follow-
up to 36 months had demonstrated that the rise in MIC may be
transient and may return to baseline with cessation of antibiotics
during the follow-up period. Therefore, there remains uncertainty
about the long-term effects of the use of prophylactic antibiotics
in the bacterial milieu in the community in terms of developing
persistent resistance in this era of constant fear of developing ’su-
per-bugs’.
Implications for research
While there is a growing body of evidence to support the use of
prophylactic antibiotics in people with COPD, better identifica-
tion of the subsets of patients who would benefit most would be
of great value in future research, so as to deliver targeted treat-
ment to the right patient. Future trialists should ensure that the
study population is well characterised, with a particular focus on
the potential effect modifiers of prophylactic antibiotic therapy,
including underlying bronchiectasis, exacerbation frequency, bac-
terial colonisation, and baseline FEV1. Future studies that incor-
porate potential biomarkers might be useful for patient selection.
Importantly, participants in all arms of clinical studies of prophy-
lactic antibiotics should receive the full package of evidence-based
interventions in COPD, as well as the study interventions.
At present, there is a larger body of data available for the use of
continuous antibiotic use and their benefit in comparison to in-
termittent or pulsed antibiotics. It would be worthwhile explor-
ing the benefit of intermittent or pulsed antibiotics further as ad-
ministering them less frequently may improve patient adherence,
reduce adverse effects, and costs to both the patient and health-
care systems.Head-to-head comparisons of pulsed versus intermit-
tent versus continuous antibiotics would be useful in this context.
Furthermore, shorter placebo-controlled studies through winter
months, when exacerbations are more common, might be useful
to determine if this is a pragmatic strategy. Regimens which focus
on winter months only might also improve adherence and reduce
costs, but this needs to be tested in a trial setting.
Duration of hospital admissions and days of disability due to an
exacerbation were not well addressed in the studies. Future studies
should document these outcomes. Additionally, a cost-effective-
ness analysis would be useful. Most of the costs in severe COPD
are related to hospitalisation. On the face of it, antibiotics may
be cheaper than some inhalers, but there are hidden costs, such as
the cost of screening for adverse effects and the direct and indirect
costs of antimicrobial resistance.
A challenge is how to balance the benefits of antibiotic therapy to
the individual over the potential harms to the community through
antibiotic resistance. The maximal duration of continuous pro-
phylactic antibiotics was 12 months, and for pulsed antibiotics it
was 36 months. Hence, there are no data on the impact of very
long-term antibiotic use on antibiotic resistance patterns in the
community. The latter will require local surveillance and the cor-
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relation of resistance and prescribing patterns. This will help us
understand if the higher MIC noted during the use of prophy-
lactic antibiotics would return to baseline when antibiotics were
discontinued and after how long, which would enable us to de-
termine the need for ’breaks’ from treatment, as well as determine
the duration of these ’breaks’. If persistent resistance patterns are
identified despite these measures, this would increase the need for
caution in the use of prophylactic antibiotics. Furthermore, mod-
elling of resistance detected in trials at a population level might be
a useful approach.
Yet to be determined is whether prophylactic antibiotics are able
to alter the rate of deterioration of lung function in COPD and,
if they do, whether this is due to antibiotic or anti-inflammatory
effects. This would be a helpful advance in the understanding
of the pathophysiology of this common and debilitating disease.
Long-term follow-up studies of participants who have been in
prophylactic antibiotic studies may help to answer these questions.
Identifing biomarkers of inflammation in these patients would
also help if antibiotics with anti-inflammatory effects work better
in this group.
Future studies directed at the use of inhaled antibiotics, which
may result in fewer systemic effects and higher local concentra-
tions, would be useful in reducing potential side effects of oral
prophylactic antibiotic therapy. Such studies were excluded from
this review.
Studies looking into continuous or intermittent antibiotic therapy
in clear relation to other interventions that are useful for frequent
exacerbators would help determine the advantages and disadvan-
tages of antibiotic therapy over the already established measures
used to reduce exacerbations. The subgroup analysis conducted
of one of the included studies (Albert 2011) suggests that further
exploration of the modifying effect of baseline treatments such as
LAMA, LABA, and ICS is warranted.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Albert 2011
Methods Prospective, randomised, double-blind, placebo-controlled clinical trial with 12-month
treatment duration
Intention-to-treat analysis
Participants N = 1142. Aged 40 years or over. Mean age (years): 65 (azithromycin) and 66 (placebo)
41% female
Severity of COPD: moderate or worse as defined by GOLD criteria
Mean FEV1 (L): 1.10 (SD 0.50) (azithromycin) and 1.12 (SD 0.52) (placebo)
Presence of either a) using continuous supplemental oxygen, or b) received systemic
glucocorticoids within the previous year/had gone to an emergency room/hospitalisation
for an acute exacerbation
No acute exacerbation of COPD for at least 4 weeks
Exclusions: asthma, resting heart rate > 100/min, prolonged QT interval > 450 ms, using
medications that prolong QTc, hearing impairment documented by audiometry
Interventions Prophylaxis:
1. Azithromycin 250 mg daily
2. Placebo
Outcomes Primary:
1. Time to the first acute exacerbation of COPD
Secondary:
1. Quality of life
2. Nasopharyngeal colonisation of selected respiratory pathogens
3. Compliance to the treatment
4. Adverse events
Notes Funding: Grants listed from National Institutes of Health
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The stratified random sequence generation
was well described in the journal article
under “protocol”: “Randomization will be
carried out by linking to the Data Coordi-
nating Center through a website, (http://
www.copdcrn.org)”
Allocation concealment (selection bias) Low risk Well explained. Central allocation was
pharmacy controlled: “Only the pharma-
cist and the staff of the Data Coordinating
Center knew this schedule and the phar-
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Albert 2011 (Continued)
macists could not know the actual assign-
ment until after the DCC specified an ac-
cession number. Treatment assignment was
only disclosed in cases of emergency.”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Active drug and placebo will be identical
in appearance. Both participants and treat-
ing medical staff were blinded: “The ac-
tual assignment will only be revealed in
cases of emergencies where caregivers need
to know what drugs the person was taking
to provide treatment, or to avoid prescrib-
ing other medications that might adversely
interact with the study drug. Active-drug
and placebo capsules will be identical in ap-
pearance.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Trial staff were unaware of the randomi-
sation: “Clinic staff (who undertook out-
come assessment) will make no attempt to
determine the content of any capsules ex-
cept in cases of emergency”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk All outcome data accounted for in a consort
diagram for the entire study
However, data on the secondary outcome
(HRQoL) had reported loss to follow-up
of 20% in the prophylactic antibiotic arm
and 18% on the placebo arm. The reasons
for the missing data pertaining to HRQoL
were not given
Selective reporting (reporting bias) Low risk All prespecified outcomes have been re-
ported
Other bias Low risk No other bias identified
Banerjee 2005
Methods Prospective, randomised, double-blind, placebo-controlled clinical trial. Treatment du-
ration of 3 months. Intention-to-treat analysis
Participants N = 67
Mean age (years): 65.1 (clarithromycin) and 68.1 (placebo)
Mean FEV1 (L): 1.12 (clarithromycin) and 1.13 (placebo)
Severity of COPD: moderate or worse according to BTS guidelines. All participants were
taking ICS
Patients enrolled from hospital clinics
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Banerjee 2005 (Continued)
No acute exacerbations of COPD over the last 6 weeks
Exclusions: Previous documented allergies tomacrolides; a clinical history of lung cancer,
asthma or bronchiectasis
Interventions Prophylaxis:
1. Clarithromycin (long-acting Klaricid XL 500 mg/daily)
2. Placebo
Outcomes Primary:
1. Health-related quality of life
Secondary:
1. Infective exacerbation rate
2. Shuttle walk test
3. Serum CRP level
4. Sputum bacterial quantities load
Notes Funding: Received grant support from Abbott Pharmaceuticals
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Block randomisationwas carried out: “Sub-
jects were then block randomised into a
prospective, double-blind controlled study.
.. Patients were randomised by the Birm-
inghamHeartlands Hospital pharmacy de-
partment, independent of trial staff ”
Allocation concealment (selection bias) Low risk Participant randomisation was not known
to the trial staff. Randomisation carried
out by the BirminghamHospital pharmacy
department: “Patients were randomised
by the Birmingham Heartlands Hospital
pharmacy department, independent of trial
staff ”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind placebo-controlled study
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Trial staff were unaware of the alloca-
tion, but blinding of outcome assessors not
clearly described
Incomplete outcome data (attrition bias)
All outcomes
Low risk All outcome data described
Selective reporting (reporting bias) Low risk All prespecified outcomes were reported
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Banerjee 2005 (Continued)
Other bias Low risk No other bias identified
Berkhof 2013
Methods Prospective, randomised, double-blind, placebo-controlled clinical trial. Treatment du-
ration of 12 weeks; 6-week post-treatment follow-up
Intention-to-treat analysis
Participants N = 84. Aged 40 years or over. Mean age (years): 67 (azithromycin) and 68 (placebo)
Female: 26% (azithromycin) and 24% (placebo)
Mean FEV1 % predicted: 49.8 (SD 16.4) (azithromycin) and 47.4 (SD 12.9) (placebo)
Clinical diagnosis of COPD:GOLDstage≥ 2 (defined as a post bronchodilator of FEV1
< 80% and a ratio of FEV1/FVC < 70%), and were suffering from chronic productive
cough, defined as cough for at least the last 12 weeks, in two subsequent years
Exclusions: prior history of asthma; use of intravenous or OCS and/or antibiotics for
an exacerbation three weeks before inclusion; other relevant lung or liver diseases at the
discretion of the treating physician; pregnancy or lactation; use of macrolides in the
last six weeks prior to inclusion; allergy or intolerance to macrolides; or use of other
investigational medication started two months prior to inclusion
Interventions Prophylaxis:
1. Azithromycin 250 mg 3 times a week
2. Placebo
Outcomes Primary:
1. mean LCQ total and domain scores
Seondary:
1. SGRQ total score
2. SF-36 score
3. Post-bronchodilator spirometry
4. Blood values
5. Microbiology
6. Time to first exacerbation of COPD
7. Exacerbations
8. Hospitalizations for COPD
9. Adverse events
Notes Funding: “We want to thank Stichting Astma Bestrijding (SAB) for financial support.”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Randomisation codes were generated us-
ing a computer allocation program, with a
1:1 ratio and a permutated block size of 4.
”
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Berkhof 2013 (Continued)
Allocation concealment (selection bias) Unclear risk Not specifically described, but probably
done
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Investigators, research nurses, and partici-
pants were masked to treatment allocation
until final analyses of the data were per-
formed”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Investigators, research nurses, and partici-
pants were masked to treatment allocation
until final analyses of the data were per-
formed”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Dropout low and balanced. All participants
accounted for in flow diagram
Selective reporting (reporting bias) Low risk FEV1 measured but not reported in a way
allowing inclusion in meta-analysis in the
published paper, but authors supplied ad-
ditional data on request
Other bias Low risk No other bias identified
Brill 2015
Methods Prospective, randomised, single-blind, placebo-controlled clinical trial. Treatment dura-
tion of 13 weeks
Intention-to-treat analysis
Participants N = 99. Aged 45 to 80 years. Mean age (years) 70.0 (moxifloxacin), 70.4 (doxycyline),
67.9 (azithromycin) and 68.7 (placebo)
Female: 32%(moxifloxacin), 28%(doxycyline), 36%(azithromycin), and25%(placebo)
Mean FEV1 % predicted: 52 (SD 13) (moxifloxacin), 53 (SD 14) (doxycyline), 44 (SD
17), (azithromycin), and 53 (SD 13) (placebo)
Stable patients with chronic bronchitis (self-reported sputum expectoration onmost days
when clinically stable) and spirometrically-confirmed COPD (defined by FEV1 < 80%
predicted, FEV1 to FVC ratio < 0.7, and a history of smoking)
Exclusions: patients who reported either treatment for an exacerbation, an episode of
symptoms worsening in the 4 weeks prior to screening, or were unable to enrol for safety
reasons (significant hepatic/renal impairment, QT prolongation, pre-existing long-term
antibiotic use, and hypersensitivity to the treatments under investigation)
Interventions Prophylaxis:
1. Moxifloxacin 400 mg daily for 5 days every 4 weeks
2. Doxycyline 100 mg daily
3. Azithromycin 250 mg 3 times a week
4. Placebo
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Brill 2015 (Continued)
Outcomes Primary:
1. Change in sputum bacterial load, as assessed by quantitative culture
Secondary:
1. Changes in resistance to the three tested antibiotics
2. Changes in FEV1
3. Adherence to therapy
4, Health status as measured by total SGRQ scores
5. Adverse events
Exploratory:
1. Changes in sputum bacterial load as assessed by 16S rRNA gene-targeted qPCR
2. Changes in sputum inflammation
Notes Funding: funded by the National Institute for Health Research (NIHR) under the Pro-
gramme Grants for Applied Research programme (RP-PG-0109-10056) and the NIHR
Royal Brompton Respiratory Biomedical Research Unit. The moxifloxacin for the study
was provided by Bayer Pharma AG, Berlin, Germany and the study sponsor was Univer-
sity College, London, UK. Neither Bayer, the funder, nor the Sponsor had any influence
in the study design, collection, analysis and interpretation of the data, the writing of the
report, or the decision to submit for publication
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Internet randomisation into groups of 1:1:
1:1 was performed using a computer-gen-
erated permuted block system of variable
sizes (Sealed Envelope, UK)”
Allocation concealment (selection bias) Low risk “Internet randomisation into groups of 1:1:
1:1 was performed using a computer-gen-
erated permuted block system of variable
sizes (Sealed Envelope, UK). Participants
remained blinded to treatment allocation”
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “Patients remained blinded to treatment al-
location”. However, not clear if study per-
sonnel were blinded. Described as single-
blind study
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No description of outcome assessor blind-
ing, although blinded participants assessed
outcomes such as quality of life
Incomplete outcome data (attrition bias)
All outcomes
Low risk Dropout low and balanced. All participants
accounted for in flow diagram
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Brill 2015 (Continued)
Selective reporting (reporting bias) Low risk Planned outcomes according to trial regis-
tration relevant to this review reported
Other bias Low risk No other bias identified
He 2010
Methods Prospective, randomised, double-blind, placebo-controlled clinical trial. Treatment du-
ration was 6 months. Intention-to-treat analysis
Participants N = 36. Participants were 40 years or older. Mean age (years): 68.8 (erythromycin) and
69.3 (placebo)
Females: 17% (erythromycin) versus 10% (placebo)
FEV1 between 30% to 70% predicted. Mean FEV1 (L): 1.12 (erythromycin) versus 1.
02 (placebo)
At least 10 pack/year smoking history
No acute exacerbations during the previous 1 month
Exclusions: patients with significant other respiratory disorders other than COPD; his-
tory of unstable cardiovascular disease; hypersensitivity to macrolides
Interventions Prophylaxis:
1. Erythromycin 125 mg 3 times a day
2. Placebo
Outcomes Primary:
1. Number of acute COPD exacerbations
2. Neutrophil count in sputum
Secondary:
1. Quality of life
2. Spirometry
Notes Funding: not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation done but not clearly ex-
plained: “Eligible participants were ran-
domly assigned to receive oral ery-
thromycin....or placebo for 6 months.”
Allocation concealment (selection bias) Unclear risk Allocation concealment was not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Described as a double-blind trial: “Eligible
participants were randomly assigned to re-
ceive oral erythromycin....or placebo for 6
months.”
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He 2010 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Blinding of outcomes assessors was not de-
scribed
Incomplete outcome data (attrition bias)
All outcomes
Low risk All outcome data described using a CON-
SORT diagram
Selective reporting (reporting bias) Low risk All prespecified outcomes were reported
Other bias Low risk No other bias identified
Mygind 2010
Methods Prospective, randomised, placebo-controlled double-blind study. Treatment duration
was 36 months. Intention-to-treat analysis
Participants N = 575. Aged > 50 years
Severity of COPD was moderate or severe with FEV1 < 60% predicted. Mean FEV1
(L) was 0.9 (both treatment and placebo arms)
At least one admission to hospital with exacerbation of COPD
Ex or current smokers
Exclusions: end stage COPD patients (if not expected to survive over 3 years), or bedrid-
den patients; patients with a history of asthma, bronchiectasis, or other significant res-
piratory disease; history of azithromycin allergy; patients with heart, liver or renal insuf-
ficiency; already receiving prophylactic antibiotic
Interventions Intermittent prophylaxis:
1. Azithromycin 500 mg/daily for 3 days every months, for 36 months
2. Placebo daily for 3 days every month, for 36 months
Outcomes Primary:
1. Rate of decline in lung function (FEV1)
Secondary:
1. Frequency of exacerbation
2. Health-related quality of life (SGRQ)
3. Adverse events
4. Mortality
5. Duration of exacerbations
6. Number of days of hospitalisation
7. Frequency of hospitalisation
Notes Funding: not stated
Risk of bias
Bias Authors’ judgement Support for judgement
43Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD) (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Mygind 2010 (Continued)
Random sequence generation (selection
bias)
Unclear risk Described as “randomised” but method of
sequence generation not described
Allocation concealment (selection bias) Unclear risk Allocation concealment was not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Described as a “double-blind study”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Blinding of outcomes assessors was not de-
scribed
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk All outcome data were presented. Only
55% completed 3 years
Selective reporting (reporting bias) Low risk All prespecified outcomes were reported
Other bias Unclear risk This was a conference presentation and not
a full publication. Attempts to contact the
authors were not successful. Only limited
data are available for evaluation of the risk
of bias
NCT00524095
Methods Prospective, randomised, controlled cross-over trial. Open-label. Planned 52 weeks treat-
ment duration
Participants Planned recruitment of 210 participants aged 45 to 85 years
Smokers or former smokers of at least 10 pack-years, COPD demonstrated by forced
spirometry with FEV1 > 0.7 L, FEV1 post-bronchodilator < 60% and FEV1/FVC <
70%, bronchodilator test performed at inclusion or no more than 6 months before
inclusion should have been negative (increase in FEV1 < 200 mL and 12%, 10 minutes
after administration of 2 puffs of salbutamol). Stable phase defined by clinical criteria of
the attending investigator, but at least 6 weeks from the last exacerbation
Exclusions: receivingOCS at any dose or another immunosuppressor, formal contraindi-
cation for sputum collection, or impossibility to obtain a sample of sputum valid for
analysis, allergy to steroids or macrolides
Interventions Prophylaxis:
1. Azithromycin 500 mg 3 times a week for 6 months and then inhaled steroids (fluti-
casone 500 µg twice a day) for 6 months
2. Inhaled steroids (fluticasone 500 µg twice a day) for 6 months and then azithromycin
500 mg 3 times a week for 6 months
3. Usual care
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NCT00524095 (Continued)
Outcomes Primary
1. Effects of treatments on bronchial inflammation parameters
Secondary:
2. Effects of treatments on exacerbations frequency (time frame: six months)
3. Effects of treatments on pulmonary function (time frame: six months)
Notes NB: study terminated before treatment phase. Reason not given
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not assessed as study terminated before
treatment phase
Allocation concealment (selection bias) Unclear risk Not assessed as study terminated before
treatment phase
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not assessed as study terminated before
treatment phase
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not assessed as study terminated before
treatment phase
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not assessed as study terminated before
treatment phase
Selective reporting (reporting bias) Unclear risk Not assessed as study terminated before
treatment phase
Other bias Unclear risk Not assessed as study terminated before
treatment phase
NCT02628769
Methods Prospective, randomised, controlled double-blind cross-over trial. Planned 12 weeks
treatment duration
Participants N = 5. Aged 45 years and older
History of cigarette smoking > 10 pack-years, post-bronchodilator FEV1/FVC of < 0.
70 and FEV1 of 30% to 79% of predicted normal value, nonpregnant females, willing
and able to comply with all study visits and procedures, a suitable candidate for oral
therapy and be able to swallow capsules intact, no evidence of active bacterial infection
in sputum by qPCR evaluation
Exclusions: acute exacerbation of COPD within the previous 60 days or during the
washout period of the study, any condition that could possibly affect oral drug absorption,
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NCT02628769 (Continued)
currently taking medication for HIV, chronic hepatitis B, or hepatitis C virus infection,
currently taking theophylline or other xanthine medication, currently taking warfarin,
known concomitant infection, QTc greater than 450 msec for males or females as cor-
rected by the Fridericia formula, current use of drugs known to prolong the QT interval,
concomitant use of drugs, foods, or herbal products known to be moderate to potent in-
hibitors of CYP3A4 isozymes, any use within the prior 7 days of drugs or herbal products
known to be moderate to potent inducers of CYP3A4 isozymes, required current use of
drugs with narrow therapeutic indices that are principally metabolised by CYP3A4 or
transported by P-glycoprotein, for which a drug interaction with solithromycin could
result in higher and possibly unsafe exposures to these drugs, history of organ transplant,
cytotoxic chemotherapy or radiation therapy within the previous 3 months, known neu-
romuscular disorder from clinical history, known significant renal, hepatic, or haemato-
logic impairment, any investigational drugs taken or investigational devices used within
4 weeks before administration of the first dose of the study drug, history of intolerance or
hypersensitivity to macrolide antibiotics, any concomitant condition that, in the opin-
ion of the Investigator, would preclude an evaluation of a response or make it unlikely
that the contemplated course of therapy and follow-up could be completed (e.g. life
expectancy < 30 days)
Interventions Prophylaxis:
1. Solithromycin 400 mg daily
2. Placebo
Outcomes Primary:
1. Number of sputum neutrophils per mL
Secondary:
1. Sputum chemokines
2. Concentrations of CXCL8 in nasal lining fluid
3. FEV1
4. R5 to R20 (assessed by impulse oscillometry)
5. CAT scores
6. Adverse events
Exploratory:
1. Activity of HDAC2 in sputum macrophages from participants
2. Activity of PI3K in sputum macrophages from participants
3. Activity of NF-κB in sputum macrophages from participants
4. Levels of the serum CRP
5. Levels of serum biomarkers fibrinogen
Notes NB: study terminated after enrolment of 5 participants due to hepatotoxicity of the
study drug
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not assessed as study terminated after en-
rolment of 5 participants
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NCT02628769 (Continued)
Allocation concealment (selection bias) Unclear risk Not assessed as study terminated after en-
rolment of 5 participants
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not assessed as study terminated after en-
rolment of 5 participants
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not assessed as study terminated after en-
rolment of 5 participants
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not assessed as study terminated after en-
rolment of 5 participants
Selective reporting (reporting bias) Unclear risk Not assessed as study terminated after en-
rolment of 5 participants
Other bias Unclear risk Not assessed as study terminated after en-
rolment of 5 participants
Seemungal 2008
Methods Prospective, randomised, double-blind, placebo-controlled clinical trial with 12 month
follow-up
Participants N = 109. Participants recruited from outpatient chest clinic from a single centre
Mean age (years): 66 (erythromycin) and 68 (placebo)
Females: 38% (erythromycin) and 36% (placebo)
Severity of COPDwas moderate to severe. FEV1 between 30% to 70% predicted. Mean
FEV1 (L): 1.27 (erythromycin) and 1.36 (placebo)
Exclusions: history of asthma, bronchiectasis, neoplasia, unstable cardiac status (includ-
ing prolonged QTc and arrhythmias), macrolide allergy, or history of abnormal liver
functions
Interventions Prophylaxis:
1. Erythromycin 250 mg twice daily
2. Placebo
Outcomes Primary:
1. Exacerbation frequency
2. Airway inflammation
Notes Calculated sample size was 115 for 90% power and P value 0.05. However only 109
participants were recruited
Funding: British Lung Foundation
Risk of bias
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Seemungal 2008 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated permuted
block random sequence generation carried
out: “Computer-generated randomization.
..Randomization was taken in blocks of 10
(5 placebo, 5 erythromycin)”
Allocation concealment (selection bias) Low risk “Computer-generated ran-
domization numbers were stored in sealed
envelopes.Medication was randomized be-
fore commencement of the study by the
hospital pharmacy, independently of trial
staff, and patients were automatically dis-
pensed the next allocated treatment”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Placebo and erythromycin (250 mg) were
concealed in identical capsules”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Unblinding occurred after data entry”
Incomplete outcome data (attrition bias)
All outcomes
Low risk All outcomes/dropouts explained in a
CONSORT diagram
Selective reporting (reporting bias) Low risk All prespecified outcomes were reported
Other bias Low risk No other bias identified
Sethi 2010
Methods Prospective double-blind randomised placebo-controlled clinical trial. Total treatment
period was 48 weeks
1. Analysis was done using intention-to-treat and per protocol. For this review, only the
results of the intention-to-treat analysis were taken
2. Exacerbation of COPD was defined by two definitions. A primary definition (any
confirmed acute exacerbation of COPD, unconfirmed pneumonia, or any other lower
respiratory tract infections) and a secondary definition (only confirmed exacerbations of
COPD, excluding confirmed/unconfirmed pneumonia and any other lower respiratory
tract infection)
For this review, only the primary definition was used as it was an extended definition
and hence was the more conservative definition
Participants N = 1157. Aged 45 years or over. Severity of COPD was GOLD stage 2 or worse. Had
at least 2 exacerbations requiring treatment with antibiotics and/or oral steroids in the
12 months prior to enrolment
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Sethi 2010 (Continued)
Total follow-up period was 72 weeks. Total treatment period was 48 weeks
Interventions Pulsed prophylaxis:
1. Moxifloxacin 400 mg/daily for 5 days. Treatment repeated every 8 weeks for a total
of 6 courses
2. Placebo daily for 5 days. Treatment repeated every 8 weeks for a total of 6 courses
Outcomes Primary:
1. Frequency of exacerbations
Secondary:
1. HRQoL (assessed using SGRQ)
2. Hospitalisations
3. Mortality
4. Changes in lung function
5. Adverse events
Notes Funding: received grant support from Bayer HealthCare AG
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Described as “randomised” but method of
sequence generation not described
Allocation concealment (selection bias) Unclear risk Allocation concealment was not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Described as “double-blind, placebo-con-
trolled”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Blinding of outcomes assessors was not de-
scribed
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk All outcome data were described using a
CONSORT diagram for the entire study
However, data on the secondary outcome,
HRQoL, had reported loss to follow-up of
12% in the prophylactic antibiotic arm and
10% in the placebo arm. The reasons for
themissingdata pertaining toHRQoLout-
come were not given
Selective reporting (reporting bias) Low risk All prespecified outcomes were well de-
scribed
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Sethi 2010 (Continued)
Other bias Low risk Data were analysed as intention-to-treat as
well as per protocol analysis. Both analyses
were published
Shafuddin 2015
Methods Prospective, randomised, double-blind, placebo-controlled trial. Duration of treatment
13 weeks with 48 week post-treatment follow up
Intention-to-treat analysis
Originally designed to investigate the role antibiotics in eradicating C. pneumoniae in
patients with COPD
Participants N = 292. Aged 45 years and above. Mean age (years): 68.5 (roxithromycin/doxycyline),
67.6 (roxithromycin), and 66.7 (placebo)
Female: 36.6% (roxithromycin/doxycyline), 14.4% (doxycyline), 28.7% (placebo)
Mean FEV1 % predicted, mean: 32.53 (SD 13.55) (roxithromycin/doxycyline), 33.93
(SD 15.3) (doxycyline), 35.8 (SD 15.2) (placebo)
Meeting spirometric criteria for COPD (FEV1 ≤ 70 % predicted, FEV1/FVC ≤ 60
%, reversibility of ≤ 10 % of predicted FEV1 or ≤ 200 mL if predicted FEV1 ≤ 2
L); smoking history ≥ 20 pack years; and at least three confirmed moderate or severe
COPD exacerbations in the past two years (i.e. requiring treatment with antibiotics and/
or OCS and/or hospitalisation), positive serology for C. pneumoniae (IgG antibody titre
≥ 1:64).
Exclusions: pulmonary disease other than COPD; treatment with antibiotics, exacer-
bation or an investigational drug in the four weeks before randomisation; pregnancy
(serum pregnancy test) or breast feeding; history of hypersensitivity to macrolides, tetra-
cyclines, beta-lactams or sulfamethoxazole:trimethoprim; serious cardiovascular, hepatic,
renal or other systemic diseases; known long QT syndrome or corrected QT interval
(QTc) > 450 ms, sick sinus syndrome, bradycardia (< 50 beats per minute) or severe
hypokalaemia; epilepsy; treatment with medicine known to have important interaction
with macrolides or tetracyclines; impaired hepatic function (aspartate aminotransferase
or alanine aminotransferase ≥ 2 times of the upper limit of normal (ULN), alkaline
phosphatase ≥ 1.25 times the ULN, bilirubin > 2 times the ULN and albumin < 30 g/
L); or unlikely to comply
Interventions Prophylaxis:
1. Roxithromycin 300 mg daily plus doxycycline 100 mg daily
2. Roxithromycin 100 mg daily
3. Placebo
Outcomes Primary:
1. COPD exacerbations over 48-week post-treatment period
Secondary
1. COPD exacerbations over the 12-week treatment period and the first and last 24-
week post-treatment periods
2. FEV1 and FVC over 60-week period
3. CRQ scores over 60-week period
4. Adverse events
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Shafuddin 2015 (Continued)
Notes Funding: supported by Sanofi-Aventis Australia Pty Ltd (formallyHoechstMarionRous-
sel Pty Ltd). Sanofi-Aventis had no role in the preparation of this manuscript for publi-
cation
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Each eligible patient was assigned a se-
quential subject number followed by ran-
domisation number provided by Hoechst
Marion Roussel, Australia. Subjects were
supplied with one of the three treatments
according to their randomisation number”.
Clinical trials registry clarified: “computer
sequence generation used for randomisa-
tion of subjects into treatment arms with
1:1:1 ratio”
Allocation concealment (selection bias) Low risk “Each eligible patient was assigned a se-
quential subject number followed by ran-
domisation number provided by Hoechst
Marion Roussel, Australia. Subjects were
supplied with one of the three treatments
according to their randomisation number.
”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Study medication was packed by Hoechst
Marion Roussel in bottles labelled with the
randomisation and batch numbers. The in-
vestigators, pharmacists and subjects were
blinded to the study medication in these
bottles.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Correspondence with trialists confirmed
that all participants, personnel, and out-
come assessors remained blinded until data
had been analysed
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk More participants dropped out of com-
bined antibiotics treatment arm (21 ver-
sus 13 in single antibiotic arm and 10 in
placebo arm), although, according to trial-
ists, reasons were not related to study med-
ication. All participants included in ITT
analysis
Selective reporting (reporting bias) Low risk Planned outcomes according to trial regis-
tration relevant to this review reported
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Shafuddin 2015 (Continued)
Other bias Low risk No other bias identified
Simpson 2014
Methods Prospective, randomised, double-blind, placebo-controlled trial. Duration of treatment
12 weeks with 12 week post-treatment follow up
Intention-to-treat analysis
Participants N = 30. Aged 55 years and above. Mean age (years): 71.7 (azithromycin) and 69.9
(placebo)
Female: 40% (azithromycin) and 33.3% (placebo)
FEV1% predicted, mean: 56.5 (SD 13.7) (azithromycin) and 51.1 (SD 13.7) (placebo)
Adults (males and nonpregnant females) with a doctor’s diagnosis of symptomatic
COPD, post-bronchodilator FEV1/FVC < 70% and FEV1 < 80% and persistent neu-
trophilic bronchitis defined as sputum neutrophil proportion of more than 61% or more
than 162 x 104/mL sputum neutrophils demonstrated on two occasions
Exclusions: no reported exacerbations or alterations in respiratory medications in the
previous 4 weeks, inability to produce an adequate sputum sample, a FEV1 < 0.5 L,
current smoking or having ceased smoking in the past 6months, a knownhypersensitivity
to macrolides, an ECG assessment showing a prolonged QTc interval or an impairment
of liver function
Interventions Prophylaxis:
1. Azithromycin 250 mg daily
2. Placebo
Outcomes Primary:
1. Reduction in sputum CXCL8
Secondary:
1. Change in sputum neutrophil proportion
2. Total bacterial load in sputum
3. Health care utilisation
4. Quality of life (SGRQ)
5. Severe exacerbations
6. Pulmonary function tests
7. Chest computed tomography to measure airway thickness
8. Adverse events
Notes Funding: funded by the National Health and Medical Research Council of Australia
through a project grant, ID 455508 2007-2009. The funders had no role in study design,
data collection and analysis, decision to publish, or preparation of the manuscript
Risk of bias
Bias Authors’ judgement Support for judgement
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Simpson 2014 (Continued)
Random sequence generation (selection
bias)
Low risk “Concealed random allocation was un-
dertaken by a blinded staff member who
took no further part in the study...A ran-
dom numbers table was computer gener-
ated (www.randomization.com) for treat-
ment allocation using permuted blocks of
six and participants were stratified accord-
ing to smoking history (never or previous
smokers).”
Allocation concealment (selection bias) Low risk “Concealed random allocation was under-
taken by a blinded staff member who took
no further part in the study..The active
medication and placebo were prepared and
packaged identically by a compounding
chemist and dispensed by the John Hunter
Hospital pharmacy according to the ran-
dom number table.”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Both participants and study staff were
blinded to the assignment of intervention.
”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The people assessing the outcomes are de-
scribed as blinded in the trial registration
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low and balanced dropout. Reasons for
discontinuation unrelated to study medi-
cation
Selective reporting (reporting bias) Low risk Planned outcomes according to trial regis-
tration relevant to this review reported
Other bias Low risk No other bias identified
Suzuki 2001
Methods Prospective, randomised, placebo-controlled clinical trial. Not blinded
Participants N = 109
Mean age (years): 69 (erythromycin) and 72 (placebo)
Mean FEV1 (L): 1.47 (erythromycin) and 1.30 (placebo)
Females: 13% in erythromycin group versus 18% in placebo group
All study participants were treated with sustained-release theophylline and inhaled anti-
cholinergic agents
Exclusions: patients diagnosed with bronchiectasis or diffuse pan bronchiolitis
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Suzuki 2001 (Continued)
Interventions Prophylaxis:
1. Erythromycin 200 mg to 400 mg/daily
2. Placebo
Outcomes 1. Acute exacerbations of COPD
2. Adverse events
Notes Funding: not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Randomization was performed by a ran-
dom-number table, and the list was held
independently of the investigators”
Allocation concealment (selection bias) Low risk “Randomization was performed by a ran-
dom-number table, and the list was held
independently of the investigators”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “This study was not blinded”.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk “This study was not blinded”.
Incomplete outcome data (attrition bias)
All outcomes
Low risk One participant excluded due to adverse
events of erythromycin, all participants
clearly accounted for
Selective reporting (reporting bias) Low risk All prespecified outcomes were reported
Other bias Low risk No other bias identified
Tan 2016
Methods Prospective, randomised controlled trial. Blinding not stated in main trial report. Treat-
ment duration 52 weeks
Participants N = 54. Age range: 49 to 70 years. Mean age (years): 68.8 (erythromycin, 12 months),
67.3 (erythromycin, 6 months) and 69.3 (control)
Female: 16.7% (erythromycin, 12 months), 5.6% (erythromycin, 6 months) and 11.
1% (control)
Mean FEV1 % predicted: 44.8 (SD 13.9) (erythromycin, 12 months), 46.5 (SD 8.9)
(erythromycin, 6 months), and 42.1 (SD 18.6) (control)
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Tan 2016 (Continued)
Stable COPD outpatients (GOLD stages II-IV of 2006 guidelines: FEV 1 < 80% pre-
dicted and FEV1/FVC < 70% after bronchial relaxation); no acute exacerbation; no
change in therapeutic schedule; and no treatment with any antibiotics or glucocorticoids
in the previous 4 weeks
Exclusions: patients with bronchial asthma, primary bronchiectasis, diffuse panbron-
chiolitis, active tuberculosis, lung cancer, pneumoconiosis, or other lung diseases with
restrictive ventilatory impairment; patients with other serious systemic illnesses such as
cardiovascular, nervous, or endocrine system illnesses, blood, hepatic, or kidney diseases,
and malignant tumours; patients who were not cooperative or were completely unable to
communicate; and patients who experienced serious adverse reactions to erythromycin
Interventions Prophylaxis:
1. Erythromycin 125 mg 3 times a day for 12 months
2. Erythromycin 125 mg 3 times a day for 6 months
3. Control group (no antibiotic treatment)
Outcomes 1. Concentrations of IL-17 and IL-23 in peripheral blood and induced sputum
2. Six-minute walk distance
(Primary and secondary outcomes not specified)
Notes Funding: funded by the National Nature Science Foundation of China (81460009)
and the Guangxi Natural Science Foundation (2015GXNSFAA139189, Z2012077, and
Z2012081)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Participants “randomly di-
vided” but method of sequence generation
not described
Allocation concealment (selection bias) Unclear risk Allocation concealment was not described
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding of participants or personnel
described. Assumed open-label (although
abstract stated double-blind). Authors con-
tacted but no response received to date
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding of outcome assessors de-
scribed. Assumed open-label (although ab-
stract stated double-blind). Authors con-
tacted but no response received to date
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Low and balanced dropout but details not
given of howmany people were analysed at
each time point
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Tan 2016 (Continued)
Selective reporting (reporting bias) Unclear risk No prospective trial registration or proto-
col identified so not clear if outcomes of
interest for this review may have been col-
lected but not reported (e.g. serious adverse
events, exacerbations, quality of life)
Other bias Low risk No additional bias identified
Uzun 2014
Methods Prospective, randomised double-blind placebo-controlled trial. Treatment duration 52
weeks
Intention-to-treat analysis
Participants N = 92. Aged 18 years and above. Mean age (years): 64.7 (azithromycin) and 64.9
(placebo)
Female: 53% (azithromycin) and 60% (placebo)
Mean FEV1 % predicted: 44.2 (SD 19.3) (azithromycin) and 45.0 (SD 19.5) (placebo)
Diagnosis of COPD according to theGOLD guidelines, had received treatment for three
or more exacerbations of COPD in the previous year for which they received steroids or
antibiotic treatment, clinically stable, and could not have had a COPD exacerbation or
respiratory-tract infection in the month before involvement in the study
Exclusions: history of other clinically significant respiratory diseases (e.g. asthma, cystic
fibrosis); presence of bronchiectasis, as assessed by CT scan; maintenance antibiotic
treatment; use of more than 10 mg prednisolone a day; allergy to macrolides; pregnancy
or lactation in women; liver disease (alanine transaminase or aspartate transaminase
concentrations that were two ormore times the upper limit of normal); malignant disease
of any kind for which the patient received treatment or was being monitored as part of
follow-up after treatment; heart failure; and the use of drugs that could adversely interact
with macrolides and for which therapeutic monitoring could not be undertaken
Interventions Prophylaxis:
1. Azithromycin 500 mg 3 times per week
2. Placebo
Outcomes Primary:
1. Rate of exacerbations of COPD
Secondary:
1. Time to first exacerbation
2. Hospital admission for acute exacerbations
3. Change in proportion of exacerbations needing admission to hospital versus treatment
in an outpatient department compared with the previous year
4. Treatment for an acute exacerbation of COPD
5. FEV1 after bronchodilation
6. FVC after bronchodilation
7. Six-minute walk test
8. Quality of life, as assessed by the SF-12 and the SGRQ
9. Acquisition of macrolide resistant microorganisms in sputum
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Uzun 2014 (Continued)
10. Adverse events
Notes Funding: SoLong Trust. The sponsor of the study had no role in study design, data
collection, data analysis, data interpretation, or writing of the report
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “An independent pharmacy randomly as-
signed patients (1:1), via a computer-gen-
erated randomisation sequence with per-
muted blocks of ten.”
Allocation concealment (selection bias) Low risk “Patients were automatically given the next
allocated treatment by clinical trials staff at
the hospital pharmacy. Participants and in-
vestigators were masked to treatment allo-
cation throughout the study”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Participants
and investigators were masked to treatment
allocation throughout the study.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “After data collection and data cleaning
were completed, and after final database
lock, investigators were unmasked and
could assess outcomes and complete the
data analysis”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Higher drop out in placebo arm, but re-
sults from the unadjusted and adjusted per-
protocol analyses were almost identical to
those from the intention-to-treat analysis
and all participants included in safety anal-
ysis
Selective reporting (reporting bias) Low risk Planned outcomes according to trial regis-
tration relevant to this review reported
Other bias Low risk No additional bias identified
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Wang 2017
Methods Prospective, parallel, randomised controlled trial. Blinding not reported. Duration of
treatment 26 weeks
Participants N = 86. Age range: 61 to 83 years. Mean age (years): 70.5 (azithromycin) and 72.4
(placebo)
Female: 44.2% (azithromycin) and 37.2 (placebo)
10 cases of cardiac functional grade II, 27 cases of grade III and 6 cases of grade IV
(azithromycin) and 11 cases of cardiac functional grade II, 23 cases of grade III and 9
cases of grade IV (placebo)
Patients with pulmonary hypertension secondary toCOPD. Patients whosemean arterial
pressure was detected as not less than 25 mmHg by right cardiac catheterisation in a
quiescent condition or as no less than 30 mmHg in a motion state, and patients who
had not suffered from acute attack of COPD or acute lung infection
Exclusions: severe cardiac, hepatic, and liver function abnormality, pulmonary throm-
boembolism, allergic rhinitis, asthma or primary pulmonary hypertension, or were al-
lergic to the drugs used in the study
Interventions Prophylaxis:
1. Azithromycin 250 mg daily
2. Control group (no antibiotic treatment)
Outcomes 1. PaO2
2. PaCO2
3. Blood pH
4. FEV1
5. FVC
6. Six minutes walking distance
7. Pulmonary arterial pressure
Notes Funding: “Grant Support & Financial Disclosures: None”.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “randomly divided into an observation
group and a control group using random
number table, 43 in each group”
Allocation concealment (selection bias) Unclear risk Allocation concealment was not described
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding of participants or personnel
described. Assumed open-label
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding of outcome assessors de-
scribed. Assumed open-label
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Wang 2017 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not described
Selective reporting (reporting bias) High risk No prospective trial registration or proto-
col identified. Dyspnea grade reported as
measured in the abstract and not reported.
Not clear currently if FEV1 and FVC vari-
ance were SDs or SEs
Other bias Low risk No additional bias identified
BTS: British Thoracic Society; CAT: COPD assessment test; COPD: chronic obstructive pulmonary disease; CRP: C-reactive protein;
CRQ: chronic respiratory disease questionnaire; CYP: cytochrome P450; CXCL8: C-X-C motif ligand 8 (interleukin 8); ECG:
electrocardiogram; FEV1: forced expiratory volume in 1 second; FVC: forced vital capacity; GOLD: Global Initiative for Chronic
Obstructive Lung Disease; HDAC2: histone deacetylase 2; HIV: human immunodeficiency virus; HRQoL: health related quality
of life; ICS: inhaled corticosteroid; IgG: immunoglobulin G; IL: interleukin; ITT: intention-to-treat; L: litres; LCQ: Leicester
Cough Questionnaire; NF-κB: nuclear factor kappa-light-chain-enhancer of activated B cells; OCS: oral corticosteroids; PaCO2:
partial pressure of carbon dioxide; PaO2: partial pressure of oxygen; pH: potential of hydrogen; PI3K: phosphoinositide 3-kinase;
qPCR: quantitative polymerase chain reaction; QTc: Q-T Corrected (corrected Q-T interval); QT: Q-T interval; rRNA: ribosomal
ribonucleic acid; R5-R20: total respiratory system resistance, measured at 5 to 20 Hz; SD: standard deviation; SF-12/36: Short-
Form 12/36; SGRQ: St George’s Respiratory Questionnaire; ULN: upper limit of normal
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Beeh 2016 Comparison: ELOM-080 (a distillate of essential oils) versus placebo
Problem: drug under investigation not a conventional antibiotic
Bier 1971 Comparison: doxycyclin versus placebo
Problem: spirometric criteria were not used in diagnosing COPD
Blasi 2010 Comparison: azithromycin 500 mg three day a week for 6 months versus placebo
Problem: pilot study, uncontrolled
Study done on tracheostomy patients
Bruninx 1973 Comparison: bactrim versus ledermycin over 1070 months
Problem: 1) heterogeneous participant population including bronchiectasis, anthracosilicosis, and bronchitis;
2) no placebo arm
Buchanan 1958 Comparison: tetracycline 250 mg twice daily versus placebo for 12 months duration
Problems: single-blinded (only participants were blinded); spirometric criteria were not used to diagnose COPD
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(Continued)
Bussi 1980 Comparison: intermittent tetracyclines 200 mg weekly for 3 years versus placebo
Problem: spirometry criteria not used for diagnosis of COPD. Heterogenic group of participants
Davies 1961 Comparison: tetracycline for 2 days each week versus placebo
Problem: spirometric criteria were not used in diagnosing COPD; blinding not known
Douglas 1957 Not a randomised controlled trial
Heterogeneous group of participants including large proportion with bronchiectasis
Intial treatment with intramuscular penicillin
Participants who failed penicillin were allocated to either chloramphenicol 0.5 g 6-hourly or oxytetracycline 0.
5 g 6-hourly
Edwards 1958 Comparison: oxytetracycline or sulfonamide versus placebo
Problems: H. influenzae vaccination co-administered; no suitable outcome measures
Elmes 1957 Comparison: oxytetracycline versus placebo
Problem: not prophylactic, antibiotic versus placebo at the onset of symptoms
Fletcher 1966 Comparison: treatment for 7 months/year over 5-year period. 1) oxytetracycline 0.5 g daily for 7 months over
years 1 to 3; 2) oxytetracycline 0.5 g twice daily over 7 months in year 4; 3) oxytetacyline 1 g twice daily over
7 months in year 5; versus placebo
Problem: spirometric criteria not used to diagnose COPD
Frances 1964 Problem: spirometric criteria were not used to diagnose COPD
Francis 1960 Comparison: 3 groups: 1) tetracycline 250 mg twice daily for 3 months; 2) penicillin V 312 mg twice daily for
3 months; 3) placebo for 3 months
Problems: spirometric criteria were not used in diagnosing COPD
Goslings 1967 Comparison: 1) sulfaphenazole 500 mg twice daily; 2) tetracycline 500 mg twice daily; 3) saccharum 500 mg
twice daily (placebo) over 5-month period
Problem: spirometric criteria were not used to diagnose COPD
Grossman 1998 Comparison: ciprofloxacin 500 mg twice daily versus placebo for acute exacerbations of chronic bronchitis,
treatment given during acute exacerbations during 12-month period versus usual care during an acute exacer-
bation
Problem: ciprofloxacin was given during an exacerbation of chronic bronchitis. Not prophylaxis
Hahn 1972 Comparison: tetracycline or ampicillin versus placebo
Problems: not a true long-term prophylaxis. Prophylaxis is defined as antibiotics instituted by the participants
at the first sign of a cold and were continued only for 5 days
Haidl 2013 Comparison: inhaled tobramycin versus placebo
Problem: antibiotic given via inhalation, not orally
Hallett 1959 Comparison: erythromycin 250 mg 4 times a day versus placebo for 12 week duration
Problem: not a randomised controlled trial; participants were matched in pairs (treatment and placebo groups)
on the basis of similar clinical characteristics
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Helm 1956 Not a randomised controlled trial
Johnston 1961 Comparison:
Four treatment arms
1.Tetracycline 500 mg twice daily for 6 months treatment per year for 5 years
2. Placebo for 6 months treatment per year for 5 years
3. Tetracycline for the first 2 winters and placebo for the next three
4. Placebo for 2 winters and tetracycline for the next three
Problem:
Partial crossover due to re-randomisation after two years
Spirometric criteria were not used to diagnose COPD
Johnston 1961 Comparison: phenethicillin versus placebo
Problems: spirometric criteria were not used to diagnose COPD
Kilpatrick 1954 Comparison: sulphadimidine 0.5 g three times daily versus placebo for 3 to 6 months
Problem: spirometric criteria were not used when diagnosing COPD
Legler 1977 Problem: not randomised
Spirometric criteria were not used for diagnosing COPD
Liippo 1987 Comparison: trimethoprim 300 mg per day versus placebo. Treatment for 6 months duration
Problem: heterogeneous group of participants. Participants with bronchiectasis and asthma included. Spirom-
etry criteria for COPD not used
Maraffi 2010 Review article on 13 previous randomised controlled trials from 1957 to 2010
Matthys 2015 Wrong intervention: drug being trialled is not an antibiotic
May 1956 Comparison: oxytetracycline or tetracycline versus ’controlled group’ who were observed and antibiotic pro-
phylaxis was not given
Problem: not a true randomised controlled trial. The ’controlled group’ consisted of 14 participants who were
observed without any prophylactic therapy. They were not randomly selected
Miravitlles 2009 Comparison: moxifloxacin 400 mg daily versus placebo
Problem: short duration of study with only 5 days of treatment
Moyes 1959 Comparison: four groups: 1) erythromycin 1g daily for 7 days ,then a course of 1 g daily for five days taken at
the sign of first infection; 2) erythromycin 1 g daily for 7 days, then a regular course of 1 g daily for five days
every 4 weeks; 3) tetracycline 1 g daily for 7 days , then a course of 1 g daily for five days taken at the sign of
first infection
4) tetracycline 1 g daily for 7 days , then 750 mg/daily for 4 months
Problems: no placebo group
Murdoch 1959 Comparison: sigamycin (167 mg of tetracycline and 83 mg of oleandomycin) versus placebo for 3 months
Problem: spirometric criteria not used in diagnosing COPD
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Murray 1964 Comparison: ampicillin 250 mg 4 times daily versus placebo over 17 months
Problem: spirometric criteria were not used to diagnose COPD. Unclear whether randomisation took place
Nicholson 2016 Problem: not a randomised controlled trial
Norman 1962 Comparison: tetracycline 1 g daily or placebo for 3 months and then the groups were crossed over with
continuation of treatment for further 3 months
Problem: randomised cross-over trial. Spirometry criteria not used when diagnosing COPD
Pines 1967 Comparison: sulphormethoxine 2 g weekly for 10 weeks versus placebo
Problems: spirometric criteria were not used in diagnosing COPD patients
Pridie 1960 Comparison: penicillin-sulphonamide, oxytetracycline versus placebo
Problem: spirometric criteria were not taken into account when diagnosing COPD
Prins 2016 Duration of intervention too short: 3 weeks of doxycycline
Ras 1984 Comparison: 1) erythromycin 1500 mg/day for 2 weeks followed by 100 mg/day for 12 weeks; 2) amoxycillin
1500 mg/day for 2 weeks followed by 100 mg/day for 12 weeks; 3) placebo
Problem: randomisation not well explained. Spirometric criteria not used when diagnosing COPD
Segal 2017 Comparison: azithromycin versus placebo
Problem: study of effect on microbiome; duration too short (8 weeks)
Siva 2014 Duration of intervention too short: 7 days of levofloxacin
Stass 2013 Problem: trial of one-off dose of inhaled ciprofloxacin to assess lung deposition patterns
Vandenbergh 1970 Comparison: sulfonamide 2 g once a week versus placebo for 6 months
Problem: none of the primary outcomes were measured (frequency of exacerbations or quality of life)
Spirometric criteria were not used in diagnosing COPD
Velzen 2016 Comparison: long-term effects of antibiotics given for acute exacerbations of COPD
Problem: antibiotics given for acute COPD, not as prophylaxis
Vermeersch 2016 Comparison: azithromycin versus placebo for acute exacerbations of COPD
Problem: antibiotics given for acute COPD, not as prophylaxis
Watanabe 1991 Comparison; 1) ofloxacin 200 mg daily for 6months; 2) ofloxacin 200 mg three times daily for 2 weeks followed
by 2 weeks without treatment for 6 months
Problem: prophylaxis was given to participants with any chronic respiratory tract infection, including bronchiec-
tasis and pulmonary tuberculosis. No placebo arm
Watanabe 1994 Comparison: ciprofloxacin 200 mg/daily versus erythromycin 200 mg/daily versus combined ciprofloxacin 200
mg/d + erythromycin 200 mg/d
Problem: no placebo. Participants with bronchiectasis included
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Watanabe 1995 Duplicate study of Watanabe 1991 with addition of 7 participants
Webster 1971 Comparison: trimethoprim-sulfamethoxazole versus sulfamethoxazole
Problem: no placebo group. Treatment duration was only 10 days
COPD: chronic obstructive pulmonary disease
Characteristics of studies awaiting assessment [ordered by study ID]
Milito 2017
Methods Multicentre randomised placebo-controlled double-blind trial
Participants 89 participants with primary antibody deficiency and chronic obstructive pulmonary disease with exacerbations
Interventions Azithomycin 250 mg three times per week on consecutive days for 24 months versus placebo
Outcomes Exacerbations, no use of additional antibiotics, an increase of respiratory volumes, an improvement of the Health-
Related Quality of Life measures
Notes Conference abstract describing study protocol and participant dropouts only. Study was due to complete inDecember
2016, but we have been unable to identify a full-text publication to confirm eligibility and extract outcomes
Characteristics of ongoing studies [ordered by study ID]
ChiCTR-IOR-16008820
Trial name or title Effect of low-dose erythromycin on the treatment of COPD
Methods Randomised parallel group controlled trial. Planned recruitment 160 participants
Participants 1. Participants meeting the GOLD 2015 diagnostic criteria for COPD (a ratio of post-bronchodilator forced
expiratory volume in 1 second (FEV1) to forced vital capacity of < 70%,and a post-bronchodilator FEV1 of
< 80% of the predicted value);
2. Participants aged 40 years and more;
3. Participants were past or present cigarette smokers with at least a 10 pack-year smoking history;
4. Participants were studied when clinically stable for at least 4 weeks following an exacerbation; no change
in any therapy; no received systemic glucocorticoids
Interventions Intervention: erythromycin
Control: placebo
Outcomes Exacerbations of COPD, lung function
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ChiCTR-IOR-16008820 (Continued)
Starting date July 2016
Contact information Zhong Xiaoning (xiaoningzhong@sina.com)
Department of Respiratory Medicine, First Affiliated Hospital of Guangxi Medical University, Nanning,
Guangxi, China
Notes Study due to complete July 2019
NCT02205242
Trial name or title BACE trial - Physical activity as a crucial patient-reported outcome in COPD
Methods Randomised parallel group controlled trial. Planned recruitment 500participants (planned tomeasure physical
activity outcomes for a subset of 60 participants)
Participants 1. Established diagnosis of COPD by medical doctor (based on clinical history OR pulmonary function test)
2. Smoking history of at least 10 pack-years (10 pack-years were defined as 20 cigarettes a day for 10 years,
or 10 cigarettes a day for 20 years, etc.)
3. Current hospitalisation for potential infectious AECOPD treated with standard therapy
4. History of at least one exacerbation during the last year (prior to the current hospital admission) for which
systemic steroids and/or antibiotics were taken
5. ECG at admission
Interventions Intervention: from day 1 up to and including day 3: 500 mg azithromycin PO once a day, from day 4 up to
and including day 90: 250 mg azithromycin PO once every 2 days
Control: from day 1 up to and including day 3: 500 mg placebo PO once a day, from day 4 up to and
including day 90: 250 mg placebo PO once every 2 days
Outcomes Objective physical activity levels measured by an activity monitor
Starting date September 2014
Contact information Wim Janssens (wim.janssens@kuleuven.be)
Katholieke Universiteit Leuven, O&N I Herestraat 49 - box 706, 3000 Leuven, Belgium
Notes Study due to complete April 2018
NCT02205255
Trial name or title BACE trial - the pharmaco-economic impact of the azithromycin intervention
Methods Randomised parallel group controlled trial. Planned recruitment 350 participants (a second subanalysis of
the BACE trial including a detailed cost-effectiveness study)
Participants 1. Established diagnosis of COPD by medical doctor (based on clinical history OR pulmonary function test)
2. Smoking history of at least 10 pack-years (10 pack-years were defined as 20 cigarettes a day for 10 years,
or 10 cigarettes a day for 20 years, etc.)
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3. Current hospitalisation for potential infectious AECOPD treated with standard therapy
4. History of at least one exacerbation during the last year (prior to the current hospital admission) for which
systemic steroids and/or antibiotics were taken
5. ECG at admission
Interventions Intervention: from day 1 up to and including day 3: 500 mg azithromycin PO once a day, from day 4 up to
and including day 90: 250 mg azithromycin PO once every 2 days
Control: from day 1 up to and including day 3: 500 mg placebo PO once a day, from day 4 up to and
including day 90: 250 mg placebo PO once every 2 days
Outcomes Total costs, direct costs, indirect costs
Starting date August 2014
Contact information Wim Janssens (wim.janssens@kuleuven.be)
Katholieke Universiteit Leuven, O&N I Herestraat 49 - box 706, 3000 Leuven, Belgium
Notes April 2018
NCT02305940
Trial name or title A phase III double-blind, randomised, placebo controlled trial of long term therapy on exacerbation rate in
patients with stable COPD using doxycycline
Methods Randomised parallel group controlled trial
Participants Aged 45 years and over
Confirmed COPD diagnosis
Severity of disease: participants with a measured FEV1 < 80% of predicted normal values
At least one treated exacerbation (participant recalled an episode of symptomatic worsening which was treated
and was consistent with a COPD exacerbation) in the previous year
Interventions Intervention: doxycycline 100 mg once daily, for a total duration of 52 weeks
Control: placebo
Outcomes Primary: rate of exacerbations (per person/year)
Secondary: lung function (FEV1, FVC, FEV1/FVC ratio, FEV1 as% predicted), SGRQ (total and individual
components) respiratory health status (using diary cards), airway bacteria numbers from sputum samples,
changes in C-reactive protein (CRP) levels from baseline, hospital admissions, time to 1st exacerbation, rate
of exacerbations treated with steroids and antibiotics, adherence, antibiotic resistance
Starting date July 2014
Contact information Wisia Wedzicha (j.wedzicha@imperial.ac.uk)
Emmanuel Kaye Building, Royal Brompton Campus, Imperial College, London, UK
Notes July 2017
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AECOPD: acute exacerbation of chronic obstructive pulmonary disease; COPD: chronic obstructive pulmonary disease; CRP: C-
reactive protein; ECG: electrocardiogram; FEV1: forced expiratory volume in 1 second; FVC: forced vital capacity; PO: per os (orally)
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D A T A A N D A N A L Y S E S
Comparison 1. Antibiotics versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Number of people with one or
more exacerbations
8 2716 Odds Ratio (M-H, Random, 95% CI) 0.57 [0.42, 0.78]
1.1 Continuous antibiotics 5 1325 Odds Ratio (M-H, Random, 95% CI) 0.53 [0.36, 0.79]
1.2 Intermittent antibiotics 3 209 Odds Ratio (M-H, Random, 95% CI) 0.39 [0.19, 0.77]
1.3 Pulsed antibiotics 2 1182 Odds Ratio (M-H, Random, 95% CI) 0.85 [0.68, 1.07]
2 Number of people with one or
more exacerbations requiring
hospitalisation
1 Odds Ratio (M-H, Random, 95% CI) Totals not selected
2.1 Intermittent antibiotics 1 Odds Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3 Annualised exacerbation rate
per patient per year during
12-week active treatment
Other data No numeric data
3.1 Continuous antibiotics Other data No numeric data
4 Rate of exacerbation per patient
per year
5 1384 Rate Ratio (Random, 95% CI) 0.67 [0.54, 0.83]
4.1 Continuous antibiotics 4 1292 Rate Ratio (Random, 95% CI) 0.69 [0.54, 0.89]
4.2 Intermittent antibiotics 1 92 Rate Ratio (Random, 95% CI) 0.58 [0.42, 0.80]
5 Time to the first exacerbation Other data No numeric data
5.1 Continuous antibiotic Other data No numeric data
5.2 Intermittent antibiotics Other data No numeric data
5.3 Pulsed antibiotics Other data No numeric data
6 Mean time to first exacerbation
(days)
1 266 Mean Difference (IV, Random, 95% CI) -16.59 [-46.05, 12.
86]
6.1 Continuous antibiotics 1 266 Mean Difference (IV, Random, 95% CI) -16.59 [-46.05, 12.
86]
7 COPD exacerbations according
to severity of COPD -
continuous antibiotics
Other data No numeric data
8 COPD exacerbations according
to severity of COPD - pulsed
antibiotics
Other data No numeric data
9 HRQoL, SGRQ (total score) 7 2237 Mean Difference (Random, 95% CI) -1.94 [-3.13, -0.75]
9.1 Continuous antibiotics 4 991 Mean Difference (Random, 95% CI) -1.96 [-3.45, -0.47]
9.2 Intermittent antibiotics 3 184 Mean Difference (Random, 95% CI) -4.59 [-8.83, -0.36]
9.3 Pulsed antibiotics 2 1062 Mean Difference (Random, 95% CI) -1.22 [-3.00, 0.55]
10 HRQoL, SGRQ (domains) 4 Mean Difference (IV, Random, 95% CI) Subtotals only
10.1 SGRQ activity 4 2077 Mean Difference (IV, Random, 95% CI) -0.99 [-2.62, 0.65]
10.2 SGRQ symptoms 4 2077 Mean Difference (IV, Random, 95% CI) -4.07 [-5.72, -2.41]
10.3 SGRQ impact 4 2077 Mean Difference (IV, Random, 95% CI) -2.56 [-5.02, -0.10]
11 HRQoL, LCQ (total) 1 Mean Difference (IV, Random, 95% CI) Totals not selected
11.1 Intermittent antibiotics 1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
12 HRQoL, SF-12 (domains) 1 Mean Difference (IV, Random, 95% CI) Totals not selected
12.1 SF-12 physical 1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
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12.2 SF-12 mental 1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13 HRQoL SF-36 (domains) 3 Mean Difference (IV, Random, 95% CI) Subtotals only
13.1 SF-36 general health 3 1071 Mean Difference (IV, Random, 95% CI) 4.06 [0.70, 7.42]
13.2 SF-36 physical
functioning
3 1071 Mean Difference (IV, Random, 95% CI) 1.88 [-1.01, 4.77]
13.3 SF-36 bodily pain 3 1072 Mean Difference (IV, Random, 95% CI) 0.53 [-2.47, 3.53]
13.4 SF-36 vitality 3 1070 Mean Difference (IV, Random, 95% CI) 2.03 [-0.38, 4.43]
13.5 SF-36 role emotional 3 1072 Mean Difference (IV, Random, 95% CI) -0.75 [-5.55, 4.04]
13.6 SF-36 social functioning 3 1072 Mean Difference (IV, Random, 95% CI) 7.19 [-2.40, 16.78]
13.7 SF-36 mental health 3 1070 Mean Difference (IV, Random, 95% CI) 2.37 [-1.13, 5.86]
13.8 SF-36 role physical 3 1072 Mean Difference (IV, Random, 95% CI) 4.63 [-9.82, 19.09]
14 HRQoL, LCQ (domains) 1 Mean Difference (IV, Random, 95% CI) Subtotals only
14.1 LCQ physical 1 79 Mean Difference (IV, Random, 95% CI) 0.40 [0.12, 0.68]
14.2 LCQ psychological 1 79 Mean Difference (IV, Random, 95% CI) 0.5 [0.22, 0.78]
14.3 LCQ social 1 79 Mean Difference (IV, Random, 95% CI) 0.4 [-0.15, 0.95]
15 HRQoL, CCQ (total) 1 Mean Difference (IV, Random, 95% CI) Totals not selected
15.1 Continuous antibiotics 1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16 HRQoL, CRQ (domains) 1 Mean Difference (IV, Random, 95% CI) Subtotals only
16.1 CRQ dyspnoea 1 275 Mean Difference (IV, Random, 95% CI) -0.42 [-1.79, 0.94]
16.2 CRQ fatigue 1 275 Mean Difference (IV, Random, 95% CI) -0.56 [-1.74, 0.62]
16.3 CRQ emotional function 1 275 Mean Difference (IV, Random, 95% CI) -0.66 [-1.94, 0.62]
16.4 CRQ mastery 1 275 Mean Difference (IV, Random, 95% CI) -0.21 [-1.29, 0.87]
17 Frequency of hospital
admissions - continuous
antibiotics
Other data No numeric data
18 Frequency of hospital
admissions - pulsed antibiotics
Other data No numeric data
19 Duration of exacerbation Other data No numeric data
19.1 Continuous antibiotics Other data No numeric data
19.2 Pulsed antibiotics Other data No numeric data
20 FEV1 (mL) 6 658 Mean Difference (Random, 95% CI) 20.21 [-26.19, 66.
61]
20.1 Continuous antibiotics 4 441 Mean Difference (Random, 95% CI) -12.69 [-77.66, 52.
28]
20.2 Intermittent antibiotics 3 184 Mean Difference (Random, 95% CI) 53.95 [-16.90, 124.
81]
20.3 Pulsed antibiotics 1 33 Mean Difference (Random, 95% CI) 58.0 [-129.63, 245.
63]
21 FVC (L) 4 514 Mean Difference (IV, Random, 95% CI) 0.12 [0.01, 0.23]
21.1 Continuous antibiotics 2 363 Mean Difference (IV, Random, 95% CI) 0.13 [-0.04, 0.30]
21.2 Intermittent antibiotics 2 151 Mean Difference (IV, Random, 95% CI) 0.17 [-0.01, 0.36]
22 FEV1 % predicted 6 1737 Mean Difference (IV, Random, 95% CI) 0.33 [-1.56, 2.22]
22.1 Continuous antibiotics 3 437 Mean Difference (IV, Random, 95% CI) 1.43 [-1.97, 4.83]
22.2 Intermittent antibiotics 2 151 Mean Difference (IV, Random, 95% CI) 1.67 [-1.33, 4.68]
22.3 Pulsed antibiotics 1 1149 Mean Difference (IV, Random, 95% CI) -1.35 [-3.28, 0.58]
23 Exercise capacity (6MWT) 2 126 Mean Difference (IV, Random, 95% CI) 67.67 [16.20, 119.
14]
23.1 Continuous antibiotics 1 49 Mean Difference (IV, Random, 95% CI) 84.20 [13.38, 155.
03]
23.2 Intermittent antibiotics 1 77 Mean Difference (IV, Random, 95% CI) 36.0 [-15.53, 87.53]
24 All-cause mortality 6 3309 Odds Ratio (M-H, Random, 95% CI) 0.87 [0.66, 1.15]
24.1 Continuous antibiotics 2 1409 Odds Ratio (M-H, Random, 95% CI) 0.86 [0.49, 1.51]
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24.2 Intermittent antibiotics 2 176 Odds Ratio (M-H, Random, 95% CI) 0.18 [0.01, 3.92]
24.3 Pulsed antibiotics 2 1724 Odds Ratio (M-H, Random, 95% CI) 0.89 [0.64, 1.23]
25 Respiratory-related mortality 2 2266 Odds Ratio (M-H, Random, 95% CI) 1.17 [0.63, 2.19]
25.1 Continuous antibiotics 1 1117 Odds Ratio (M-H, Random, 95% CI) 1.44 [0.54, 3.81]
25.2 Pulsed antibiotics 1 1149 Odds Ratio (M-H, Random, 95% CI) 1.02 [0.45, 2.29]
26 Serious adverse events 9 2978 Odds Ratio (M-H, Random, 95% CI) 0.88 [0.74, 1.05]
26.1 Continuous antibiotics 7 1671 Odds Ratio (M-H, Random, 95% CI) 0.85 [0.68, 1.05]
26.2 Intermittent antibiotics 2 125 Odds Ratio (M-H, Random, 95% CI) 0.55 [0.12, 2.43]
26.3 Pulsed antibiotics 2 1182 Odds Ratio (M-H, Random, 95% CI) 0.99 [0.72, 1.34]
27 Any adverse event 4 512 Odds Ratio (M-H, Random, 95% CI) 1.07 [0.69, 1.67]
27.1 Continuous antibiotics 3 355 Odds Ratio (M-H, Random, 95% CI) 1.03 [0.62, 1.73]
27.2 Intermittent antibiotics 2 124 Odds Ratio (M-H, Random, 95% CI) 0.95 [0.37, 2.41]
27.3 Pulsed antibiotics 1 33 Odds Ratio (M-H, Random, 95% CI) 11.52 [0.60, 221.75]
28 Adverse events (specific) 6 Odds Ratio (M-H, Random, 95% CI) Subtotals only
28.1 Respiratory disorders 3 2350 Odds Ratio (M-H, Random, 95% CI) 1.07 [0.33, 3.41]
28.2 Gastrointestinal disorders 6 2522 Odds Ratio (M-H, Random, 95% CI) 1.16 [0.43, 3.11]
28.3 QTc prolongation 1 1117 Odds Ratio (M-H, Random, 95% CI) 1.17 [0.39, 3.51]
28.4 Hearing impairment 1 1117 Odds Ratio (M-H, Random, 95% CI) 1.39 [1.05, 1.85]
28.5 Musculoskeletal
disorders
1 1149 Odds Ratio (M-H, Random, 95% CI) 3.07 [0.32, 29.59]
28.6 Hypersensitivity/skin
rash
2 1258 Odds Ratio (M-H, Random, 95% CI) 1.63 [0.63, 4.26]
28.7 Nervous system disorders 2 1179 Odds Ratio (M-H, Random, 95% CI) 1.25 [0.38, 4.08]
28.8 Cardiovascular 1 84 Odds Ratio (M-H, Random, 95% CI) 2.05 [0.18, 23.51]
Comparison 2. Subgroup analyses
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Subgroup analysis: number
of people with one or more
exacerbations by mean %
predicted FEV1
8 2716 Odds Ratio (M-H, Random, 95% CI) 0.57 [0.42, 0.78]
1.1 Mean FEV1 % ≥ 50 1 30 Odds Ratio (M-H, Random, 95% CI) 0.24 [0.05, 1.13]
1.2 Mean FEV1 % < 50 7 2686 Odds Ratio (M-H, Random, 95% CI) 0.60 [0.44, 0.81]
2 Subgroup analysis: number
of people with one or more
exacerbations by treatment
duration
8 2716 Odds Ratio (M-H, Random, 95% CI) 0.57 [0.42, 0.78]
2.1≥ 3 months to < 6 months 3 213 Odds Ratio (M-H, Random, 95% CI) 0.51 [0.28, 0.94]
2.2 ≥ 6 months to < 12
months
2 1185 Odds Ratio (M-H, Random, 95% CI) 0.63 [0.24, 1.69]
2.3 ≥ 12 months 3 1318 Odds Ratio (M-H, Random, 95% CI) 0.45 [0.25, 0.81]
3 Subgroup analysis: number
of people with one or more
exacerbations by year carried
out
8 2716 Odds Ratio (M-H, Random, 95% CI) 0.57 [0.42, 0.78]
3.1 2005 to 2009 1 109 Odds Ratio (M-H, Random, 95% CI) 0.37 [0.17, 0.84]
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3.2 2010 to 2014 6 2508 Odds Ratio (M-H, Random, 95% CI) 0.57 [0.39, 0.83]
3.3 2015 to 2019 1 99 Odds Ratio (M-H, Random, 95% CI) 0.74 [0.29, 1.89]
4 Subgroup analysis: number
of people with one or more
exacerbations by regimen
8 2716 Odds Ratio (M-H, Random, 95% CI) 0.57 [0.42, 0.78]
4.1 Once daily antibiotic 3 1180 Odds Ratio (M-H, Random, 95% CI) 0.61 [0.34, 1.09]
4.2 Twice or three times daily
antibiotic
2 145 Odds Ratio (M-H, Random, 95% CI) 0.35 [0.17, 0.71]
4.3 Three times a week
antibiotic
3 209 Odds Ratio (M-H, Random, 95% CI) 0.39 [0.19, 0.77]
4.4 Pulsed antibiotic 2 1182 Odds Ratio (M-H, Random, 95% CI) 0.85 [0.68, 1.07]
5 Subgroup analysis: number
of people with one or more
exacerbations by exacerbation
history
8 2716 Odds Ratio (M-H, Random, 95% CI) 0.57 [0.42, 0.78]
5.1 Inclusion criteria of ≥ 1
exacerbation in preceding year
3 2358 Odds Ratio (M-H, Random, 95% CI) 0.66 [0.43, 0.99]
5.2 Exacerbation history not
an inclusion criteria
5 358 Odds Ratio (M-H, Random, 95% CI) 0.44 [0.27, 0.69]
Analysis 1.1. Comparison 1 Antibiotics versus placebo, Outcome 1 Number of people with one or more
exacerbations.
Review: Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD)
Comparison: 1 Antibiotics versus placebo
Outcome: 1 Number of people with one or more exacerbations
Study or subgroup Antibiotics Placebo Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Continuous antibiotics
Albert 2011 (1) 317/558 380/559 29.4 % 0.62 [ 0.49, 0.79 ]
Brill 2015 (2) 15/25 4/8 3.3 % 1.50 [ 0.30, 7.43 ]
He 2010 (3) 9/18 14/18 4.0 % 0.29 [ 0.07, 1.21 ]
Seemungal 2008 (4) 28/53 42/56 10.3 % 0.37 [ 0.17, 0.84 ]
Simpson 2014 (5) 4/15 9/15 3.6 % 0.24 [ 0.05, 1.13 ]
Subtotal (95% CI) 669 656 50.6 % 0.53 [ 0.36, 0.79 ]
Total events: 373 (Antibiotics), 449 (Placebo)
Heterogeneity: Tau2 = 0.05; Chi2 = 4.92, df = 4 (P = 0.30); I2 =19%
Test for overall effect: Z = 3.16 (P = 0.0016)
2 Intermittent antibiotics
0.05 0.2 1 5 20
Favours antibiotic Favours placebo
(Continued . . . )
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(. . . Continued)
Study or subgroup Antibiotics Placebo Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Berkhof 2013 (6) 10/42 17/42 8.2 % 0.46 [ 0.18, 1.18 ]
Brill 2015 (7) 10/25 4/8 3.3 % 0.67 [ 0.13, 3.30 ]
Uzun 2014 (8) 34/47 42/45 4.6 % 0.19 [ 0.05, 0.71 ]
Subtotal (95% CI) 114 95 16.2 % 0.39 [ 0.19, 0.77 ]
Total events: 54 (Antibiotics), 63 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.73, df = 2 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 2.69 (P = 0.0072)
3 Pulsed antibiotics
Brill 2015 (9) 10/25 5/8 3.2 % 0.40 [ 0.08, 2.06 ]
Sethi 2010 (10) 269/569 295/580 29.9 % 0.87 [ 0.69, 1.09 ]
Subtotal (95% CI) 594 588 33.2 % 0.85 [ 0.68, 1.07 ]
Total events: 279 (Antibiotics), 300 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.84, df = 1 (P = 0.36); I2 =0.0%
Test for overall effect: Z = 1.36 (P = 0.17)
Total (95% CI) 1377 1339 100.0 % 0.57 [ 0.42, 0.78 ]
Total events: 706 (Antibiotics), 812 (Placebo)
Heterogeneity: Tau2 = 0.07; Chi2 = 15.58, df = 9 (P = 0.08); I2 =42%
Test for overall effect: Z = 3.55 (P = 0.00038)
Test for subgroup differences: Chi2 = 7.49, df = 2 (P = 0.02), I2 =73%
0.05 0.2 1 5 20
Favours antibiotic Favours placebo
(1) Azithromycin 250mg daily for 12 months.
(2) Doxycycline 100mg daily for 13 weeks. Control group split three ways.
(3) Erythromycin 125mg three times/day for six months.
(4) Erythromycin 250mg twice/day for 12 months.
(5) Azithromycin 250mg daily for 12 weeks. Outcome reported at 26 weeks.
(6) Azithromycin 250mg three times/week for 12 weeks.
(7) Azithromycin 250mg three times/week for 13 weeks. Control group split three ways.
(8) Azithromycin 500mg three times/week for 12 months.
(9) Pulsed moxifloxacin 400mg daily for five days every four weeks for 13 weeks. Control group split three ways.
(10) Moxifloxacin 400mg daily for for five days every eight weeks for 48 weeks.
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Analysis 1.2. Comparison 1 Antibiotics versus placebo, Outcome 2 Number of people with one or more
exacerbations requiring hospitalisation.
Review: Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD)
Comparison: 1 Antibiotics versus placebo
Outcome: 2 Number of people with one or more exacerbations requiring hospitalisation
Study or subgroup Antibiotics Control Odds Ratio Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Intermittent antibiotics
Berkhof 2013 (1) 4/42 5/42 0.78 [ 0.19, 3.13 ]
0.01 0.1 1 10 100
Favours antibtiocs Favours control
(1) Azithromycin 250 mg three times/week for 12 weeks.
Analysis 1.3. Comparison 1 Antibiotics versus placebo, Outcome 3 Annualised exacerbation rate per
patient per year during 12-week active treatment.
Annualised exacerbation rate per patient per year during 12-week active treatment
Study Intervention arm Rate per patient per year P value compared to control
Continuous antibiotics
Shafuddin 2015 Roxithromycin 1.74 0.2545
Shafuddin 2015 Roxithromycin+doxycyline 1.64 0.1709
Shafuddin 2015 Placebo 2.25 N/A
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Analysis 1.4. Comparison 1 Antibiotics versus placebo, Outcome 4 Rate of exacerbation per patient per
year.
Review: Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD)
Comparison: 1 Antibiotics versus placebo
Outcome: 4 Rate of exacerbation per patient per year
Study or subgroup Antibiotics Placebo log [Rate Ratio] Rate Ratio Weight Rate Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
1 Continuous antibiotics
Albert 2011 (1) 558 559 -0.1863 (0.0725) 37.1 % 0.83 [ 0.72, 0.96 ]
He 2010 (2) 18 18 -0.5906 (0.2897) 11.0 % 0.55 [ 0.31, 0.98 ]
Seemungal 2008 (3) 53 56 -0.4339 (0.1436) 25.3 % 0.65 [ 0.49, 0.86 ]
Simpson 2014 (4) 15 15 -0.9676 (0.5095) 4.3 % 0.38 [ 0.14, 1.03 ]
Subtotal (95% CI) 644 648 77.7 % 0.69 [ 0.54, 0.89 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 5.73, df = 3 (P = 0.13); I2 =48%
Test for overall effect: Z = 2.94 (P = 0.0032)
2 Intermittent antibiotics
Uzun 2014 (5) 47 45 -0.5447 (0.1647) 22.3 % 0.58 [ 0.42, 0.80 ]
Subtotal (95% CI) 47 45 22.3 % 0.58 [ 0.42, 0.80 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.31 (P = 0.00094)
Total (95% CI) 691 693 100.0 % 0.67 [ 0.54, 0.83 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 8.26, df = 4 (P = 0.08); I2 =52%
Test for overall effect: Z = 3.68 (P = 0.00024)
Test for subgroup differences: Chi2 = 0.76, df = 1 (P = 0.38), I2 =0.0%
0.1 0.2 0.5 1 2 5 10
Favours antibiotics Favours placebo
(1) Azithromycin 250 mg daily for 12 months.
(2) Erythromycin 125mg three times/day for six months.
(3) Erythromycin 250mg twice a day for 12 months.
(4) Azithromycin 250 mg daily for 12 weeks. Outcome reported at 26 weeks.
(5) Azithromycin 500mg three times/week for 12 months.
Analysis 1.5. Comparison 1 Antibiotics versus placebo, Outcome 5 Time to the first exacerbation.
Time to the first exacerbation
Study MEDIAN Time
to 1st exacerbation
(days) treatment
MEDIAN Time
to 1st exacerbation
(days) placebo
P value Test used Hazard ratio
Continuous antibiotic
Albert 2011 266 (227 to 313) 174 (143 to 215) P < 0.001 log-rank test 0.73 (0.63, 0.84)
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Time to the first exacerbation (Continued)
He 2010 155 86 P = 0.032 Kaplan-Meier survival
analysis
not given
Seemungal 2008 271 89 P = 0.02 log-rank test not given
Intermittent antibiotics
Berkhof 2013 20th percentile time
to the first exacerba-
tion 105 (30)
20th percentile time
to the first exacerba-
tion 66 (21)
P = 0.13 log-rank test not given
Uzun 2014 130 (95% CI 28 to
232)
59 (95% CI 31 to
87)
P = 0.001 log-rank test not given
Pulsed antibiotics
Sethi 2010 364 336 P = 0.062 Kaplan-Meier survival
analysis
not given
Analysis 1.6. Comparison 1 Antibiotics versus placebo, Outcome 6 Mean time to first exacerbation (days).
Review: Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD)
Comparison: 1 Antibiotics versus placebo
Outcome: 6 Mean time to first exacerbation (days)
Study or subgroup Antibiotics Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Continuous antibiotics
Shafuddin 2015 (1) 87 121 (113) 44 147 (115) 50.5 % -26.00 [ -67.45, 15.45 ]
Shafuddin 2015 (2) 92 140 (117) 43 147 (115) 49.5 % -7.00 [ -48.87, 34.87 ]
Total (95% CI) 179 87 100.0 % -16.59 [ -46.05, 12.86 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.40, df = 1 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 1.10 (P = 0.27)
Test for subgroup differences: Not applicable
-50 -25 0 25 50
Favours placebo Favours antibiotics
(1) Roxithromycin 300mg daily + doxycyline 100mg daily. Outcome reported at 60 weeks. Control group halved.
(2) Roxithromycin 300mg daily for 12 weeks. Outcome reported at 60 weeks. Control group halved.
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Analysis 1.7. Comparison 1 Antibiotics versus placebo, Outcome 7 COPD exacerbations according to
severity of COPD - continuous antibiotics.
COPD exacerbations according to severity of COPD - continuous antibiotics
Study Gold stage Rate of exacerbations per patient year on
azithromycin (Mean +/- SD)
Rate of exacerbations per patient year on
placebo (Mean +/- SD)
Albert 2011 2 : FEV1 (80% - 50%) 1.02 (+/- 0.15) 1.68 (+/- 0.16)
Albert 2011 3 : FEV1 (50% - 30%) 1.53 (+/- 0.13) 1.75 (+/- 0.13)
Albert 2011 4 : FEV1 < 30% 1.75 (+/- 0.12) 2.05 (+/- 0.28)
Analysis 1.8. Comparison 1 Antibiotics versus placebo, Outcome 8 COPD exacerbations according to
severity of COPD - pulsed antibiotics.
COPD exacerbations according to severity of COPD - pulsed antibiotics
Study Gold stage Odds ratio for exacerbations, moxifloxacin
vs placebo (95% CI)
P value
Sethi 2010 2 : FEV1 (80% - 50%) 0.65 (0.39 to 1.06) 0.091
Sethi 2010 3 : FEV1 (50% - 30%) 0.81 (0.58 to 1.10) 0.192
Sethi 2010 4 : FEV1 (< 30%) 0.83 (0.54 to 1.28) 0.459
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Analysis 1.9. Comparison 1 Antibiotics versus placebo, Outcome 9 HRQoL, SGRQ (total score).
Review: Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD)
Comparison: 1 Antibiotics versus placebo
Outcome: 9 HRQoL, SGRQ (total score)
Study or subgroup Antibiotics Placebo Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Random,95% CI IV,Random,95% CI
1 Continuous antibiotics
Albert 2011 (1) 444 453 -2.2 (0.7853) 47.7 % -2.20 [ -3.74, -0.66 ]
Brill 2015 (2) 25 8 1.02 (4.5689) 1.7 % 1.02 [ -7.93, 9.97 ]
He 2010 (3) 16 15 -3 (5.6801) 1.1 % -3.00 [ -14.13, 8.13 ]
Simpson 2014 (4) 15 15 6.1 (5.3357) 1.3 % 6.10 [ -4.36, 16.56 ]
Subtotal (95% CI) 500 491 51.9 % -1.96 [ -3.45, -0.47 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 2.83, df = 3 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 2.58 (P = 0.0099)
2 Intermittent antibiotics
Berkhof 2013 (5) 37 37 -7.5 (2.5456) 5.5 % -7.50 [ -12.49, -2.51 ]
Brill 2015 (6) 25 8 -2.29 (4.4529) 1.8 % -2.29 [ -11.02, 6.44 ]
Uzun 2014 (7) 41 36 -1.1 (3.6923) 2.7 % -1.10 [ -8.34, 6.14 ]
Subtotal (95% CI) 103 81 10.1 % -4.59 [ -8.83, -0.36 ]
Heterogeneity: Tau2 = 2.72; Chi2 = 2.45, df = 2 (P = 0.29); I2 =18%
Test for overall effect: Z = 2.13 (P = 0.033)
3 Pulsed antibiotics
Brill 2015 (8) 25 8 -1.88 (4.8662) 1.5 % -1.88 [ -11.42, 7.66 ]
Sethi 2010 (9) 503 526 -1.2 (0.9231) 36.5 % -1.20 [ -3.01, 0.61 ]
Subtotal (95% CI) 528 534 38.1 % -1.22 [ -3.00, 0.55 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.02, df = 1 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 1.35 (P = 0.18)
Total (95% CI) 1131 1106 100.0 % -1.94 [ -3.13, -0.75 ]
Heterogeneity: Tau2 = 0.15; Chi2 = 8.31, df = 8 (P = 0.40); I2 =4%
Test for overall effect: Z = 3.20 (P = 0.0014)
Test for subgroup differences: Chi2 = 2.11, df = 2 (P = 0.35), I2 =5%
-10 -5 0 5 10
Favours antibitoics Favours placebo
(1) Azithromycin 250mg daily for 12 months.
(2) Doxycycline 100mg daily for 13 weeks. Control group split three ways.
(3) Erythromycin 125mg three times/day for six months.
(4) Azithromycin 250mg daily for 12 weeks. Outcome reported at 26 weeks.
(5) Azithromycin 250mg three times/week for 12 weeks.
(6) Azithromycin 250mg three times/week for 13 weeks. Control group split three ways.
(7) Azithromycin 500mg three times/week for 12 months.
(8) Pulsed moxifloxacin 400mg daily for 5 days every 4 weeks for 13 weeks. Control group split three ways.
(9) Moxifloxacin 400mg daily for for 5 days every 8 weeks for 48 weeks.
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Analysis 1.10. Comparison 1 Antibiotics versus placebo, Outcome 10 HRQoL, SGRQ (domains).
Review: Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD)
Comparison: 1 Antibiotics versus placebo
Outcome: 10 HRQoL, SGRQ (domains)
Study or subgroup Antibiotics Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 SGRQ activity
Albert 2011 (1) 444 -1.6 (14.9) 453 0.2 (14.3) 50.0 % -1.80 [ -3.71, 0.11 ]
Berkhof 2013 (2) 37 -4.1 (13.9904) 37 0.2 (13.9904) 6.3 % -4.30 [ -10.68, 2.08 ]
Sethi 2010 (3) 503 -1.9 (17.6) 526 -2.4 (18.5) 40.8 % 0.50 [ -1.71, 2.71 ]
Uzun 2014 (4) 41 75.5 (22.4) 36 76.1 (19.9) 2.9 % -0.60 [ -10.05, 8.85 ]
Subtotal (95% CI) 1025 1052 100.0 % -0.99 [ -2.62, 0.65 ]
Heterogeneity: Tau2 = 0.44; Chi2 = 3.48, df = 3 (P = 0.32); I2 =14%
Test for overall effect: Z = 1.18 (P = 0.24)
2 SGRQ symptoms
Albert 2011 (5) 444 -7 (17.9) 453 -3.7 (16.5) 53.9 % -3.30 [ -5.55, -1.05 ]
Berkhof 2013 (6) 37 -9.2 (18.2483) 37 0.1 (18.2483) 4.0 % -9.30 [ -17.62, -0.98 ]
Sethi 2010 (7) 503 -8.2 (23.5) 526 -3.8 (20.9) 37.0 % -4.40 [ -7.12, -1.68 ]
Uzun 2014 (8) 41 57.3 (18) 36 63 (14.4) 5.2 % -5.70 [ -12.94, 1.54 ]
Subtotal (95% CI) 1025 1052 100.0 % -4.07 [ -5.72, -2.41 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 2.22, df = 3 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 4.82 (P < 0.00001)
3 SGRQ impact
Albert 2011 (9) 444 -2.1 (14.3) 453 0 (13.8) 40.3 % -2.10 [ -3.94, -0.26 ]
Berkhof 2013 (10) 37 -7.3 (12.1655) 37 1.6 (12.1655) 14.3 % -8.90 [ -14.44, -3.36 ]
Sethi 2010 (11) 503 -4 (17) 526 -2.8 (17.5) 37.6 % -1.20 [ -3.31, 0.91 ]
Uzun 2014 (12) 41 44.6 (17.8) 36 44.5 (18.3) 7.8 % 0.10 [ -7.99, 8.19 ]
Subtotal (95% CI) 1025 1052 100.0 % -2.56 [ -5.02, -0.10 ]
Heterogeneity: Tau2 = 3.03; Chi2 = 6.76, df = 3 (P = 0.08); I2 =56%
Test for overall effect: Z = 2.04 (P = 0.041)
Test for subgroup differences: Chi2 = 6.75, df = 2 (P = 0.03), I2 =70%
-20 -10 0 10 20
Favours antibiotics Favours placebo
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(1) Azithromycin 250mg daily for 12 months.
(2) Azithromycin 250mg three times/week for 12 weeks.
(3) Moxifloxacin 400mg daily for for five days every eight weeks for 48 weeks.
(4) Azithromycin 500mg three times/week for 12 months.
(5) Azithromycin 250mg daily for 12 months.
(6) Azithromycin 250mg three times/week for 12 weeks.
(7) Moxifloxacin 400mg daily for five days every eight weeks for 48 weeks.
(8) Azithromycin 500mg three times/week for 12 months.
(9) Azithromycin 250mg daily for 12 months.
(10) Azithromycin 250mg three times/week for 12 weeks.
(11) Moxifloxacin 400mg daily for five days every eight weeks for 48 weeks.
(12) Azithromycin 500mg three times/week for 12 months.
Analysis 1.11. Comparison 1 Antibiotics versus placebo, Outcome 11 HRQoL, LCQ (total).
Review: Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD)
Comparison: 1 Antibiotics versus placebo
Outcome: 11 HRQoL, LCQ (total)
Study or subgroup Antibiotics Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Intermittent antibiotics
Berkhof 2013 (1) 38 2.2 (2.4658) 41 0.9 (1.9209) 1.30 [ 0.32, 2.28 ]
-2 -1 0 1 2
Favours placebo Favours antibiotics
(1) Azithromycin 250mg three times/week for 12 weeks.
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Analysis 1.12. Comparison 1 Antibiotics versus placebo, Outcome 12 HRQoL, SF-12 (domains).
Review: Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD)
Comparison: 1 Antibiotics versus placebo
Outcome: 12 HRQoL, SF-12 (domains)
Study or subgroup Antibiotics Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 SF-12 physical
Uzun 2014 (1) 41 32.3 (10.7) 36 32.7 (10.3) -0.40 [ -5.10, 4.30 ]
2 SF-12 mental
Uzun 2014 (2) 41 36.8 (11.7) 36 35.9 (13.1) 0.90 [ -4.68, 6.48 ]
-10 -5 0 5 10
Favours placebo Favours antibiotics
(1) Azithromycin 500mg three times/week for 12 months.
(2) Azithromycin 500mg three times/week for 12 months.
Analysis 1.13. Comparison 1 Antibiotics versus placebo, Outcome 13 HRQoL SF-36 (domains).
Review: Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD)
Comparison: 1 Antibiotics versus placebo
Outcome: 13 HRQoL SF-36 (domains)
Study or subgroup Antibiotics Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 SF-36 general health
Albert 2011 (1) 484 41.8 (20.9) 483 39.1 (20.3) 72.2 % 2.70 [ 0.10, 5.30 ]
Berkhof 2013 (2) 36 4.5 (14.4) 36 -3.8 (14.4) 21.2 % 8.30 [ 1.65, 14.95 ]
He 2010 (3) 16 45.1 (19.5172) 16 39.8 (17.2652) 6.6 % 5.30 [ -7.47, 18.07 ]
Subtotal (95% CI) 536 535 100.0 % 4.06 [ 0.70, 7.42 ]
Heterogeneity: Tau2 = 2.31; Chi2 = 2.44, df = 2 (P = 0.30); I2 =18%
Test for overall effect: Z = 2.37 (P = 0.018)
2 SF-36 physical functioning
Albert 2011 (4) 484 39.3 (25.8) 483 38.6 (24.1) 74.4 % 0.70 [ -2.45, 3.85 ]
Berkhof 2013 (5) 37 5.5 (13.3821) 36 0.7 (13.8) 20.8 % 4.80 [ -1.44, 11.04 ]
-100 -50 0 50 100
Favours placebo Favours antibiotics
(Continued . . . )
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(. . . Continued)
Study or subgroup Antibiotics Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
He 2010 (6) 16 65 (18.3912) 15 57.6 (18.5994) 4.9 % 7.40 [ -5.63, 20.43 ]
Subtotal (95% CI) 537 534 100.0 % 1.88 [ -1.01, 4.77 ]
Heterogeneity: Tau2 = 0.35; Chi2 = 2.07, df = 2 (P = 0.36); I2 =3%
Test for overall effect: Z = 1.27 (P = 0.20)
3 SF-36 bodily pain
Albert 2011 (7) 484 68.9 (26.2) 483 69.1 (26) 83.0 % -0.20 [ -3.49, 3.09 ]
Berkhof 2013 (8) 37 5.6 (20.0731) 37 -0.9 (20.0731) 10.7 % 6.50 [ -2.65, 15.65 ]
He 2010 (9) 16 80.4 (17.4529) 15 80.4 (16.613) 6.2 % 0.0 [ -11.99, 11.99 ]
Subtotal (95% CI) 537 535 100.0 % 0.53 [ -2.47, 3.53 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.83, df = 2 (P = 0.40); I2 =0.0%
Test for overall effect: Z = 0.35 (P = 0.73)
4 SF-36 vitality
Albert 2011 (10) 484 48.3 (21.1) 483 46.9 (20.8) 82.6 % 1.40 [ -1.24, 4.04 ]
Berkhof 2013 (11) 36 4 (14.4) 36 -2 (14.4) 13.0 % 6.00 [ -0.65, 12.65 ]
He 2010 (12) 16 66.1 (18.9542) 15 64.1 (13.5432) 4.3 % 2.00 [ -9.54, 13.54 ]
Subtotal (95% CI) 536 534 100.0 % 2.03 [ -0.38, 4.43 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.59, df = 2 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 1.65 (P = 0.098)
5 SF-36 role emotional
Albert 2011 (13) 484 66.5 (41.3) 483 68.3 (41.5) 84.4 % -1.80 [ -7.02, 3.42 ]
Berkhof 2013 (14) 37 -0.4 (34.0635) 37 -6.3 (34.0635) 9.5 % 5.90 [ -9.62, 21.42 ]
He 2010 (15) 16 63.4 (33.7798) 15 60 (20.5857) 6.0 % 3.40 [ -16.16, 22.96 ]
Subtotal (95% CI) 537 535 100.0 % -0.75 [ -5.55, 4.04 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.03, df = 2 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 0.31 (P = 0.76)
6 SF-36 social functioning
Albert 2011 (16) 484 71.7 (25.4) 483 70.8 (26.9) 45.7 % 0.90 [ -2.40, 4.20 ]
Berkhof 2013 (17) 37 4.4 (18.8566) 37 -8.5 (18.8566) 34.8 % 12.90 [ 4.31, 21.49 ]
He 2010 (18) 16 70.5 (24.2089) 15 58.8 (23.2944) 19.6 % 11.70 [ -5.02, 28.42 ]
Subtotal (95% CI) 537 535 100.0 % 7.19 [ -2.40, 16.78 ]
Heterogeneity: Tau2 = 49.60; Chi2 = 7.67, df = 2 (P = 0.02); I2 =74%
Test for overall effect: Z = 1.47 (P = 0.14)
7 SF-36 mental health
Albert 2011 (19) 484 75.9 (17.7) 483 75.2 (18) 63.3 % 0.70 [ -1.55, 2.95 ]
Berkhof 2013 (20) 36 2.2 (11.4) 36 -3.5 (11.4) 29.1 % 5.70 [ 0.43, 10.97 ]
He 2010 (21) 16 80 (17.4529) 15 76.5 (16.7936) 7.7 % 3.50 [ -8.56, 15.56 ]
Subtotal (95% CI) 536 534 100.0 % 2.37 [ -1.13, 5.86 ]
-100 -50 0 50 100
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(. . . Continued)
Study or subgroup Antibiotics Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Heterogeneity: Tau2 = 3.71; Chi2 = 3.03, df = 2 (P = 0.22); I2 =34%
Test for overall effect: Z = 1.33 (P = 0.18)
8 SF-36 role physical
Albert 2011 (22) 484 39.3 (25.8) 483 41.4 (41) 50.9 % -2.10 [ -6.42, 2.22 ]
Berkhof 2013 (23) 37 16.2 (32.8469) 37 -1.1 (32.8469) 33.9 % 17.30 [ 2.33, 32.27 ]
He 2010 (24) 16 45.1 (44.6644) 15 46.2 (44.4218) 15.2 % -1.10 [ -32.47, 30.27 ]
Subtotal (95% CI) 537 535 100.0 % 4.63 [ -9.82, 19.09 ]
Heterogeneity: Tau2 = 102.06; Chi2 = 5.96, df = 2 (P = 0.05); I2 =66%
Test for overall effect: Z = 0.63 (P = 0.53)
Test for subgroup differences: Chi2 = 4.93, df = 7 (P = 0.67), I2 =0.0%
-100 -50 0 50 100
Favours placebo Favours antibiotics
(1) Azithromycin 250mg daily for 12 months. Outcome extracted at 6 months.
(2) Azithromycin 250mg three times/week for 12 weeks.
(3) Erythromycin 125mg three times/day for 6 months.
(4) Azithromycin 250mg daily for 12 months. Outcome extracted at 6 months.
(5) Azithromycin 250mg three times/week for 12 weeks.
(6) Erythromycin 125mg three times/day for 6 months.
(7) Azithromycin 250mg daily for 12 months. Outcome extracted at 6 months.
(8) Azithromycin 250mg three times/week for 12 weeks.
(9) Erythromycin 125mg three times/day for 6 months.
(10) Azithromycin 250mg daily for 12 months. Outcome extracted at 6 months.
(11) Azithromycin 250mg three times/week for 12 weeks.
(12) Erythromycin 125mg three times/day for 6 months.
(13) Azithromycin 250mg daily for 12 months. Outcome extracted at 6 months.
(14) Azithromycin 250mg three times/week for 12 weeks.
(15) Erythromycin 125mg three times/day for 6 months.
(16) Azithromycin 250mg daily for 12 months. Outcome extracted at 6 months.
(17) Azithromycin 250mg three times/week for 12 weeks.
(18) Erythromycin 125mg three times/day for 6 months.
(19) Azithromycin 250mg daily for 12 months. Outcome extracted at 6 months.
(20) Azithromycin 250mg three times/week for 12 weeks.
(21) Erythromycin 125mg three times/day for 6 months.
(22) Azithromycin 250mg daily for 12 months. Outcome extracted at 6 months.
(23) Azithromycin 250mg three times/week for 12 weeks.
(24) Erythromycin 125mg three times/day for 6 months.
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Analysis 1.14. Comparison 1 Antibiotics versus placebo, Outcome 14 HRQoL, LCQ (domains).
Review: Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD)
Comparison: 1 Antibiotics versus placebo
Outcome: 14 HRQoL, LCQ (domains)
Study or subgroup Antibiotiocs Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 LCQ physical
Berkhof 2013 (1) 38 0.6 (0.6164) 41 0.2 (0.6403) 100.0 % 0.40 [ 0.12, 0.68 ]
Subtotal (95% CI) 38 41 100.0 % 0.40 [ 0.12, 0.68 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.83 (P = 0.0047)
2 LCQ psychological
Berkhof 2013 (2) 38 0.8 (0.6164) 41 0.3 (0.6403) 100.0 % 0.50 [ 0.22, 0.78 ]
Subtotal (95% CI) 38 41 100.0 % 0.50 [ 0.22, 0.78 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.54 (P = 0.00041)
3 LCQ social
Berkhof 2013 (3) 38 0.8 (1.2329) 41 0.4 (1.2806) 100.0 % 0.40 [ -0.15, 0.95 ]
Subtotal (95% CI) 38 41 100.0 % 0.40 [ -0.15, 0.95 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.41 (P = 0.16)
Test for subgroup differences: Chi2 = 0.28, df = 2 (P = 0.87), I2 =0.0%
-2 -1 0 1 2
Favours placebo Favours antibiotics
(1) Azithromycin 250mg three times/week for 12 weeks.
(2) Azithromycin 250mg three times/week for 12 weeks.
(3) Azithromycin 250mg three times/week for 12 weeks.
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Analysis 1.15. Comparison 1 Antibiotics versus placebo, Outcome 15 HRQoL, CCQ (total).
Review: Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD)
Comparison: 1 Antibiotics versus placebo
Outcome: 15 HRQoL, CCQ (total)
Study or subgroup Antibiotics Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Continuous antibiotics
Simpson 2014 (1) 15 16.9 (10.1) 15 15.1 (9.2) 1.80 [ -5.11, 8.71 ]
-20 -10 0 10 20
Favours antibiotics Favours placebo
(1) Azithromycin 250mg daily for 12 weeks. Outcome reported at 26 weeks.
Analysis 1.16. Comparison 1 Antibiotics versus placebo, Outcome 16 HRQoL, CRQ (domains).
Review: Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD)
Comparison: 1 Antibiotics versus placebo
Outcome: 16 HRQoL, CRQ (domains)
Study or subgroup Antibiotics Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 CRQ dyspnoea
Shafuddin 2015 (1) 93 2.21 (5.35) 44 2.33 (5.58) 47.7 % -0.12 [ -2.10, 1.86 ]
Shafuddin 2015 (2) 94 1.63 (4.53) 44 2.33 (5.58) 52.3 % -0.70 [ -2.59, 1.19 ]
Subtotal (95% CI) 187 88 100.0 % -0.42 [ -1.79, 0.94 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.17, df = 1 (P = 0.68); I2 =0.0%
Test for overall effect: Z = 0.61 (P = 0.54)
2 CRQ fatigue
Shafuddin 2015 (3) 93 0.68 (3.79) 44 1.23 (4.99) 50.2 % -0.55 [ -2.21, 1.11 ]
Shafuddin 2015 (4) 94 0.663 (3.87) 44 1.23 (4.99) 49.8 % -0.57 [ -2.24, 1.10 ]
Subtotal (95% CI) 187 88 100.0 % -0.56 [ -1.74, 0.62 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 0.93 (P = 0.35)
3 CRQ emotional function
-4 -2 0 2 4
Favours antibiotics Favours placebo
(Continued . . . )
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(. . . Continued)
Study or subgroup Antibiotics Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Shafuddin 2015 (5) 93 0.45 (5.04) 44 1.3 (5.18) 48.3 % -0.85 [ -2.69, 0.99 ]
Shafuddin 2015 (6) 94 0.82 (4.48) 44 1.3 (5.18) 51.7 % -0.48 [ -2.26, 1.30 ]
Subtotal (95% CI) 187 88 100.0 % -0.66 [ -1.94, 0.62 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.08, df = 1 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 1.01 (P = 0.31)
4 CRQ mastery
Shafuddin 2015 (7) 93 0.53 (3.42) 44 1.13 (4.5) 51.8 % -0.60 [ -2.10, 0.91 ]
Shafuddin 2015 (8) 94 1.32 (4) 44 1.13 (4.5) 48.2 % 0.20 [ -1.36, 1.75 ]
Subtotal (95% CI) 187 88 100.0 % -0.21 [ -1.29, 0.87 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.51, df = 1 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 0.39 (P = 0.70)
Test for subgroup differences: Chi2 = 0.32, df = 3 (P = 0.96), I2 =0.0%
-4 -2 0 2 4
Favours antibiotics Favours placebo
(1) Roxithromycin 300mg daily + doxycyline 100mg daily. Outcome reported at 12 weeks. Control group halved.
(2) Roxithromycin 300mg daily for 12 weeks. Outcome reported at 12 weeks. Control group halved.
(3) Roxithromycin 300mg daily + doxycyline 100mg daily. Outcome reported at 12 weeks. Control group halved.
(4) Roxithromycin 300mg daily for 12 weeks. Outcome reported at 12 weeks. Control group halved.
(5) Roxithromycin 300mg daily + doxycyline 100mg daily. Outcome reported at 12 weeks. Control group halved.
(6) Roxithromycin 300mg daily for 12 weeks. Outcome reported at 12 weeks. Control group halved.
(7) Roxithromycin 300mg daily + doxycyline 100mg daily. Outcome reported at 12 weeks. Control group halved.
(8) Roxithromycin 300mg daily for 12 weeks. Outcome reported at 12 weeks. Control group halved.
Analysis 1.17. Comparison 1 Antibiotics versus placebo, Outcome 17 Frequency of hospital admissions -
continuous antibiotics.
Frequency of hospital admissions - continuous antibiotics
Study GOLD stage Rate of hospitalisations per patient year
on moxifloxacin (Mean +/-SD)
Rate of hospitalisations per patient year
on placebo (Mean +/-SD)
Albert 2011 2 : FEV1 (80% - 50%) 0.50 +/-0.12 0.65 +/- 0.11
Albert 2011 3 : FEV1 (50% - 30%) 0.85 +/- 0.12 0.96 +/- 0.12
Albert 2011 4 : FEV1 < 30% 0.74 +/- 0.12 1.03 +/- 0.27
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Analysis 1.18. Comparison 1 Antibiotics versus placebo, Outcome 18 Frequency of hospital admissions -
pulsed antibiotics.
Frequency of hospital admissions - pulsed antibiotics
Study Frequency of hospitalisation (%) on
moxifloxacin
Frequency of hospitalisation (%) on
placebo
P value
Sethi 2010 131 (23.02%) 136 (23.45%) 0.46
Analysis 1.19. Comparison 1 Antibiotics versus placebo, Outcome 19 Duration of exacerbation.
Duration of exacerbation
Study Median days of exacerbation,
treatment arm
Median days of exacerbation,
placebo arm
P value
Continuous antibiotics
Seemungal 2008 9 (6 to14) 13 (6 to 24) 0.036 Mann-Whitney test
Pulsed antibiotics
Mygind 2010 93 (total exacerbation days at home
or hospitalised)
111 (total exacerbations days at
home or hospitalised)
0.04
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Analysis 1.20. Comparison 1 Antibiotics versus placebo, Outcome 20 FEV1 (mL).
Review: Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD)
Comparison: 1 Antibiotics versus placebo
Outcome: 20 FEV1 (mL)
Study or subgroup Antibiotics Placebo Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Random,95% CI IV,Random,95% CI
1 Continuous antibiotics
Brill 2015 (1) 25 8 39 (89.9277) 6.9 % 39.00 [ -137.26, 215.26 ]
Seemungal 2008 (2) 44 45 -120 (119.2524) 3.9 % -120.00 [ -353.73, 113.73 ]
Shafuddin 2015 (3) 88 44 -36 (56.9489) 17.3 % -36.00 [ -147.62, 75.62 ]
Shafuddin 2015 (4) 94 44 -26 (59.1383) 16.0 % -26.00 [ -141.91, 89.91 ]
Tan 2016 (5) 17 8 110 (139.0197) 2.9 % 110.00 [ -162.47, 382.47 ]
Tan 2016 (6) 17 7 70 (119.4525) 3.9 % 70.00 [ -164.12, 304.12 ]
Subtotal (95% CI) 285 156 51.0 % -12.69 [ -77.66, 52.28 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 2.62, df = 5 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 0.38 (P = 0.70)
2 Intermittent antibiotics
Berkhof 2013 (7) 35 39 58 (42.7846) 30.6 % 58.00 [ -25.86, 141.86 ]
Brill 2015 (8) 25 8 -1 (90.6529) 6.8 % -1.00 [ -178.68, 176.68 ]
Uzun 2014 (9) 41 36 100 (101.4288) 5.4 % 100.00 [ -98.80, 298.80 ]
Subtotal (95% CI) 101 83 42.9 % 53.95 [ -16.90, 124.81 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.58, df = 2 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 1.49 (P = 0.14)
3 Pulsed antibiotics
Brill 2015 (10) 25 8 58 (95.7294) 6.1 % 58.00 [ -129.63, 245.63 ]
Subtotal (95% CI) 25 8 6.1 % 58.00 [ -129.63, 245.63 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.61 (P = 0.54)
Total (95% CI) 411 247 100.0 % 20.21 [ -26.19, 66.61 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 5.21, df = 9 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 0.85 (P = 0.39)
Test for subgroup differences: Chi2 = 2.01, df = 2 (P = 0.37), I2 =1%
-500 -250 0 250 500
Favours placebo Favours antibiotics
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(1) Doxycycline 100mg daily for 13 weeks. Control group split three ways.
(2) Erythromycin 250mg twice/day for 12 months.
(3) Roxithromycin 300mg daily + doxycyline 100mg for 12 weeks. Outcome reported at 12 weeks. Control group halved.
(4) Roxithromycin 300mg daily for 12 weeks. Outcome reported at 12 weeks. Control group halved.
(5) Erythromycin 125mg three times/day for 12 months. Control group halved.
(6) Erythromycin 125mg three times/day for six months. Control group halved.
(7) Azithromycin 250mg three times/week for 12 weeks. Extracted from database supplied by author.
(8) Azithromycin 250mg three times/week for 13 weeks. Control group split three ways.
(9) Azithromycin 500mg three times/week for 12 months.
(10) Moxifloxacin 400mg daily for five days every four weeks for 13 weeks. Control group split three ways.
Analysis 1.21. Comparison 1 Antibiotics versus placebo, Outcome 21 FVC (L).
Review: Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD)
Comparison: 1 Antibiotics versus placebo
Outcome: 21 FVC (L)
Study or subgroup Antibiotics Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Continuous antibiotics
Shafuddin 2015 (1) 88 0.06 (0.46) 88 0.04 (0.64) 34.9 % 0.02 [ -0.15, 0.18 ]
Shafuddin 2015 (2) 94 0.09 (0.55) 44 0.04 (0.64) 21.3 % 0.05 [ -0.17, 0.27 ]
Tan 2016 (3) 17 2.41 (0.76) 7 2.04 (0.39) 5.2 % 0.37 [ -0.09, 0.83 ]
Tan 2016 (4) 17 2.43 (0.53) 8 2.04 (0.39) 8.1 % 0.39 [ 0.02, 0.76 ]
Subtotal (95% CI) 216 147 69.4 % 0.13 [ -0.04, 0.30 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 4.84, df = 3 (P = 0.18); I2 =38%
Test for overall effect: Z = 1.45 (P = 0.15)
2 Intermittent antibiotics
Berkhof 2013 (5) 35 0.083 (0.44) 39 -0.08 (0.48) 23.1 % 0.17 [ -0.04, 0.37 ]
Uzun 2014 (6) 41 2.9 (0.93) 36 2.7 (0.79) 7.5 % 0.20 [ -0.18, 0.58 ]
Subtotal (95% CI) 76 75 30.6 % 0.17 [ -0.01, 0.36 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.02, df = 1 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 1.84 (P = 0.065)
Total (95% CI) 292 222 100.0 % 0.12 [ 0.01, 0.23 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 5.43, df = 5 (P = 0.37); I2 =8%
Test for overall effect: Z = 2.19 (P = 0.028)
Test for subgroup differences: Chi2 = 0.14, df = 1 (P = 0.71), I2 =0.0%
-1 -0.5 0 0.5 1
Favours placebo Favours antibiotics
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(1) Roxithromycin 300mg daily + doxycyline 100mg for 12 weeks. Outcome reported at 12 weeks. Control group halved.
(2) Roxithromycin 300mg daily for 12 weeks. Outcome reported at 12 weeks. Control group halved.
(3) Erythromycin 125mg three times/day for 12 months. Control group halved.
(4) Erythromycin 125mg three times/day for six months. Control group halved.
(5) Azithromycin 250mg three times/week for 12 weeks. Extracted from database supplied by author.
(6) Azithromycin 500mg three times/week for 12 months.
Analysis 1.22. Comparison 1 Antibiotics versus placebo, Outcome 22 FEV1 % predicted.
Review: Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD)
Comparison: 1 Antibiotics versus placebo
Outcome: 22 FEV1 % predicted
Study or subgroup Antibiotics Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Continuous antibiotics
Shafuddin 2015 (1) 88 1.7 (9) 88 3.03 (11) 19.5 % -1.33 [ -4.30, 1.64 ]
Shafuddin 2015 (2) 94 1.87 (11) 88 3.03 (11) 18.1 % -1.16 [ -4.36, 2.04 ]
Simpson 2014 (3) 15 57.79 (13.9) 15 52.17 (14.3) 3.2 % 5.62 [ -4.47, 15.71 ]
Tan 2016 (4) 17 45.49 (9.09) 8 40.03 (8.5) 5.7 % 5.46 [ -1.85, 12.77 ]
Tan 2016 (5) 17 48.58 (13.24) 7 40.03 (8.5) 4.0 % 8.55 [ -0.35, 17.45 ]
Subtotal (95% CI) 231 206 50.6 % 1.43 [ -1.97, 4.83 ]
Heterogeneity: Tau2 = 6.72; Chi2 = 8.16, df = 4 (P = 0.09); I2 =51%
Test for overall effect: Z = 0.82 (P = 0.41)
2 Intermittent antibiotics
Berkhof 2013 (6) 35 1.4 (6.5) 39 -0.62 (7.59) 18.1 % 2.02 [ -1.19, 5.23 ]
Uzun 2014 (7) 41 43.4 (17.9) 36 44.2 (20.1) 4.3 % -0.80 [ -9.35, 7.75 ]
Subtotal (95% CI) 76 75 22.4 % 1.67 [ -1.33, 4.68 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.37, df = 1 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 1.09 (P = 0.28)
3 Pulsed antibiotics
Sethi 2010 (8) 569 39.79 (16.793) 580 41.14 (16.6174) 27.1 % -1.35 [ -3.28, 0.58 ]
Subtotal (95% CI) 569 580 27.1 % -1.35 [ -3.28, 0.58 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.37 (P = 0.17)
Total (95% CI) 876 861 100.0 % 0.33 [ -1.56, 2.22 ]
Heterogeneity: Tau2 = 2.46; Chi2 = 11.40, df = 7 (P = 0.12); I2 =39%
Test for overall effect: Z = 0.34 (P = 0.73)
Test for subgroup differences: Chi2 = 3.72, df = 2 (P = 0.16), I2 =46%
-20 -10 0 10 20
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(1) Roxithromycin 300mg daily + doxycyline 100mg for 12 weeks. Change from baseline. Outcome reported at ?12 weeks. Control group halved.
(2) Roxithromycin 300mg daily for 12 weeks. Change from baseline. Outcome reported at ?12 weeks. Control group halved.
(3) Azithromycin 250mg daily for 12 weeks. Outcome reported at 26 weeks. ?Endpoint
(4) Erythromycin 125mg three times/day for six months. Control group halved.
(5) Erythromycin 125mg three times/day for 12 months. Control group halved.
(6) Azithromycin 250mg three times/week for 12 weeks. Extracted from database supplied by author.
(7) Azithromycin 500mg three times/week for 12 months.
(8) Moxifloxacin 400mg daily for for five days every eight weeks for 48 weeks.
Analysis 1.23. Comparison 1 Antibiotics versus placebo, Outcome 23 Exercise capacity (6MWT).
Review: Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD)
Comparison: 1 Antibiotics versus placebo
Outcome: 23 Exercise capacity (6MWT)
Study or subgroup Antibiotics Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Continuous antibiotics
Tan 2016 (1) 17 425.07 (32.84) 7 304.86 (70.55) 33.0 % 120.21 [ 65.67, 174.75 ]
Tan 2016 (2) 17 352.8 (53.87) 8 304.86 (70.55) 32.7 % 47.94 [ -7.25, 103.13 ]
Subtotal (95% CI) 34 15 65.7 % 84.20 [ 13.38, 155.03 ]
Heterogeneity: Tau2 = 1827.80; Chi2 = 3.33, df = 1 (P = 0.07); I2 =70%
Test for overall effect: Z = 2.33 (P = 0.020)
2 Intermittent antibiotics
Uzun 2014 (3) 41 415 (108) 36 379 (121) 34.3 % 36.00 [ -15.53, 87.53 ]
Subtotal (95% CI) 41 36 34.3 % 36.00 [ -15.53, 87.53 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.37 (P = 0.17)
Total (95% CI) 75 51 100.0 % 67.67 [ 16.20, 119.14 ]
Heterogeneity: Tau2 = 1316.81; Chi2 = 5.50, df = 2 (P = 0.06); I2 =64%
Test for overall effect: Z = 2.58 (P = 0.010)
Test for subgroup differences: Chi2 = 1.16, df = 1 (P = 0.28), I2 =14%
-100 -50 0 50 100
Favours placebo Favours antibiotics
(1) Erythromycin 125mg three times/day for 12 months. Control group halved.
(2) Erythromycin 125mg three times/day for six months. Control group halved.
(3) Azithromycin 500mg three times/week for 12 months.
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Analysis 1.24. Comparison 1 Antibiotics versus placebo, Outcome 24 All-cause mortality.
Review: Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD)
Comparison: 1 Antibiotics versus placebo
Outcome: 24 All-cause mortality
Study or subgroup Antibiotics Placebo Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Continuous antibiotics
Albert 2011 (1) 18/558 20/559 18.9 % 0.90 [ 0.47, 1.72 ]
Shafuddin 2015 (2) 3/97 3/47 3.0 % 0.47 [ 0.09, 2.41 ]
Shafuddin 2015 (3) 5/101 2/47 2.8 % 1.17 [ 0.22, 6.27 ]
Subtotal (95% CI) 756 653 24.7 % 0.86 [ 0.49, 1.51 ]
Total events: 26 (Antibiotics), 25 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.68, df = 2 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 0.54 (P = 0.59)
2 Intermittent antibiotics
Berkhof 2013 (4) 0/42 0/42 Not estimable
Uzun 2014 (5) 0/47 2/45 0.8 % 0.18 [ 0.01, 3.92 ]
Subtotal (95% CI) 89 87 0.8 % 0.18 [ 0.01, 3.92 ]
Total events: 0 (Antibiotics), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.09 (P = 0.28)
3 Pulsed antibiotics
Mygind 2010 (6) 74/287 81/288 58.4 % 0.89 [ 0.61, 1.28 ]
Sethi 2010 (7) 15/569 17/580 16.0 % 0.90 [ 0.44, 1.81 ]
Subtotal (95% CI) 856 868 74.5 % 0.89 [ 0.64, 1.23 ]
Total events: 89 (Antibiotics), 98 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 0.70 (P = 0.48)
Total (95% CI) 1701 1608 100.0 % 0.87 [ 0.66, 1.15 ]
Total events: 115 (Antibiotics), 125 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.69, df = 5 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 0.97 (P = 0.33)
Test for subgroup differences: Chi2 = 1.01, df = 2 (P = 0.60), I2 =0.0%
0.005 0.1 1 10 200
Favours antibiotics Favours placebo
(1) Azithromycin 250mg daily for 12 months.
(2) Roxithromycin 300mg daily for 12 weeks. Outcome reported at 60 weeks. Control group (5 deaths total) halved.
(3) Roxithromycin 300mg daily + doxycyline 100mg for 12 weeks. Outcome reported at 60 weeks. Control group (5 deaths total) halved.
(4) Azithromycin 250mg three times/week for 12 weeks.
(5) Azithromycin 500mg three times/week for 12 months.
(6) Azithromycin 500mg daily for 3 days every month for 36 months.
(7) Moxifloxacin 400mg daily for five days every eight weeks for 48 weeks.
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Analysis 1.25. Comparison 1 Antibiotics versus placebo, Outcome 25 Respiratory-related mortality.
Review: Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD)
Comparison: 1 Antibiotics versus placebo
Outcome: 25 Respiratory-related mortality
Study or subgroup Antibiotics Placebo Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Continuous antibiotics
Albert 2011 (1) 10/558 7/559 40.8 % 1.44 [ 0.54, 3.81 ]
Subtotal (95% CI) 558 559 40.8 % 1.44 [ 0.54, 3.81 ]
Total events: 10 (Antibiotics), 7 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.73 (P = 0.46)
2 Pulsed antibiotics
Sethi 2010 (2) 12/569 12/580 59.2 % 1.02 [ 0.45, 2.29 ]
Subtotal (95% CI) 569 580 59.2 % 1.02 [ 0.45, 2.29 ]
Total events: 12 (Antibiotics), 12 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.05 (P = 0.96)
Total (95% CI) 1127 1139 100.0 % 1.17 [ 0.63, 2.19 ]
Total events: 22 (Antibiotics), 19 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.28, df = 1 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 0.50 (P = 0.61)
Test for subgroup differences: Chi2 = 0.28, df = 1 (P = 0.59), I2 =0.0%
0.5 0.7 1 1.5 2
Favours antibiotics Favours placebo
(1) Azithromycin 250mg daily for 12 months.
(2) Moxifloxacin 400mg daily for for five days every eight weeks for 48 weeks.
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Analysis 1.26. Comparison 1 Antibiotics versus placebo, Outcome 26 Serious adverse events.
Review: Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD)
Comparison: 1 Antibiotics versus placebo
Outcome: 26 Serious adverse events
Study or subgroup Antibiotics Placebo Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Continuous antibiotics
Albert 2011 (1) 184/558 212/559 51.4 % 0.81 [ 0.63, 1.03 ]
Brill 2015 (2) 0/25 0/8 Not estimable
He 2010 (3) 2/18 3/18 0.8 % 0.63 [ 0.09, 4.28 ]
Seemungal 2008 (4) 14/53 12/56 4.0 % 1.32 [ 0.54, 3.18 ]
Shafuddin 2015 (5) 24/101 10/47 4.4 % 1.15 [ 0.50, 2.66 ]
Shafuddin 2015 (6) 23/97 10/47 4.4 % 1.15 [ 0.50, 2.67 ]
Simpson 2014 (7) 1/15 4/15 0.6 % 0.20 [ 0.02, 2.02 ]
Tan 2016 (8) 2/36 3/18 0.9 % 0.29 [ 0.04, 1.95 ]
Subtotal (95% CI) 903 768 66.5 % 0.85 [ 0.68, 1.05 ]
Total events: 250 (Antibiotics), 254 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.96, df = 6 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 1.53 (P = 0.13)
2 Intermittent antibiotics
Brill 2015 (9) 0/25 0/8 Not estimable
Uzun 2014 (10) 3/47 5/45 1.4 % 0.55 [ 0.12, 2.43 ]
Subtotal (95% CI) 72 53 1.4 % 0.55 [ 0.12, 2.43 ]
Total events: 3 (Antibiotics), 5 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.80 (P = 0.43)
3 Pulsed antibiotics
Brill 2015 (11) 0/25 0/8 Not estimable
Sethi 2010 (12) 94/569 97/580 32.1 % 0.99 [ 0.72, 1.34 ]
Subtotal (95% CI) 594 588 32.1 % 0.99 [ 0.72, 1.34 ]
Total events: 94 (Antibiotics), 97 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.09 (P = 0.93)
Total (95% CI) 1569 1409 100.0 % 0.88 [ 0.74, 1.05 ]
Total events: 347 (Antibiotics), 356 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 6.00, df = 8 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 1.39 (P = 0.16)
Test for subgroup differences: Chi2 = 1.04, df = 2 (P = 0.60), I2 =0.0%
0.01 0.1 1 10 100
Favours antibiotics Favours placebo
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(1) Azithromycin 250mg daily for 12 months.
(2) Doxycycline 100mg daily. Control group split (No events reported)
(3) Erythromycin 125mg three times/day for six months.
(4) Erythromycin 250mg twice a day for 12 months.
(5) Roxithromycin 300mg daily + doxycyline 100mg daily. Outcome reported at 60 weeks. Control group halved.
(6) Roxithromycin 300mg daily for 12 weeks. Outcome reported at 60 weeks. Control group halved.
(7) Azithromycin 250mg daily for 12 weeks. Outcome reported at 26 weeks.
(8) Adverse event leading to discontinuation. Two erythromycin arms combined (erythromycin 125mg three times/day for 6 months and 12 months; 1 discontinuation in
each arm).
(9) Azithromycin 250mg three times/week. Control group split (No events reported)
(10) Azithromycin 500mg three times/week for 12 months.
(11) Pulsed moxifloxacin 400mg daily for five days every four weeks for 13 weeks. Control group split (No events reported).
(12) Moxifloxacin 400mg daily for for five days every eight weeks for 48 weeks.
Analysis 1.27. Comparison 1 Antibiotics versus placebo, Outcome 27 Any adverse event.
Review: Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD)
Comparison: 1 Antibiotics versus placebo
Outcome: 27 Any adverse event
Study or subgroup Antibiotics Placebo Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Continuous antibiotics
Brill 2015 (1) 2/25 0/8 2.0 % 1.81 [ 0.08, 41.62 ]
Shafuddin 2015 (2) 73/101 34/47 33.1 % 1.00 [ 0.46, 2.16 ]
Shafuddin 2015 (3) 74/97 34/47 31.6 % 1.23 [ 0.56, 2.72 ]
Simpson 2014 (4) 9/15 11/15 8.3 % 0.55 [ 0.12, 2.55 ]
Subtotal (95% CI) 238 117 75.0 % 1.03 [ 0.62, 1.73 ]
Total events: 158 (Antibiotics), 79 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.98, df = 3 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 0.13 (P = 0.90)
2 Intermittent antibiotics
Brill 2015 (5) 1/24 0/8 1.8 % 1.09 [ 0.04, 29.28 ]
Uzun 2014 (6) 36/47 35/45 20.9 % 0.94 [ 0.35, 2.48 ]
Subtotal (95% CI) 71 53 22.7 % 0.95 [ 0.37, 2.41 ]
Total events: 37 (Antibiotics), 35 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.01, df = 1 (P = 0.93); I2 =0.0%
0.005 0.1 1 10 200
Favours antibiotics Favours placebo
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(. . . Continued)
Study or subgroup Antibiotics Placebo Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Test for overall effect: Z = 0.12 (P = 0.91)
3 Pulsed antibiotics
Brill 2015 (7) 10/25 0/8 2.3 % 11.52 [ 0.60, 221.75 ]
Subtotal (95% CI) 25 8 2.3 % 11.52 [ 0.60, 221.75 ]
Total events: 10 (Antibiotics), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.62 (P = 0.11)
Total (95% CI) 334 178 100.0 % 1.07 [ 0.69, 1.67 ]
Total events: 205 (Antibiotics), 114 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.61, df = 6 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 0.30 (P = 0.76)
Test for subgroup differences: Chi2 = 2.56, df = 2 (P = 0.28), I2 =22%
0.005 0.1 1 10 200
Favours antibiotics Favours placebo
(1) Doxycycline 100mg daily for 13 weeks. Treatment related AEs. Control group split three ways.
(2) Roxithromycin 300mg daily + doxycyline 100mg daily. Outcome reported at 60 weeks. Control group halved.
(3) Roxithromycin 300mg daily for 12 weeks. Outcome reported at 60 weeks. Control group halved.
(4) Azithromycin 250mg daily for 12 weeks. ”Other” adverse event. Outcome reported at 26 weeks.
(5) Azithromycin 250mg three times/week for 13 weeks. Treatment related AEs. Control group split three ways
(6) Azithromycin 500mg three times/week for 12 months.
(7) Pulsed moxifloxacin 400mg daily for five days every four weeks for 13 weeks. Treatment related AEs. Control group split three ways.
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Analysis 1.28. Comparison 1 Antibiotics versus placebo, Outcome 28 Adverse events (specific).
Review: Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD)
Comparison: 1 Antibiotics versus placebo
Outcome: 28 Adverse events (specific)
Study or subgroup Antibiotics Placebo Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Respiratory disorders
Albert 2011 (1) 26/558 41/559 50.5 % 0.62 [ 0.37, 1.02 ]
Berkhof 2013 (2) 7/42 8/42 36.8 % 0.85 [ 0.28, 2.60 ]
Sethi 2010 (3) 8/569 0/580 12.8 % 17.58 [ 1.01, 305.21 ]
Subtotal (95% CI) 1169 1181 100.0 % 1.07 [ 0.33, 3.41 ]
Total events: 41 (Antibiotics), 49 (Placebo)
Heterogeneity: Tau2 = 0.63; Chi2 = 5.71, df = 2 (P = 0.06); I2 =65%
Test for overall effect: Z = 0.11 (P = 0.92)
2 Gastrointestinal disorders
Albert 2011 (4) 15/558 21/559 23.5 % 0.71 [ 0.36, 1.39 ]
Berkhof 2013 (5) 5/42 6/42 18.4 % 0.81 [ 0.23, 2.89 ]
He 2010 (6) 1/18 0/18 6.8 % 3.17 [ 0.12, 83.17 ]
Seemungal 2008 (7) 8/53 8/53 20.2 % 1.00 [ 0.35, 2.90 ]
Sethi 2010 (8) 27/569 4/580 20.3 % 7.17 [ 2.49, 20.63 ]
Simpson 2014 (9) 1/15 5/15 10.9 % 0.14 [ 0.01, 1.42 ]
Subtotal (95% CI) 1255 1267 100.0 % 1.16 [ 0.43, 3.11 ]
Total events: 57 (Antibiotics), 44 (Placebo)
Heterogeneity: Tau2 = 0.96; Chi2 = 17.87, df = 5 (P = 0.003); I2 =72%
Test for overall effect: Z = 0.29 (P = 0.77)
3 QTc prolongation
Albert 2011 (10) 7/558 6/559 100.0 % 1.17 [ 0.39, 3.51 ]
Subtotal (95% CI) 558 559 100.0 % 1.17 [ 0.39, 3.51 ]
Total events: 7 (Antibiotics), 6 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.28 (P = 0.78)
4 Hearing impairment
Albert 2011 (11) 142/558 110/559 100.0 % 1.39 [ 1.05, 1.85 ]
Subtotal (95% CI) 558 559 100.0 % 1.39 [ 1.05, 1.85 ]
Total events: 142 (Antibiotics), 110 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.30 (P = 0.021)
5 Musculoskeletal disorders
0.01 0.1 1 10 100
Favours antibiotics Favours placebo
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Study or subgroup Antibiotics Placebo Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Sethi 2010 (12) 3/569 1/580 100.0 % 3.07 [ 0.32, 29.59 ]
Subtotal (95% CI) 569 580 100.0 % 3.07 [ 0.32, 29.59 ]
Total events: 3 (Antibiotics), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.97 (P = 0.33)
6 Hypersensitivity/skin rash
Seemungal 2008 (13) 3/53 2/56 27.4 % 1.62 [ 0.26, 10.10 ]
Sethi 2010 (14) 8/569 5/580 72.6 % 1.64 [ 0.53, 5.04 ]
Subtotal (95% CI) 622 636 100.0 % 1.63 [ 0.63, 4.26 ]
Total events: 11 (Antibiotics), 7 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 1.01 (P = 0.31)
7 Nervous system disorders
Sethi 2010 (15) 6/569 4/580 87.0 % 1.53 [ 0.43, 5.47 ]
Simpson 2014 (16) 0/15 1/15 13.0 % 0.31 [ 0.01, 8.28 ]
Subtotal (95% CI) 584 595 100.0 % 1.25 [ 0.38, 4.08 ]
Total events: 6 (Antibiotics), 5 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.79, df = 1 (P = 0.37); I2 =0.0%
Test for overall effect: Z = 0.36 (P = 0.72)
8 Cardiovascular
Berkhof 2013 (17) 2/42 1/42 100.0 % 2.05 [ 0.18, 23.51 ]
Subtotal (95% CI) 42 42 100.0 % 2.05 [ 0.18, 23.51 ]
Total events: 2 (Antibiotics), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.58 (P = 0.56)
Test for subgroup differences: Chi2 = 1.13, df = 7 (P = 0.99), I2 =0.0%
0.01 0.1 1 10 100
Favours antibiotics Favours placebo
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(1) Azithromycin 250mg daily for 12 months.
(2) Azithromycin 250mg three times/week for 12 weeks.
(3) Moxifloxacin 400mg daily for for five days every eight weeks for 48 weeks (pulsed).
(4) Azithromycin 250mg daily for 12 months.
(5) Azithromycin 250mg three times/week for 12 weeks.
(6) Erythromycin 125mg three times/day for six months.
(7) Erythromycin 250mg twice/day for 12 months.
(8) Moxifloxacin 400mg daily for for five days every eight weeks for 48 weeks (pulsed).
(9) Azithromycin 250mg daily for 12 weeks. ”Diarrhoea”. Outcome reported at 26 weeks.
(10) Azithromycin 250mg daily for 12 months.
(11) Azithromycin 250mg daily for 12 months.
(12) Moxifloxacin 400mg daily for for five days every eight weeks for 48 weeks (pulsed).
(13) Erythromycin 250mg twice/day for 12 months.
(14) Moxifloxacin 400mg daily for for five days every eight weeks for 48 weeks (pulsed).
(15) Moxifloxacin 400mg daily for for five days every eight weeks for 48 weeks (pulsed).
(16) Azithromycin 250mg daily for 12 weeks. ”Headache”. Outcome reported at 26 weeks.
(17) Azithromycin 250mg three times/week for 12 weeks.
Analysis 2.1. Comparison 2 Subgroup analyses, Outcome 1 Subgroup analysis: number of people with one
or more exacerbations by mean % predicted FEV1.
Review: Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD)
Comparison: 2 Subgroup analyses
Outcome: 1 Subgroup analysis: number of people with one or more exacerbations by mean % predicted FEV1
Study or subgroup Antibiotics Placebo Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Mean FEV1 %≥ 50
Simpson 2014 (1) 4/15 9/15 3.6 % 0.24 [ 0.05, 1.13 ]
Subtotal (95% CI) 15 15 3.6 % 0.24 [ 0.05, 1.13 ]
Total events: 4 (Antibiotics), 9 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.80 (P = 0.072)
2 Mean FEV1 % < 50
Albert 2011 (2) 317/558 380/559 29.4 % 0.62 [ 0.49, 0.79 ]
Berkhof 2013 (3) 10/42 17/42 8.2 % 0.46 [ 0.18, 1.18 ]
Brill 2015 (4) 15/25 4/8 3.3 % 1.50 [ 0.30, 7.43 ]
Brill 2015 (5) 10/25 4/8 3.3 % 0.67 [ 0.13, 3.30 ]
0.02 0.1 1 10 50
Favours antibiotic Favours placebo
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(. . . Continued)
Study or subgroup Antibiotics Placebo Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Brill 2015 (6) 10/25 5/8 3.2 % 0.40 [ 0.08, 2.06 ]
He 2010 (7) 9/18 14/18 4.0 % 0.29 [ 0.07, 1.21 ]
Seemungal 2008 (8) 28/53 42/56 10.3 % 0.37 [ 0.17, 0.84 ]
Sethi 2010 (9) 269/569 295/580 29.9 % 0.87 [ 0.69, 1.09 ]
Uzun 2014 (10) 34/47 42/45 4.6 % 0.19 [ 0.05, 0.71 ]
Subtotal (95% CI) 1362 1324 96.4 % 0.60 [ 0.44, 0.81 ]
Total events: 702 (Antibiotics), 803 (Placebo)
Heterogeneity: Tau2 = 0.06; Chi2 = 13.83, df = 8 (P = 0.09); I2 =42%
Test for overall effect: Z = 3.33 (P = 0.00087)
Total (95% CI) 1377 1339 100.0 % 0.57 [ 0.42, 0.78 ]
Total events: 706 (Antibiotics), 812 (Placebo)
Heterogeneity: Tau2 = 0.07; Chi2 = 15.58, df = 9 (P = 0.08); I2 =42%
Test for overall effect: Z = 3.55 (P = 0.00038)
Test for subgroup differences: Chi2 = 1.26, df = 1 (P = 0.26), I2 =21%
0.02 0.1 1 10 50
Favours antibiotic Favours placebo
(1) Azithromycin 250mg daily for 12 weeks. Severe exacerbations (requiring unscheduled visit, antibiotics and/or steroids). Outcome reported at 26 weeks.
(2) Azithromycin 250mg daily for 12 months.
(3) Azithromycin 250mg three times/week for 12 weeks. Outcome reported at 18 weeks.
(4) Doxycycline 100mg daily for 13 weeks. Control group split three ways.
(5) Azithromycin 250mg three times/week for 13 weeks. Control group split three ways.
(6) Moxifloxacin 400mg daily for five days every four weeks for 13 weeks. Control group split three ways.
(7) Erythromycin 125mg three times/day for six months.
(8) Erythromycin 250mg twice/day for 12 months.
(9) Moxifloxacin 400mg daily for for five days every eight weeks for 48 weeks.
(10) Azithromycin 500mg three times/week for 12 months.
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Analysis 2.2. Comparison 2 Subgroup analyses, Outcome 2 Subgroup analysis: number of people with one
or more exacerbations by treatment duration.
Review: Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD)
Comparison: 2 Subgroup analyses
Outcome: 2 Subgroup analysis: number of people with one or more exacerbations by treatment duration
Study or subgroup Antibiotics Placebo Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1≥ 3 months to < 6 months
Berkhof 2013 (1) 10/42 17/42 8.2 % 0.46 [ 0.18, 1.18 ]
Brill 2015 (2) 10/25 4/8 3.3 % 0.67 [ 0.13, 3.30 ]
Brill 2015 (3) 10/25 5/8 3.2 % 0.40 [ 0.08, 2.06 ]
Brill 2015 (4) 15/25 4/8 3.3 % 1.50 [ 0.30, 7.43 ]
Simpson 2014 (5) 4/15 9/15 3.6 % 0.24 [ 0.05, 1.13 ]
Subtotal (95% CI) 132 81 21.7 % 0.51 [ 0.28, 0.94 ]
Total events: 49 (Antibiotics), 39 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.88, df = 4 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 2.16 (P = 0.030)
2≥ 6 months to < 12 months
He 2010 (6) 9/18 14/18 4.0 % 0.29 [ 0.07, 1.21 ]
Sethi 2010 (7) 269/569 295/580 29.9 % 0.87 [ 0.69, 1.09 ]
Subtotal (95% CI) 587 598 34.0 % 0.63 [ 0.24, 1.69 ]
Total events: 278 (Antibiotics), 309 (Placebo)
Heterogeneity: Tau2 = 0.34; Chi2 = 2.21, df = 1 (P = 0.14); I2 =55%
Test for overall effect: Z = 0.92 (P = 0.36)
3≥ 12 months
Albert 2011 (8) 317/558 380/559 29.4 % 0.62 [ 0.49, 0.79 ]
Seemungal 2008 (9) 28/53 42/56 10.3 % 0.37 [ 0.17, 0.84 ]
Uzun 2014 (10) 34/47 42/45 4.6 % 0.19 [ 0.05, 0.71 ]
Subtotal (95% CI) 658 660 44.3 % 0.45 [ 0.25, 0.81 ]
Total events: 379 (Antibiotics), 464 (Placebo)
Heterogeneity: Tau2 = 0.15; Chi2 = 4.18, df = 2 (P = 0.12); I2 =52%
Test for overall effect: Z = 2.65 (P = 0.0081)
Total (95% CI) 1377 1339 100.0 % 0.57 [ 0.42, 0.78 ]
Total events: 706 (Antibiotics), 812 (Placebo)
Heterogeneity: Tau2 = 0.07; Chi2 = 15.58, df = 9 (P = 0.08); I2 =42%
Test for overall effect: Z = 3.55 (P = 0.00038)
Test for subgroup differences: Chi2 = 0.36, df = 2 (P = 0.84), I2 =0.0%
0.05 0.2 1 5 20
Favours antibiotic Favours placebo
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(1) Azithromycin 250mg three times/week for 12 weeks. Outcome reported at 18 weeks.
(2) Azithromycin 250mg three times/week for 13 weeks. Control group split three ways.
(3) Moxifloxacin 400mg daily for five days every four weeks for 13 weeks. Control group split three ways.
(4) Doxycycline 100mg daily for 13 weeks. Control group split three ways.
(5) Azithromycin 250mg daily for 12 weeks. Severe exacerbations (requiring unscheduled visit, antibiotics and/or steroids). Outcome reported at 26 weeks.
(6) Erythromycin 125mg three times/day for six months.
(7) Moxifloxacin 400mg daily for for five days every eight weeks for 48 weeks.
(8) Azithromycin 250mg daily for 12 months.
(9) Erythromycin 250mg twice/day for 12 months.
(10) Azithromycin 500mg three times/week for 12 months.
Analysis 2.3. Comparison 2 Subgroup analyses, Outcome 3 Subgroup analysis: number of people with one
or more exacerbations by year carried out.
Review: Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD)
Comparison: 2 Subgroup analyses
Outcome: 3 Subgroup analysis: number of people with one or more exacerbations by year carried out
Study or subgroup Antibiotics Placebo Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 2005 to 2009
Seemungal 2008 (1) 28/53 42/56 10.3 % 0.37 [ 0.17, 0.84 ]
Subtotal (95% CI) 53 56 10.3 % 0.37 [ 0.17, 0.84 ]
Total events: 28 (Antibiotics), 42 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.38 (P = 0.017)
2 2010 to 2014
Albert 2011 (2) 317/558 380/559 29.4 % 0.62 [ 0.49, 0.79 ]
Berkhof 2013 (3) 10/42 17/42 8.2 % 0.46 [ 0.18, 1.18 ]
He 2010 (4) 9/18 14/18 4.0 % 0.29 [ 0.07, 1.21 ]
Sethi 2010 (5) 269/569 295/580 29.9 % 0.87 [ 0.69, 1.09 ]
Simpson 2014 (6) 4/15 9/15 3.6 % 0.24 [ 0.05, 1.13 ]
Uzun 2014 (7) 34/47 42/45 4.6 % 0.19 [ 0.05, 0.71 ]
Subtotal (95% CI) 1249 1259 79.8 % 0.57 [ 0.39, 0.83 ]
Total events: 643 (Antibiotics), 757 (Placebo)
Heterogeneity: Tau2 = 0.09; Chi2 = 12.05, df = 5 (P = 0.03); I2 =58%
Test for overall effect: Z = 2.97 (P = 0.0030)
0.05 0.2 1 5 20
Favours antibiotic Favours placebo
(Continued . . . )
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(. . . Continued)
Study or subgroup Antibiotics Placebo Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
3 2015 to 2019
Brill 2015 (8) 10/25 4/8 3.3 % 0.67 [ 0.13, 3.30 ]
Brill 2015 (9) 10/25 5/8 3.2 % 0.40 [ 0.08, 2.06 ]
Brill 2015 (10) 15/25 4/8 3.3 % 1.50 [ 0.30, 7.43 ]
Subtotal (95% CI) 75 24 9.9 % 0.74 [ 0.29, 1.89 ]
Total events: 35 (Antibiotics), 13 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.31, df = 2 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 0.62 (P = 0.53)
Total (95% CI) 1377 1339 100.0 % 0.57 [ 0.42, 0.78 ]
Total events: 706 (Antibiotics), 812 (Placebo)
Heterogeneity: Tau2 = 0.07; Chi2 = 15.58, df = 9 (P = 0.08); I2 =42%
Test for overall effect: Z = 3.55 (P = 0.00038)
Test for subgroup differences: Chi2 = 1.32, df = 2 (P = 0.52), I2 =0.0%
0.05 0.2 1 5 20
Favours antibiotic Favours placebo
(1) Erythromycin 250mg twice/day for 12 months.
(2) Azithromycin 250mg daily for 12 months.
(3) Azithromycin 250mg three times/week for 12 weeks.
(4) Erythromycin 125mg three times/day for six months.
(5) Moxifloxacin 400mg daily for for five days every eight weeks for 48 weeks.
(6) Azithromycin 250mg daily for 12 weeks. Severe exacerbations (requiring unscheduled visit, antibiotics and/or steroids). Outcome reported at 26 weeks.
(7) Azithromycin 500mg three times/week for 12 months.
(8) Azithromycin 250mg three times/week for 13 weeks. Control group split three ways.
(9) Moxifloxacin 400mg daily for five days every four weeks for 13 weeks. Control group split three ways.
(10) Doxycycline 100mg daily for 13 weeks. Control group split three ways.
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Analysis 2.4. Comparison 2 Subgroup analyses, Outcome 4 Subgroup analysis: number of people with one
or more exacerbations by regimen.
Review: Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD)
Comparison: 2 Subgroup analyses
Outcome: 4 Subgroup analysis: number of people with one or more exacerbations by regimen
Study or subgroup Antibiotics Placebo Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Once daily antibiotic
Albert 2011 (1) 317/558 380/559 29.4 % 0.62 [ 0.49, 0.79 ]
Brill 2015 (2) 15/25 4/8 3.3 % 1.50 [ 0.30, 7.43 ]
Simpson 2014 (3) 4/15 9/15 3.6 % 0.24 [ 0.05, 1.13 ]
Subtotal (95% CI) 598 582 36.3 % 0.61 [ 0.34, 1.09 ]
Total events: 336 (Antibiotics), 393 (Placebo)
Heterogeneity: Tau2 = 0.10; Chi2 = 2.60, df = 2 (P = 0.27); I2 =23%
Test for overall effect: Z = 1.66 (P = 0.096)
2 Twice or three times daily antibiotic
He 2010 (4) 9/18 14/18 4.0 % 0.29 [ 0.07, 1.21 ]
Seemungal 2008 (5) 28/53 42/56 10.3 % 0.37 [ 0.17, 0.84 ]
Subtotal (95% CI) 71 74 14.3 % 0.35 [ 0.17, 0.71 ]
Total events: 37 (Antibiotics), 56 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.10, df = 1 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 2.91 (P = 0.0036)
3 Three times a week antibiotic
Berkhof 2013 (6) 10/42 17/42 8.2 % 0.46 [ 0.18, 1.18 ]
Brill 2015 (7) 10/25 4/8 3.3 % 0.67 [ 0.13, 3.30 ]
Uzun 2014 (8) 34/47 42/45 4.6 % 0.19 [ 0.05, 0.71 ]
Subtotal (95% CI) 114 95 16.2 % 0.39 [ 0.19, 0.77 ]
Total events: 54 (Antibiotics), 63 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.73, df = 2 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 2.69 (P = 0.0072)
4 Pulsed antibiotic
Brill 2015 (9) 10/25 5/8 3.2 % 0.40 [ 0.08, 2.06 ]
Sethi 2010 (10) 269/569 295/580 29.9 % 0.87 [ 0.69, 1.09 ]
Subtotal (95% CI) 594 588 33.2 % 0.85 [ 0.68, 1.07 ]
Total events: 279 (Antibiotics), 300 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.84, df = 1 (P = 0.36); I2 =0.0%
Test for overall effect: Z = 1.36 (P = 0.17)
Total (95% CI) 1377 1339 100.0 % 0.57 [ 0.42, 0.78 ]
0.05 0.2 1 5 20
Favours antibiotic Favours placebo
(Continued . . . )
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(. . . Continued)
Study or subgroup Antibiotics Placebo Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total events: 706 (Antibiotics), 812 (Placebo)
Heterogeneity: Tau2 = 0.07; Chi2 = 15.58, df = 9 (P = 0.08); I2 =42%
Test for overall effect: Z = 3.55 (P = 0.00038)
Test for subgroup differences: Chi2 = 9.51, df = 3 (P = 0.02), I2 =68%
0.05 0.2 1 5 20
Favours antibiotic Favours placebo
(1) Azithromycin 250mg daily for 12 months.
(2) Doxycycline 100mg daily for 13 weeks. Control group split three ways.
(3) Azithromycin 250mg daily for 12 weeks. Severe exacerbations (requiring unscheduled visit, antibiotics and/or steroids). Outcome reported at 26 weeks.
(4) Erythromycin 125mg three times/day for six months.
(5) Erythromycin 250mg twice/day for 12 months.
(6) Azithromycin 250mg three times/week for 12 weeks.
(7) Azithromycin 250mg three times/week for 13 weeks. Control group split three ways.
(8) Azithromycin 500mg three times/week for 12 months.
(9) Moxifloxacin 400mg daily for five days every four weeks for 13 weeks. Control group split three ways.
(10) Moxifloxacin 400mg daily for for five days every eight weeks for 48 weeks.
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Analysis 2.5. Comparison 2 Subgroup analyses, Outcome 5 Subgroup analysis: number of people with one
or more exacerbations by exacerbation history.
Review: Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD)
Comparison: 2 Subgroup analyses
Outcome: 5 Subgroup analysis: number of people with one or more exacerbations by exacerbation history
Study or subgroup Antibiotics Placebo Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Inclusion criteria of≥ 1 exacerbation in preceding year
Albert 2011 (1) 317/558 380/559 29.4 % 0.62 [ 0.49, 0.79 ]
Sethi 2010 (2) 269/569 295/580 29.9 % 0.87 [ 0.69, 1.09 ]
Uzun 2014 (3) 34/47 42/45 4.6 % 0.19 [ 0.05, 0.71 ]
Subtotal (95% CI) 1174 1184 64.0 % 0.66 [ 0.43, 0.99 ]
Total events: 620 (Antibiotics), 717 (Placebo)
Heterogeneity: Tau2 = 0.08; Chi2 = 7.83, df = 2 (P = 0.02); I2 =74%
Test for overall effect: Z = 2.00 (P = 0.046)
2 Exacerbation history not an inclusion criteria
Berkhof 2013 (4) 10/42 17/42 8.2 % 0.46 [ 0.18, 1.18 ]
Brill 2015 (5) 10/25 4/8 3.3 % 0.67 [ 0.13, 3.30 ]
Brill 2015 (6) 10/25 5/8 3.2 % 0.40 [ 0.08, 2.06 ]
Brill 2015 (7) 15/25 4/8 3.3 % 1.50 [ 0.30, 7.43 ]
He 2010 (8) 9/18 14/18 4.0 % 0.29 [ 0.07, 1.21 ]
Seemungal 2008 (9) 28/53 42/56 10.3 % 0.37 [ 0.17, 0.84 ]
Simpson 2014 (10) 4/15 9/15 3.6 % 0.24 [ 0.05, 1.13 ]
Subtotal (95% CI) 203 155 36.0 % 0.44 [ 0.27, 0.69 ]
Total events: 86 (Antibiotics), 95 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.61, df = 6 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 3.54 (P = 0.00040)
Total (95% CI) 1377 1339 100.0 % 0.57 [ 0.42, 0.78 ]
Total events: 706 (Antibiotics), 812 (Placebo)
Heterogeneity: Tau2 = 0.07; Chi2 = 15.58, df = 9 (P = 0.08); I2 =42%
Test for overall effect: Z = 3.55 (P = 0.00038)
Test for subgroup differences: Chi2 = 1.69, df = 1 (P = 0.19), I2 =41%
0.05 0.2 1 5 20
Favours antibiotic Favours placebo
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(1) Azithromycin 250mg daily for 12 months.
(2) Moxifloxacin 400mg daily for for five days every eight weeks for 48 weeks.
(3) Azithromycin 500mg three times/week for 12 months.
(4) Azithromycin 250mg three times/week for 12 weeks.
(5) Azithromycin 250mg three times/week for 13 weeks. Control group split three ways.
(6) Moxifloxacin 400mg daily for five days every four weeks for 13 weeks. Control group split three ways.
(7) Doxycycline 100mg daily for 13 weeks. Control group split three ways.
(8) Erythromycin 125mg three times/day for six months.
(9) Erythromycin 250mg twice/day for 12 months.
(10) Azithromycin 250mg daily for 12 weeks. Severe exacerbations (requiring unscheduled visit, antibiotics and/or steroids). Outcome reported at 26 weeks.
A D D I T I O N A L T A B L E S
Table 1. Summary of study characteristics
Study Country No. of
patients
Age (range
unless other-
wise stated)
% predicted
FEV1 (range )
unless other-
wise stated
Intervention Comparator Duration of
treatment
Albert 2011 United States
of America
1142 65 - 66 39 - 40 Azithromycin
250 mg daily
Placebo 12 months
Banerjee 2005 United King-
dom
67 65.1 - 68.1 42.5 - 43.9 Clar-
ithromycin
- long-acting
Klaricid XL
500 mg daily
Placebo 3 months
Berkhof 2013 Netherlands 84 67 - 68 47.4 - 49.8 Azithro-
mycin 250 mg
3 times a week
Placebo 12 weeks
Brill 2015 United King-
dom
99 67.9 - 70.4 44 - 53 Mox-
ifloxacin 400
mg/day for 5
days every 4
weeks
Placebo 13 weeks
Doxycycline
100 mg daily
Azithro-
mycin 250 mg
3 times a week
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Table 1. Summary of study characteristics (Continued)
He 2010 China 36 68.8 - 69.3 42.1 - 44.3 Erythromycin
125 mg 3
times a day
Placebo 6 months
Mygind 2010 Denmark 575 71 (median) 38.4 (median) Azithromycin
500 mg 3 days
a month
Placebo 36 months
NCT00524095
(terminated;
details given
represent pro-
posal)
Italy 210 45 - 85 N/A Azithro-
mycin 500 mg
3 times a week
for 6 months,
then fluticas-
one 500 µg
twice a day for
6 months
Usual care 1 year
Fluti-
casone 500 µg
twice a day
for 6 months,
then azithro-
mycin 500 mg
3 times a week
for 6 months
NCT02628769
(terminated;
details given
represent pro-
posal)
United King-
dom
5 N/A N/A Solithromycin
400 mg daily
Placebo 28 days
Seemungal
2008
United King-
dom
109 66 - 68 49.25 - 50.55 Erythromycin
250 mg twice
a day
Placebo 12 months
Sethi 2010 International 1157 66.1 - 66.6 40.6 - 42.2 Moxifloxacin
400 mg daily
for 5 days ev-
ery 8 weeks
Placebo 48 weeks
Shafuddin
2015
Australia &
New Zealand
292 65.8 - 67.6 32.53 - 35.8 Rox-
ithromycin
300 mg daily
and Doxycy-
cline 100 mg
daily
Placebo 12 weeks
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Table 1. Summary of study characteristics (Continued)
Rox-
ithromycin
300 mg daily
Simpson 2014 Australia 30 69.9 - 71.1 51.1 - 56.5 Azithromycin
250 mg daily
Placebo 12 weeks
Suzuki 2001 Japan 109 69.1 - 71.7 1.3 - 1.47 L Erythromycin
200 - 400 mg
daily
Riboflavin 10
mg daily
Unclear
Tan 2016 China 54 67.3 - 69.3 42.1 - 46.5 Erythromycin
125 mg 3
times a day for
12 months
Placebo 12 months
Erythrom-
cyin 125 mg 3
times a day for
6 months
Uzun 2014 Netherlands 92 64.7 - 64.9 44.2 - 45 Azithromycin
500 mg three
times a week
Placebo 12 months
Wang 2017 China 86 70.54 - 72.43 Unclear Azithromycin
250 mg daily
Simvastatin
20 mg daily
6 months
FEV1: forced expiratory volume in one second.
A P P E N D I C E S
Appendix 1. Sources and search methods for the Cochrane Airways Group Specialised Register
(CAGR)
Electronic searches: core databases
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Database Dates searched Frequency of search
CENTRAL (via the Cochrane Register of
Studies (CRS))
From inception Monthly
MEDLINE (Ovid) 1946 onwards Weekly
Embase (Ovid) 1974 onwards Weekly
PsycINFO (Ovid) 1967 onwards Monthly
CINAHL (EBSCO) 1937 onwards Monthly
AMED (EBSCO) From inception Monthly
Handsearches: core respiratory conference abstracts
Conference Years searched
AmericanAcademyofAllergy, Asthma and Immunology (AAAAI) 2001 onwards
American Thoracic Society (ATS) 2001 onwards
Asia Pacific Society of Respirology (APSR) 2004 onwards
British Thoracic Society Winter Meeting (BTS) 2000 onwards
Chest Meeting 2003 onwards
European Respiratory Society (ERS) 1992, 1994, 2000 onwards
International PrimaryCareRespiratoryGroupCongress (IPCRG) 2002 onwards
Thoracic Society of Australia and New Zealand (TSANZ) 1999 onwards
MEDLINE search strategy used to identify trials for the CAGR
COPD/chronic bronchitis search
1. Lung Diseases, Obstructive/
2. exp Pulmonary Disease, Chronic Obstructive/
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3. emphysema$.mp.
4. (chronic$ adj3 bronchiti$).mp.
5. (obstruct$ adj3 (pulmonary or lung$ or airway$ or airflow$ or bronch$ or respirat$)).mp.
6. COPD.mp.
7. COAD.mp.
8. COBD.mp.
9. AECB.mp.
10. or/1-9
Filter to identify RCTs
1. exp “clinical trial [publication type]”/
2. (randomised or randomised).ab,ti.
3. placebo.ab,ti.
4. dt.fs.
5. randomly.ab,ti.
6. trial.ab,ti.
7. groups.ab,ti.
8. or/1-7
9. Animals/
10. Humans/
11. 9 not (9 and 10)
12. 8 not 11
[The MEDLINE strategy and RCT filter are adapted to identify trials in other electronic databases]
Appendix 2. Search strategy to identify relevant records from the Cochrane Airways Trials Register
#1 MeSH DESCRIPTOR Pulmonary Disease, Chronic Obstructive Explode All
#2 MeSH DESCRIPTOR Bronchitis, Chronic
#3 (obstruct*) near3 (pulmonary or lung* or airway* or airflow* or bronch* or respirat*)
#4 COPD:MISC1
#5 (COPD OR COAD OR COBD):TI,AB,KW
#6 #1 OR #2 OR #3 OR #4 OR #5
#7 MeSH DESCRIPTOR Anti-Bacterial Agents Explode 1
#8 chemoprophylaxis
#9 antibiotic* NEAR prophyla*
#10 continuous NEAR antibiotic*
#11 antibiotic*
#12 penicillin
#13 phenoxymethylpenicillin
#14 phenethicillin
#15 amoxicillin
#16 amoxycillin
#17 clavulanic acid
#18 tetracycline
#19 oxytetracycline
#20 doxycycline
#21 quinolone
#22 ciprofloxacin
#23 moxifloxacin
#24 macrolide
#25 erythromycin
#26 roxithromycin
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#27 azithromycin
#28 sulphonamide
#29 co-trimoxazole
#30 sulphaphenazole
#31 trimethoprim
#32 sigmamycin
#33 tetracycline AND oleandomycin
#34 sulfamethoxazole
#35 sulfaphenazole
#36 sulfonamide
#37 #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #
25 or #26 or #27 or #28 or #29 or #30 or #31 or #32 or #33 or #34 or #35 or #36
#38 #6 and #37
Appendix 3. Search strategy for ClinicalTrials.gov
Intervention antibiotic OR *cillin OR *mycin OR *cycline OR *floxacin OR *azole ORmacrolide OR clavulanic OR sulfonamide
OR quinolone OR trimethoprim
Condition COPD
Study type Interventional
F E E D B A C K
Feedback, 30 June 2014
Summary
1) One of the conclusions in the review was that there was no significant difference in total serious adverse events (SAE) between
treatment and placebo. The definition of a serious adverse event includes any untoward medical occurrence that results in death, is life-
threatening, requires hospitalisation or prolongation of hospitalisation, or results in persistent or significant disability (1).
According to this definition, a moderate to severe COPD exacerbation would be considered a SAE. It is unclear whether the four
analysed studies (Albert, He, Seemungal, Sethi) included COPD exacerbation in their SAE data. The following concerns only exist if
trial authors included moderate to severe COPD exacerbations as SAEs. If the total numbers of SAEs are approximately equal between
the treatment arms and COPD exacerbations were decreased in the antibiotic group, one can expect another type of SAE to have
increased in the antibiotic group. Our fear is that there may be an unidentified SAE occurring in the antibiotic arm that is not present
in the placebo arm.
We noted your documentation of attempting to contact the Mygind authors for more information and were curious as to whether
Banerjee or Suzuki could be reached to determine more about SAE reporting in their trials. We also emailed the authors of Albert 2011
to inquire about how SAEs were classified and documented in that trial.
Furthermore, the three studies for which SAE data were not available (Banerjee, Suzuki, Mygind) have 751 participants, which equates
to 23.5% of the total review participants. The missing SAE data from these three studies could potentially change the conclusion of
this review on SAEs. Based on the two concerns we expressed above, additional information will be needed to confirm any difference
in SAEs between treatment and placebo.
In addition, these further conclusions about the possible SAEs associated with prophylactic antibiotics are required before patients can
make an informed decision about whether the benefits of therapy justify the risks.
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2) In the review, the authors discussed that a cost-effectiveness analysis would be useful in deciding the value of antibiotics in prophylaxis
of COPD exacerbation. Upon reviewing the Albert 2011 trial, we noted that cost-effectiveness was a secondary outcome that was
included in the study protocol but not reported in the final data. The protocol suggested that this would have been calculated as the
ratio of incremental costs to the ratio of incremental quality-adjusted life years. If this missing data can be obtained from the authors
and included into the review, it will be an added piece of valuable information for the readers when considering practice changes.
3) In the analysis on frequency of hospitalisation, the authors report the rate ratios of exacerbation requiring hospitalisation (/patient/
year), but stated it as the rate ratios of exacerbation (/patient/year). Since the Albert 2011 trial reported both the rates of exacerbation
(/patient/year) and the rates of exacerbation requiring hospitalisation (/patient/year), we feel it would be in the interest of clarity to
state “rate of exacerbations requiring hospitalisation per patient per year according to the severity of COPD by the GOLD criteria.”
References
1. Therapeutics Initiative. Serious adverse event analysis: lipid-lowering therapy revisited. Therapeutics Letter. 2001 Aug-Oct; Issue
42. Available from: www.ti.ubc.ca/pages/letter42.htm [cited 2014 Jun 22]
Reply
Question 1
We agree that elucidating all antibiotic-related SAEs is of paramount importance for patients and physicians prescribing these prophy-
lactic antibiotics in order to make informed choices.
1. Albert and colleagues included COPD as a cause of fatal SAE causing death in 10 patients in the antibiotic group and 7 patients
in the placebo group. However, given that there were 317 exacerbations in 558 patients in the antibiotic group and 380 exacerbations
in 559 patients in the placebo group, it does not seem possible that COPD exacerbations were looked at and included as SAEs.
However, we agree that this needs to be clarified with the authors and we have written to Albert and colleagues requesting clarification
as to whether they included moderate to severe COPD exacerbations as a SAE.
2. In the Seemungal and colleagues study, the only listed adverse events are upper GI, lower GI, rash, and “other”. Relooking at the
raw data, 28 out of the 53 patients in the treatment group and 42 out of the 56 patients in the placebo group had experienced COPD
exacerbations; hence they did not include COPD exacerbations as SAEs.
3. In the He study, listed adverse events were abdominal pain and heart failure in two patients in the antibiotic group and
respiratory insuffiencey in two patients in the placebo group. Again, the COPD exacerbations were not included as SAEs.
4. In the Sethi and colleagues study, COPD exacerbations were not reported as SAEs. Looking closely at the adverse event table
from the paper, only four patients reported dyspnoea in the treatment group and no patients reported dyspnoea in the placebo group.
Given the much larger number of COPD exacerbations that had occurred in both groups, it seems that exacerbations were not
included as SAEs.
5. The Mygind study did not report SAEs in detail. However, they categorised adverse events as upper GI, lower GI, infection and
“other” and did not include COPD exacerbations as adverse events. However, these data were from an oral presentation slide and, as
mentioned in the paper, we did not receive a response from the authors.
6. The Banerjee study had indicated in the paper that one participant withdrew in the treatment arm due to GI disturbance.
7. The Suzuki study had listed that one patient was excluded from the treatment group due to diarrhoea, with no other antibiotic-
related adverse event listed.
In summary, all four papers with detailed data on adverse events (Albert, He, Seemungal, Sethi) did not include COPD exacerbations
as SAEs according to the raw data we have. Albert had included COPD as a cause of death and we have written to the authors to clarify
this point. The three studies with limited data (Banerjee, Suzuki, and Mygind) had not listed COPD exacerbations as SAEs.
While moderate to severe COPD exacerbations, by definition, qualify as SAEs, the most likely rationale for reporting these as separate
entities was that exacerbations were the primary outcomes assessed by these studies. Separating exacerbations from adverse events will
give a better idea of whether there are other SAEs that would occur in the treatment group (other than the assessed primary outcome
of exacerbations).
Question 2
We agree with this point. Assessing cost-effectiveness of this intervention is of fundamental importance and we have written to the
Albert group requesting that the group supply these data. This certainly is a factor that we will explore during the future updates.
Question 3
We agree that the sentence you have suggested clarifies the meaning better and have made the suggested change.
At the time of publication of this feedback, we await a response from Albert and colleagues.
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Contributors
Debbie Au and Caitlin Lang, Lower Mainland Pharmacy Services, Pharmacy Residents, UBC
Dr. Aaron Tejani, Lower Mainland Pharmacy Services, Medication Use Evaluation Coordinator
WH A T ’ S N E W
Date Event Description
27 July 2018 New citation required and conclusions have changed Conclusions strengthened and evidence now suggests that
continuous and intermittent regimens may be more effective
than pulsed regimens. Additonal information about antibi-
otic resistance added. Text updated throughout review
Two new authors added to author team for 2018 update.
Seven new studies added to qualitative synthesis (Berkhof
2013; Brill 2015; Shafuddin 2015; Simpson 2014; Tan 2016;
Uzun 2014; Wang 2017). Fourteen studies now included in
qualitative synthesis and eight studies in quantitative synthe-
sis. Outcomes subgrouped by antibiotic regimen (continu-
ous, intermittent, and pulsed)
27 July 2018 New search has been performed Literature search updated.
H I S T O R Y
Protocol first published: Issue 4, 2012
Review first published: Issue 11, 2013
Date Event Description
26 August 2014 Feedback has been incorporated Feedback and author response added to the review.
C O N T R I B U T I O N S O F A U T H O R S
For the 2013 version of the review, equal contributions were made from both authors (SH and PP) to the protocol, data extraction,
analysis, write-up, and response to reviewers comments.
For the 2018 update, SH and RN screened included studies, with input from PP. SH, SM, and RN performed data extraction and
entry and carried out the analysis, with advice and input from PP. SM updated the background text, methods, and results. All four
authors contributed to interpreting the analyses, writing up results, and discussion and all approved the final version of the review.
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D E C L A R A T I O N S O F I N T E R E S T
RN is joint Coordinating Editor of Cochrane Airways and supported by an National Institute of Health Research grant.
S O U R C E S O F S U P P O R T
Internal sources
• Rebecca Normansell, UK.
St George’s, University of London
External sources
• National Institute for Health Research, UK.
Cochrane Programme Grant 16/114/21: NHS priorities in the management of chronic respiratory disease.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
The original protocol stated that studies using antibiotics at least three times a week for a minimum period of three months would be
included. We have amended this to include a regular schedule of pulsed antibiotics for a period of at least three months in order to
include more studies using pulsed antibiotics. Furthermore, in the 2018 update, we chose to group analyses into continuous antibiotic
regimens (at least daily), intermittent (i.e. two to three times per week) and pulsed (e.g. five days of antibiotics every eight weeks).
In 2018, we also extracted and included data on functional capacity (i.e. six-minute walk test). Before seeing the results, it was agreed
amongst the author team that this was a patient-important outcome and if data were available, they should be extracted and presented.
For the 2018 update we used a random-effects rather than fixed-effect model in the meta-analyses because we judged a random-effects
model to more accurately reflect the underlying clinical heterogeneity of the included studies. Furthermore, we added cut-offs for
identifying statistical heterogeneity according to Higgins 2011.
Some additional text has been added to the background and discussion for the 2018 update.
In a post-hoc decision, we excluded data from Suzuki 2001 from the primary analysis as the study was not blinded.
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Disease Progression; ∗Quality of Life; Anti-Bacterial Agents [∗therapeutic use]; Antibiotic Prophylaxis [∗methods]; Aza Compounds
[therapeutic use]; Azithromycin [therapeutic use]; Clarithromycin [therapeutic use]; Erythromycin [therapeutic use]; Fluoroquinolones;
Pulmonary Disease, Chronic Obstructive [∗drug therapy]; Quinolines [therapeutic use]; Randomized Controlled Trials as Topic
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MeSH check words
Aged; Humans
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